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S0HHABY
Since the enantioiaers of a number of racemic drugs have been found 
to have different activities or modes of action, enantioselective analysis ' 
is becoming more important. A number of different approaches to 
chromatographic chiral resolutions have been evaluated for their ability 
to resolve the enantiomers of racemic beta blacking drugs.
Three chiral HPLC columns were investigated; a cyclodextrin phase, an 
(S)~3,5-dinitrobensoylphenylglycine phase and a protein phase. The oc» 
acid glycoprotein phase successfully resolved atenolol, alprenolol, 
metoprolol, oxprenolol, propranolol and verapamil with 0.0IM phosphate 
buffer eluents modified with either acetonitrile or isopropanol. The <R>- 
3,5-dinitrobenzoylphenylglycine phase was used with eluents of 
isopropanol in hexane and resolutions of propranolol, oxprenolol, 
metoprolol, alprenolol and pronethalol were achieved after formation of 
the 1- or 2-naphthamide derivatives, although no separations were 
achieved for the underivatised samples. The cyclodextrin phase was also 
found to be unsuccessful in resolving underivatised samples of 
propranolol and verapamil. However preliminary results indicate that 
resolutions are passible after the formation of their trifluoroacetyl 
derivatives. The cyclodextrin phase was also successfully used to 
resolve the enantiomers of chlorpheniramine and the geometric isomers of 
clomiphene.
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In addition to the chiral HPLC stationary phases, a (+)~1Q~ 
camphorsulphanic acid mobile phase additive was investigated, although 
this was found to be completely unsuccessful.
Finally the use of a chiral diamide GLC column was investigated. This 
was not suited to the analysis of beta blockers, even after 
derivatisation, although derivatised amino acids were well resolved.
The use of computer modelling to predict the degree of separation of 
enantiomers was also investigated for the <E)-3,5-dinltrobensoyl 
phenylglycine phase, with the interaction energies between the phase and 
both isomers of each compound calculated for the most stable 
conformation. From a comparison with the experimental results, it was 
shown that this approach to prediction was unsuccessful,
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CHAPTER 1
IITRODUCTIQI TO CHIRALITY
1.1 Chirality
Two or more compounds whose structures differ only in the three 
dimensional arrangement of the constituent atoms are classified as 
stereoisomers, Such isomerism can be either enantiomeric or 
diastereomeric, depending on whether the isomers are related as abject 
and nonsuperimposable mirror image or not; enantiomers are those isomers 
which are so related, whereas diastereomers are not.
The study of chirality was initiated at the beginning of the nineteenth 
century, when, following the discovery of the polarisation of light by 
Malus in 1808, work by Blot, Arago and Fresnel showed that certain 
materials, in particular quarts, caused a rotation of the plane of plane 
polarised light. Detailed examination of quarts showed that the crystals 
were not symmetrical and that two forms were present which were mirror 
images of each other. On separation it was found that one caused the 
plane of polarisation to rotate to the right, while the other caused 
rotation to the left. Further research was limited and did not explain 
the rotatory effects of other liquid substances such as camphor, oil of 
turpentine and sugar solutions,
In 1848, the research of Pasteur [13 was centred on tartaric acid, a 
compound of unknown structure with the formula C.+HeOe. Tartaric acid
was known to exist in two forms, one which was optically inactive, and 
another which caused clockwise rotation of the plane of polarisation,
The crystals of the dextrorotatory form were found to be asymmetric, but 
the recrystallisation of the optically inactive form, instead of yielding 
crystals of a different, symmetrical structure as expected, showed an 
approximately equal mixture of the same left and right handed crystals as
found for the other form [23. On separation, the right handed crystals
showed dextrorotation of polarised light, while the left handed crystals 
showed laevorotatory effects. This proved that compounds with 
asymmetric crystals could exist in two enantiomeric forms, each having an 
equal and opposite effect on polarised light, and that compounds may be 
optically inactive because of compensation between the opposite rotations
if both forms are present in equal quantities.
Although Pasteur’s work was centred on the idea of crystalline 
dissymmetry, the concept of asymmetric molecular structures was not 
introduced until many years later, after ICelcule had developed a theory 
based on the existance of a tetravalent carbon atom in 1865. Prom this, 
Van't Hoff [33 and Le Bel [43 independently postulated that if the four 
valencies of the carbon atom were arranged in a tetrahedral manner, then 
only when all four substituents were different could the structures exist 
as nonsuperimposable mirror images (see fig. i.l>, and exhibit optical 
isomerism.
An Example of a Pair of Enantiomers
Figure 1.1
The link between molecular asymmetry of compounds and their ability to 
rotate the plane of plane polarised light is now well established and 
such compounds are termed as chiral. Since it is the overall molecular 
symmetry which determines the chirality of a molecule, an asymmetric 
carbon atom is not a necessary prerequisite to optical activity, Hence, 
although the majority of enantiomeric molecules contain one or more 
asymmetric carbon atoms, some do not have a well defined chiral centre, 
with the asymmetry being caused by, for example, a substituted cyclic 
system. Molecules which are not optically active are termed achiral, 
while those where chirality may be achieved by means of a single 
chemical transformation are described as prochiral C5L
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Although enantiomeric pairs of molecules are completely different 
spatially, they have identical physical properties such as melting and 
bailing points, solubilities, chromatographic characteristics and spectra. 
In fact, generally the only difference between the enantiomers is in their 
ability to rotate the plane of plane polarised light, each isomer having 
equal and apposite rotatory powers. The energy difference between the 
two enantiomers is so small as to make any distinction between them 
virtually Impossible except in a chiral environment. In this case 
attractive and repulsive forces such as covalent or ionic bonds, which 
are spatially dependant, cause the physical and chemical properties of 
the enantiomers to differ more markedly. If therefore, a pair of 
enantiomers of one compound, A+and A--, are reacted with a single 
enantiomer of a different compound, B-<», then the products, A.+B+- and A~B-»., 
will be diastereomers, which have significant differences in both 
physical and chemical properties.
There are several different styles of nomenclature applied to 
differentiate between enantiomers C6], with the simplest using the prefix 
<+> for enantiomers which rotate the plane of polarisation to the right, 
in a clockwise direction, and (-) for the antipodes which rotate the 
plane to the left, in an anticlockwise direction. Associated with this 
are the designations d- and 1~ which stand for dextrorotatory, or 
rotation to the right, and lae vara tat ory, or rotation to the left 
respectively. These should not be confused with the notation D- and L-, 
which was the original system introduced by Fischer, and later expanded 
by Rosanoxf [71, for discrimination between enantiomers. This was based 
on the arbitrary assignment of a particular spatial formula to the
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dextrorotatory glyceraldehyde enantlamer which was then designated D~ 
glyceraldehyde, with the enantiomeric laevorotatory form having the 
opposite spatial arrangement and being termed L-glyceraldehyde. From 
this, all compounds which could be directly or indirectly transformed to 
D-glyceraldehyde were prefixed D-, and all those chemically related to L- 
glyceraldehyde were prefixed L-, This system is limited in application, 
as it can only be used for compounds which can be related to 
glyceraldehyde.
The third system in common use was introduced by Calm, Ingold and Prelog 
in 1951, and relies on a set of sequence rules C81. Priorities are 
assigned to the substituents on the chiral centre, based initially on the 
atomic number of the adjacent atoms, and the molecule is viewed with the 
substituent of lowest priority, or atomic number, pointing away. If the 
priorities of the substituents decreases clockwise about the chiral 
centre, then the configuration is termed R-, and conversely, if the 
priorities decrease in an anticlockwise direction, the molecule is 
prefixed S-. This is more widely used than the D~ and L- nomenclature 
since it may be applied to any molecule, and not just those with 
structures similar to glyceraldehyde, and is also more easily applied to 
diaster earners and molecules with more than one chiral centre.
1,2 Chirality in Pharmacology
One field where stereochemical considerations are of prime importance is 
that of pharmacology, the study of the actions and interactions of 
chemicals, or drugs, within the body. Despite a high degree of external
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anatomical symmetry, the body is in fact an intensely chiral environment, 
and the majority of the chemical reactions essential to a living system 
are stereospecific [93. Although the origins of optical isomerism are 
still the subject of much debate, such stereospecificity appears to have 
been acquired very early in the evolutionary process [10,113, and while 
two contrasting theories dispute whether optical Isomerism originated 
with the creation of the universe or whether it occurred as a consequence 
of the biological evolution of life, the fact that the stability of DIA 
requires that the component proteins are L-amino acids [12,133 indicates 
that stereoselectivity was of critical importance in the development of 
life.
As the action of a drug depends on a number of steric interactions, such 
stereoselectivity is a crucial factor in the determination of the 
pharmacological and toxicological effects, The study of pharmacology can 
be subdivided into several sections including pharmacodynamics, concerned 
with the physiological and biological action of drugs, drug disposition, 
concerning the distribution, and transport mechanisms within the body, and 
metabolism or elimination of the drug from the body. All these aspects 
are linked, and factors which affect one will have an influence on the 
others. It has long been accepted that stereochemistry is an important 
factor in pharmacodynamics, due to the chirality of the receptor sites, 
but it is onfy recently that stereochemical effects have been considered 
important in the mechanisms involved in the transport and metabolic 
elimination of drugs, and in order to determine the effect of the 
molecular structure on the action of the drug, the steric interactions in 
each of the processes must be individually evaluated.
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1,2.1 Pharmacodynamics
The interaction of drugs with living systems at a molecular level is 
not yet clearly understood, but two types of interaction, specific and nan 
specific, have been postulated. In non specific interactions, the drug 
exerts a general effect on a particular aspect of cell function, and since 
it has been found that changes in the structure of the drug have little 
effect on its activity, the process is unlikely to be stereospecific. 
However, with specific interactions, the drug acts at a specific drug 
receptor or active enzyme site within the cell, and minor structural 
alterations in the drug have large effects on the activity at the site of 
action, Research in this area has led to the development of a model of a 
drug receptor site consisting of a three dimensional arrangement of 
chemical groups on a macromolecular cell component, and hence it can be 
seen that specific spatial arrangements of groups within the drug 
molecule are required if the molecule is to "fit" properly in the receptor 
site, Enantiomers of a given drug, having different spatial 
configurations of groups would therefore appear as separate compounds at 
the receptor site, leading to marked differences in both the type and 
degree of activity, as shown in tables 1.1 and 1.2.
Although the interaction between the drug and receptor may be reversible 
or irreversible, the response produced by the drug-receptor complex is a 
function of a number of factors including the number of receptor sites 
occupied by the drug molecule and also the efficacy or intrinsic activity 
of the drug.
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Enantiomers With Different Types of Activity
Compound <+>/R <->/S REF
Bupivicane anaesthetic anaesthetic, 14
vasoconstrictor
DMBB (Barbiturate) convulsant depressant 15
Ketamine hypnotic CNS stimulant 16
lorphinan analgesic antitussive 17
Indacrinone diuretic, uric uricosuric 18
acid retention
Timalol reduces intraocular reduces intraocular 19
pressure pressure, J3 adrenergic
antagonist
Table 1.1
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Enantioraere With Different Degrees of Activity 
Compound Most Active Enantiomer REF
Ibuprofen (S> 20
Propranolol <S)/(~) 21
Hexobarbital (S)/<+) 22
Warfarin (S)/(~) 23
Verapamil (~) 24
Terbutaline (-) 25
Fenfluramine (-) 26
Table 1.2
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In order for any drug receptor interaction to occur, the drug must 
first be present at the site of action. Any factors influencing this, for 
example the rate and extent of absorption, transport to and distribution 
at the site of action and elimination of the drug will affect the rate, 
magnitude and duration of the response to the drug.
In order for the drug to enter the bloodstream, the molecules must 
traverse at least one cell membrane. This is normally achieved by 
passive diffusion, although in some cases active transport, occurs.
Passive diffusion is based on the principle that the drug molecules, 
present in aqueous solution on one side of the membrane, dissolve in and 
diffuse across the lipid membrane and out into the aqueous bloodstream on 
the other side. For the process to occur, the drugs must be soluble in 
the both aqueous and lipid phases, and the rate of transport is dependent 
on the concentration gradient across the membrane, and hence the lipid 
affinity. Although factors such as pH have a large effect on the rate 
and extent of diffusion, the process is governed by solubilities, a 
function which is not stereospecific, and hence passive diffusion is 
unlikely to be enantioselective.
Amino acids, sugars, and some salts and vitamins can traverse a membrane 
against a concentration gradient by a process of active transport. A 
number of mechanisms have been postulated to explain this process, the 
oldest involving a mobile carrier which ferries the substrate from one 
side across the membrane, rotating as it does so, to present the 
substrate at the opposite face. Another model was based on a transfer
1,2.2 Drug D isp osition
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channel or chainlike arrangement of sites in the membrane, with which the 
substrate sequentially combines until it has traversed the membrane. The 
more modern explanation is that transport is catalysed by the proteins 
spanning the lipid bilayer undergoing conformational changes to allow the 
passage of specific substrates. The channels act as small pumps, moving 
the material from one side to the other. In each case, the spatial 
arrangement of the substrate molecule will affect the passage, and hence 
the mechanism is stereospecific, as demonstrated by the more rapid 
absorption of L-amino acids than D-amino acids,
Once the drug has been absorbed into the bloodstream, it is transported 
to the various tissues reversibly bound to the plasma proteins, in 
particular human serum albumin and oci acid glycoprotein, which act as a 
mass transport system for the drug. The drug is then taken up by tissue, 
by either passive or active transport, at a rate proportional to the rate 
of blood flow to the area. At equilibrium, the drug is partitioned 
between the plasma protein, plasma water and the tissue, with the 
distribution between the three determined by lipid solubilities and 
affinities.
Since the response to a drug is determined by its interaction with tissue 
receptor sites, the rate at which the drug can reach the receptor 
determines the rate of response of the drug, and is influenced by the 
flow of blood to the organ, The magnitude of the response is, however, 
based on the free drug concentration at the receptor site. Since plasma 
protein binding is stereospecific, this could lead to an increased 
response for a particular enantiomer of a racemically administered drug
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if the other is preferentially hound by the plasma proteins. Examples of 
this include warfarin, where the <S)/<~) enantiomer binds more strongly 
to human serum albumin than the (S)/(-f) enantiomer [273, as do the (S) 
enantiomers of substituted l,4--3:>eiisadiazepines such as oxazepam [283
1.2.3 Drug Elimination
Drugs are eliminated from the 3)ody by excretion, predominantly from 
the kidneys, but also from other organs such as the gut, skin, lungs, 
sweat and salivary glands. Although in some cases the drug is eliminated 
in an unchanged form, it is more common for a drug to undergo a 
metabolic reaction prior to excretion. The process of metabolism 
increases the polarity of the lipid soluble drugs, thus increasing the 
rate of elimination. Lipid soluble drugs are widely distributed 
throughout the body with only a small proportion found in plasma, and 
hence plasma clearance is slaw. In addition to this, the high 
lipophilicity promotes the reabsorption of the drug,
Metabolism may occur in all tissues, but in general the major metabolic 
reactions occur in the liver and may be considered in two stages, Phase 
1 metabolism, or biotransfarmatian, involves the introduction of new 
functional groups within the molecule by oxidation, reduction or 
hydrolysis reactions, thus increasing the polarity. However, although the 
metabolite is less lipophilic than the parent compound, it is not 
necessarily less active. Phase 11 metabolism involves the conjugation of 
the original drug or metabolite with a small endogenous molecule, for 
example an organic acid, to produce a highly water soluble compound which 
is generally pharmacologically inactive,
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Since metabolism is caused by various microsomal enzyme systems, the 
metabolic reactions are generally stereospecific, and hence the rate of 
plasma elimination of one enantiomer may be considerably different to its 
antipode. This, in turn, will influence the concentration of each isomer 
at the site of action of the drug causing possible differences in the 
magnitude of the receptor response. Examples of drugs which exhibit such 
enantiomeric differences in clearance rates include propranolol [29] and 
verapamil [30], for which the (-) enantiomer is cleared faster than the 
(+) isomer, and hexobarbital [31] and acenocoumarol [32], where the (8) 
form is cleared more rapidly than the (R), The <R) isomers of 2-phenyl 
propionic acids such as ibuprofen are inverted to the more active (S) 
enantiomers and hence the <R) isomers have faster clearance rates [333.
The metabolic pathways may also differ between enantiomers, with one 
isomer forming a totally different and possibly more active metabolite to 
the other. There are also a number of cases where one enantiomer forms 
a toxic metabolite, and examples of this include raephenytoin, where the 
metabolite of the <R) isomer has the major therapeutic effect and that of 
the <S) enantiomer is thought to be a bone marrow toxin [343, and 
prilocaine, a local anaesthetic whose <R) enantiomer is hydrolysed to 
form a toxin causing methemoglobinemia [353.
The process is further complicated by metabolic transformations, which 
can introduce chirality to a previously achiral or prochiral drug, 
rendering further metabolic pathways subject to stereochemical 
considerations. These transformations can occur in phase 1 metabolism by 
reactions at either the prochiral centre or at a group on the prochiral
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centre, or as a result of conjugation of an achiral drug molecule with a 
chiral endogenous molecule in phase 11 metabolism.
1.2.4 Drug Interactions
It has long been known that certain drugs interact with one another, 
and if present in combination, may produce either beneficial or adverse 
results. The mechanisms of such interactions may take several forms and 
occur at each stage of the pharmacological process. Drugs which are 
transported by the plasma proteins may displace one another from protein 
binding sites, causing increased blood levels of the displaced species, 
and competition may also occur at the tissue receptor sites, increasing 
the concentration of one drug-receptor complex at the expense of the 
other. The action of the drug metabolising enzyme systems may be 
induced by certain compounds, thus accelerating their metabolism and that 
of other* drugs, or inhibited if two drugs compete for the same metabolic 
pathway, resulting in one delaying the metabolism of the other.
Interactions also occur in the actions of enantiomeric drugs, where one 
isomer has an opposite effect to its antipode, There are a number of 
examples of this including pincenadol, where the (+) isomer is an opiod 
agonist and the (-) enantiomer has a competitive antagonist action [363, 
and isopropylnoradrenaline, active on av adrenergic receptors, where the 
<-) isomer is the agonist and the (+) isomer the antagonist C373.
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1,3 Analytical Methods in Pharmacology
The role of analytical chemistry in pharmacology and routine drug 
monitoring has long been accepted, and this has led to an extensive range 
of techniques being available to measure drug concentrations in various 
biological specimens. However, the necessity of finding rapid and 
accurate methods of analysis for enantiomeric compounds is becoming 
increasingly important, particularly in pharmacology, where evidence 
exists to show that many drugs, produced as racemic mixtures, are 
stereoselective in their action.
Until recently, the problem of optical isomerism in drugs has been 
largely ignored, occasionally with tragic consequences such as the 
Thalidomide disaster, where it was discovered that the teratogenic effect 
was due to the S (~) form while the R<+) isomer was responsible for the 
therapeutic effect [381, The resolution of enantiomeric molecules is not 
an easy task and therefore progress has been slow. Although this is due 
in part to the lack of analytical methodology for the determination of 
the enantiomeric composition of chiral molecules in a biological matrix, 
it is also due to the fact that, as a whole, stereochemical considerations 
in the in-vivo pharmacological activity of drugs have received a low 
priority.
The effects of stereospecificity, however, extends beyond the 
pharmaceutical industry and is also apparent in agrochemicals, as many 
herbicides, insecticides and fungicides are chiral and have been found to 
show significant differences in biological activities between the
- 21 -
enantiomers C39-443, but as yet little has been done to prevent the 
desecration of the environment associated with the use of vast quantities 
of, for example, a biologically inactive pesticide enantiomer [45].
Until recently, the pharmacological parameters of enantiomeric drugs have 
been determined by studying each enantiomer separately, but this approach 
neglects the possibility that the two enantiomers may interact causing 
the racemate to have a different effect, either quantitatively or 
qualitatively, than either of the pure isomers. This has recently been 
demonstrated by a study of the antiarrythinic agent, disopyramide [46], 
the two enantiomers of which, when administered in a pure form, have 
identical properties but the administration of the racemate causes d~ 
disopyramide to have a longer half life and a smaller volume of 
distribution than 1-disopyramide.
In addition to the previous examples, there are many other cases of 
enantioselectivity in the overall pharmacological action of drugs, whether 
due to stereoselective metabolism, distribution or receptor binding, and 
these include amphetamine [47,48], phensuxiraide [493, glutethimlde E503, 
oxyphenonium [513 and the benzodiazepinones [523. These are just several 
examples from a much more extensive list, which is more fully presented 
in a book edited by Ariens [93. A particularly interesting situation 
occurs in the case of the synthetic opiates such as methadone [533, for 
which there are l^ etween three and five stereoselective opiate receptor 
sites, each triggering a different response.
At the present time, the majority of drugs are produced by non 
stereospecific synthesis which results in the formation of a racemic 
mixture. In order to produce an enantiomerically pure form of the active 
isomer, either the synthesis of the compound must be altered to ensure 
stereoselectivity or the racemate must be resolved into the composite 
enantiomers and the inactive form discarded, both of which are usually 
difficult and correspondingly costly options. Due to economic 
considerations, the introduction of drugs preseibed in an enantiomerically 
pure form is likely to be a slow process and will require the development 
of accurate methods of stereoselective analysis, both to establish the 
pharmacological response of the enantiomers of chiral drugs and to 
monitor the optical purity of such compounds.
A fundamental assumption in pharmacology is that, for any given drug, the 
magnitude of the response is directly related to the number of receptor 
sites occupied by the drug molecules. However it was not until the early 
1940's that it was recognised that the number of occupied receptor sites 
could be more reliably correlated to the plasma concentration [54,551, 
assumed to be proportional to that at the site of action, than to the 
administered dose of the drug, as had previously been thought. Analysis 
of plasma drug concentrations, therefore, became increasingly important 
and led to the development of various methods for routine drug monitoring 
in biological fluids,
There are a number of different methods available for chemical analysis, 
and the choice of technique depends on factors such as the nature of the
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analyte, the sample matrix, the expected concentration range, any possible 
interferences and the information required from the analysis.
In general, drug analysis involves mainly quantitative methods, although 
it is sometimes necessary to perform qualitative analysis to identify for 
example, a metabolite. The three main techniques used for such structural 
analysis are:
1.3.1 Infra Red Spectroscopy
If a molecule is irradiated with infra red radiation then this will 
cause the interatomic bonds to oscillate, The frequency of the vibrations 
and hence the energy required to produce such vibrations is 
characteristic of each individual bond, Therefore, if a spectrum of the 
absorption of energy at each frequency is obtained, then it is possible 
to determine which bonds are present and thus elucidate the molecular 
structure [561.
1.3.2 luclear Magnetic Resonance Spectroscopy
Certain nuclei, when placed in an external magnetic field, exist in 
one of two possible quantum spin states. If irradiated with energy of 
radio frequencies, an interchange between the spin states, known as 
resonance, can occur resulting in the absorption of those frequencies 
corresponding to the energy difference between the two spin states, 
Although this energy difference is dependant on the strength of the 
external field, it is also affected by the magnitudes of local magnetic 
fields caused by the electrons of neighbouring nuclei in a process known 
as shielding. Since differing adjacent nuclei shield to different degrees,
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the frequencies at which resonance occurs for a sample is indicative of 
its molecular structure [57 3. The technique of nuclear magnetic 
resonance is limited to nuclei with spin, in particular where the spin 
quantum number, I=JA or 1, and is most commonly used with 1H and 13C 
although 1 ®F, 31P and :S4Si may also be used.
1.3.3 Mass Spectrometry
This is one of the most specific, and also most expensive 
qualitative techniques in routine use. It is based on the principle that, 
if a sample is bombarded with, for example, a stream of high energy 
electrons, then fragmentation and ionization of the sample molecule will 
occur. These fragments are detected according to their mass to charge 
ratio. Possible molecular structures can therefore be deducted from a 
study of the fragmentation pattern and the relative abundance of each 
fragment [583.
Due to a greater demand, there are many more techniques available for the 
quantitative analysis of a sample than for structural determinations, 
although not all are suitable for the routine analysis of drugs in 
biological fluids, The methods most widely used include the following:
1.3.4 Electronic Spectroscopy
If a sample is irradiated with electromagnetic radiation, the energy 
of the incident photons may be transferred to the sample molecules, 
raising the electrons from the ground state to an excited state. This 
process is known as absorption, and since the energy absorbed must be
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equal to the energy difference between the excited and ground states, 
only radiation of specific frequencies or wavelengths can be absorbed.
Ultraviolet and visible absorption spectroscopy [591 relies on measuring 
the absorption or percentage transmission of radiation at one particular 
wavelength, usually near the wavelength of maximum absorption of the 
compound of interest, of an unknown sample. The concentration of the 
sample can then be determined by comparison with a calibration curve, 
prepared by measuring the response of standards of known concentrations 
at the same wavelength.
As the technique depends on the characteristic absorption of individual 
functional groups or chromophores within the molecule, the method is not 
particularly specific; two different compounds sharing common functional 
groups, in particular a drug and the metabolite, will have similar 
absorption spectra and hence the presence of one will interfere with the 
measurement of the other. The second disadvantage of this technique is a 
lack of sensitivity due to the problems involved in measuring small 
changes in transmitted radiation against a background of intense incident 
radiation.
Fluorescent spectroscopy is not concerned with the energy absorbed in 
exciting the molecule, but with that emitted as it decays back to the 
ground state. In most molecules, the energy emitted is at an identical 
frequency to that absorbed and hence cannot be measured, However with 
molecules that fluoresce, same of the excess vibrational energy of the 
excited state is lost through interm a lecular collisions, and thus the
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radiation emitted on decay to the ground state is at a lower frequency to 
that absorbed [603.
This makes the technique much more specific, as it becomes less likely 
that two compounds will absorb and emit radiation at the same 
frequencies. Fluorescence is also more sensitive, since a low 
concentration of a fluorescent sample corresponds to a low signal, which 
can be readily amplified, whereas a low concentration of an absorbent 
material corresponds to a very small reduction in the maximum signal, the 
amplification of which increases the noise level. In addition to this, 
the photomultiplier tube can be located perpendicular to the excitation 
source within the detector, thus being more shielded from incident 
radiation than in an absorbance spectrometer. As with absorption 
spectroscopy, the intensity of the emitted radiation of an unknown sample 
is related to the concentration by comparison to a calibration curve 
produced by measuring the intensity of emission from standards of known 
concentrations.
Phosphorescence is similar in principle to fluorescence, but is much less 
widely used as an analytical technique. This is due to a number of 
reasons, not least of which is that the number of compounds which exhibit 
phosphorescence is small, and very low temperatures <8010 are required 
for significant emission. Since the process of phosphorescence involves 
a spectroscopically forbidden transition, the decay to the ground state is 
slow and the compound will continue to emit radiation for some time after 
the Initial excitation, limiting its analytical applications C613.
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This technique is based on competition between labelled and 
unlabelled forms of the analyte for a limited number of antibody binding 
sites [62], If a known amount of radiolabelled analyte is added to an 
unknown sample and allowed to equilibriate with a small amount of 
antisera, then some of the antibody binding sites, Ab, will be occupied by 
the labelled antigen, Ag*, and some by the unlabelled antigen, Ag, As 
there are less antibody binding sites than antigen molecules, some of 
both the labelled and unlabelled antigen will remain free, or unbound to 
the antibody, as shown overleaf:
1.3,5 Radioimmunoassay
Ab + Ag + Ag*
Once the antibody bound fraction is separated from .the free fraction by 
any suitable technique, the distribution of radioactivity between the two 
fractions can be related to the amount of radiolabelled antigen originally 
added in order to calculate the amount of unlabelled antigen in the 
sample.
Radioimmunoassay methods can be applied to a large number of compounds 
providing that antibodies can be raised, and is, in general, a very 
sensitive and simple technique, requiring only minimal sample preparation 
in many cases, The disadvantages lie in the time and cost of raising the 
antisera, and also in the risk of interferences arising from metabolites
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which, being similar in structure to the antigen, also compete for the 
antibody binding sites,
There are several other immunoassay techniques which do not require the 
use of radiochemicals. These include enzyme immunoassays [633, where an 
enzyme, such as peroxidase, is used as a marker in place of the 
radiolabel, and the reactivity of the enzyme fractions are determined by 
an appropriated enzyme reaction, and fluorescent immunoassays [643, where 
a fluorescent dye is used to label the antigen. In both cases, the 
determinations can often be carried out without performing the separative 
step necessary for radioimmunoassay.
1.3.6 Chromatography
Although this is probably one of the most commonly used techniques 
for the analysis of drugs in biological fluids [65-673, it is, however, 
only a means of separation and must therefore rely on some additional 
form of detection system for quantitative analysis.
A chromatographic separation is based on the idea that, if a sample is 
passed through a stationary phase under the influence of a mobile phase, 
then partition will occur between the stationary and mobile phases 
resulting in differing components of the sample being retained to 
different degrees. The rate at which individual components move through 
the column is dependent on the relative affinity of each for the two 
phases, and hence the component which is retained least strongly in the 
stationary phase will be eluted first, and that most strongly retained,
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eluted last. The separation is therefore dependant on the nature of the 
stationary and mobile phases, and the interaction between the two,
Although the range of applications is very wide, the importance of the 
technique lies with the enhanced sensitivities achieved with 
chromatographic detection systems in comparison to that achieved by 
using a similar detector alone. Since the compounds are separated one 
from the other by the chromatography step the detectors used are, 
theoretically, only responding to individual components, thus reducing the 
possible interferences and therefore increasing the sensitivity.
There are a number of chromatographic techniques based on the nature of 
the phases involved, with the three main areas outlined below:
(i) High Performance Liquid Chromatography (HPLC), in which the 
stationary phase is linked to a solid support and packed into tubular 
columns through which a liquid mobile phase is pumped at a constant rate. 
Both the stationary and mobile phases can be altered to achieve the 
separation.
(ii) Gas Liquid Chromatography <GLC), in which separation occurs between 
the stationary phase, usually a high boiling point liquid coated onto an 
inert solid support, and an inert carrier gas at high temperatures. In 
this case the stationary phase and temperature can be altered to effect 
the separation, and the samples must be easily volatalised and not 
decompose at high temperatures. To conform to these criteria, samples 
sometimes require some form of prior derivatisation.
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(iii) Thin Layer Chromatography (TLC), involves thin layers of stationary 
phase coated onto inert backing supports, such as glass plates, placed in 
a reservoir of mobile phase, which migrates across a flat surface. Both 
stationary and mobile phases can be adjusted, and better separations can 
sometimes be achieved by using 2-dimensional TLC, where the sample is 
run in one direction with one solvent system and then run perpendicular 
to this with a second solvent system. An extension of TLC is High 
Performance (HP) TLC, which uses stationary phases ox a smaller particle 
size and a narrower particle size distribution, hence increasing 
sensitivity, selectivity and resolution.
1.3.7 Polarography
Polarography is an electrochemical technique used for the 
quantitative analysis of those organic or inorganic compounds which can 
be either oxidised or more commonly, reduced, in solution by an electric 
current [683. If a fixed potential is applied across two electrodes, one 
of which was classically a dropping mercury electrode, then the current 
flowing between them is a function of the concentration of the analyte in 
the sample. The applied potential is characteristic of the sample 
molecule, being determined by the number and nature of reducible or 
oxidisable bonds, but again drug analysis may suffer from interference 3>y 
metabolites, which are likely to contain similar electroactive groups.
Thus the technique is most widely used after some form of separation 
stage, such as chromatography.
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1.3.8 Isotope Dilution Analysis
If a radio label led form of the analyte is thoroughly mixed with the 
sample, and the total analyte separated and purified, using conventional 
methods, then the specific activity of the purified material can be 
related to that of the radiolabelled analyte added, to give an accurate 
estimation of the concentration of the analyte in the sample. The method 
requires fairly large amounts of sample, and so is not commonly used in 
drug monitoring,
1.3.9 Isotope Derivative Analysis
This is a similar technique involving the reaction of the sample 
with a radiolabelled reagent, thus rendering the compound more sensitive 
to radiodetectors, As the radiolabelled reagent is normally present in 
excess, problems may arise in the separation of the compound of interest 
from the unreacted reagent and any other side products that may have 
been formed, prior to detection. Once again this technique is only rarely
used for routine drug analysis,
1.4 Methods for Enantioselective Analysis
In order to determine the pharmacological effects of enantiomeric drugs, 
it is important to develop methods capable of measuring the plasma 
concentration of each enantiomer of a racemic drug. Since the properties
of a pair of enantiomers are identical, none of the previously described
classical methods of analysis are directly applicable to chiral 
determinations.
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At the beginning of the century, the only method available for 
enantiomeric determinations aside from Pasteur's crystallisation 
techniques, was polarimetry, This involved a comparison between the 
angle of rotation of the plane of plane polarised light caused by the 
unknown mixture and that caused by the pure enantiomer. This method was 
not particularly accurate or sensitive, and prompted further work on the 
development of other methods. There are now a number of techniques 
available for the resolution of enantiomers and the method of choice 
depends on a number of criteria such as the scale of the resolution, the 
availability of reagents and the information required from the analysis. 
For large scale preparative resolutions, crystallisation is the most 
suitable choice. Other techniques such as isotope dilution analysis, 
kinetic resolutions and differential microcalorimetry provide information 
on the optical and hence the enantiomeric purity of the sample, This is 
equivalent to the percentage composition of the enantiomeric mixture, and 
hence, if the absolute concentrations of each enantiomer are required, the 
total concentration of the analyte in the sample must either be known or 
determined in a prior analysis. These methods are also based on a 
comparison between one particular property of the unknown mixture and 
that of the pure racemate, and thus are dependant on the availability of 
a suitably pure sample of the racemate,
Chromatographic techniques are more suited to the routine analysis of 
large numbers of samples, and, in addition to the determination of optical 
purity, may be used for the determination of the absolute concentrations 
of each analyte enantiomer in the sample. Muclear magnetic resonance
- 33 -
methods can also be used in this way, as can the relatively new technique 
of enantioselective radioimmunoassay.
Although these techniques can all be used to determine the relative 
concentrations of each enantiomer in a mixture, the only way that the 
absolute configurations of enantiomeric molecules can be ascertained is 
by using X-ray crystallography techniques [69,703. This is limited, 
however, to structural determinations of compounds in a crystalline state, 
which may be different from that in solution, a more relevent factor in 
biochemical and pharmacological studies.
Stereoselective determinations may be carried out on enantiomers or 
diasterearaers with or without prior separation. Those methods which 
employ some form of separation include crystallisation, chromatography 
and stereospecific reactions, while those that do not involve separation 
require simultaneous analysis of the stereolsomeric components and 
include polarimetry, nuclear magnetic resonance spectroscopy, and more 
recently, differential mlcracalorimetry.
1.4,1 Crystallisation Techniques
These techniques may be subdivided into two main groups depending 
on whether the resolution is achieved directly, or indirectly via the 
formation of diastereomers [713. Crystallisation is normally only used 
as a preparative separation step, and the attainment of optical purity 
is monitored by techniques such as nuclear magnetic resonance 
spectroscopy, thin layer chromatography or gas liquid chromatography.
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There are several different approaches to the direct resolution of 
enantiomers [72], the simplest being the method used by Pasteur with 
tartaric acid, of allowing a solution to crystallise then manually 
separating the enantiomeric forms. A variation of this involves seeding 
a supersaturated racemic solution with crystals of the pure enantiomers 
[733. Crystals form around the seed and are of the same enantiomeric 
structure of the seed crystal, thus eliminating the need for manual 
sorting E743,
More commonly used is the technique of preferential crystallisation, first 
observed by Gernes in 1866 C753, and later by Werner in 1914 [763. This 
is based on the theory that a supersaturated solution of one enantiomer 
will not crystallise in the presence of a crystal of its antipode, Thus, 
if a racemic solution is seeded with a crystal of one enantiomer, 
crystals of only that enantiomer will be farmed and the solution will be 
enriched with respect to the other. This technique is limited to 
compounds where the racemate is more soluble than the enantiomers.
The solubilities of optically active substances are affected by factors 
such as the solvent matrix, and since these techniques are based on 
solubility differences between the racemate and the pure enantiomers, the 
resolutions may be improved by the use of optically active solvents or 
co-solutes [77-793.
The resolution of a racemic mixture of enantiomers is facilitated by the 
formation of diastereomers which have several different properties that
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may be used to achieve a separation. Once separated, each diastereomer 
may be cleaved to yield the pure enantiomer together with the reactant.
The diastereomers, A+B-*. and A B+, are farmed by reacting the racemic
mixture, A±, with an optically pure resolving agent, B.+.. There are 
numerous different types of resolving agent [803 and the choice of which 
one to use depends largely on the chemical nature of the racemic mixture, 
The most widely used methods involve the formation of diastereomeric 
salts from chiral acids and bases, although Lewis acid-base molecular 
complexes, inclusion complexes and transition metal complexes have also 
been used.
The diastereomers differ, one from the other, in many physical ways 
including crystal structures, densities [8.13, melting points, enthalpies of 
fusion and solubilities, and although in some cases the densities differ 
enough to theoretically allow separation by centrifugation [823, it is the 
differences in solubilities which is most often exploited to effect a 
separation by crystallisation. It is generally the case that the greater 
the difference in solubilities between the diastereomers the easier, and 
more successful the separation [83-853.
The formation of diastereomers is not limited to dissociable salt 
complexes, it is also possible to produce covalent diastereomeric 
derivatives, such as esters and amides £863, However, due to the greater 
bond strength of covalent compounds, consideration must be given to 
prevent racemisation of the resolving agent or the mixture of 
enantiomers, if the latter is not racemic, and also to the method of
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cleavage of the covalent diastereoraers if the enantiomers are required in 
a pure form.
1,4.2 Isotope Dilution Analysis
The technique of isotope dilution analysis as used to determine the 
optical purity of an enantiomeric mixture is very similar to the 
procedure for achiral determinations. A measured amount of radiolabelled 
racemic analyte is added and thoroughly mixed with the analyte in the 
sample under test, and the total compound isolated from the sample. The 
optical purity of the sample analyte may be established by using a 
mathematical equation relating the mass and specific activity of the 
added racemate and the specific activity of the reisolated mixture to the 
mass of analyte initially in the sample [873. This method was first used 
to determine the optical purity of D- and L- amino acids in 1940 by 
Graff, Rittenberg and Foster [883, but was not recognised as a general 
technique until 1955 after work by Berson and Ben Efraim C893,
Although this technique has been successfully used to determine the 
optical purity of a number of compounds, each of the various practical 
methodologies relies on the assumption that the mass of analyte initially 
present in the sample is a known quantity. Since this is generally not 
the case, then some form of prior analysis, whether by achiral isotope 
dilution or a different method, is required to establish this, thus 
complicating the enantiomeric analysis. The technique also suffers from 
the same disadvantage as it's achiral counterpart, that is that large 
samples are required, which renders the method unsuitable to routine drug 
monitoring.
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A similar technique to isotope dilution analysis is that of the 
radiotracer method. This is used for the determination of the optical 
purity of samples of very high enantiomeric purity [90], Again, this 
method relies on measuring various specific activities which can then be 
related to the optical purity of the sample by a mathematical equation. 
The disadvantage of this method is that, in order to solve the equation 
and find the optical purity, it is necessary to know the approximate 
enantiomeric purity of the sample,
1.4.3 Kinetic Techniques
Kinetic resolution methods are based on the difference in reaction 
rates of enantiomers with chiral reagents, the rates reflecting the 
differences in activation energies of the diastereameric transition states 
[911. If a racemic mixture of an analyte A±, is reacted with a non 
stoichiometric quantity of an enantiomerically pure reactant, B+-, then the 
two reactions will take place at different rates and hence the products, 
and A-B-.-, will be formed in a ratio corresponding to the ratio of 
the rate constants for each reaction, and the residual analyte will be 
enriched with the enantiomer with the lowest rate constant,
The main experimental procedure is that of the double resolution method 
[923, a relative method performed as a two stage determination, in which 
an unknown optical purity of a substance is correlated to that of another 
substance of known composition. Initially a known amount of the analyte 
is reacted with an insufficient quantity of an enantiomerically pure 
reagent, and the specific rotation of the remaining analyte determined,
In a second resolution, a known quantity of the racemic reagent, is
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reacted, with an insufficient quantity of the optically active analyte, and 
again, the specific activity of the residual mixture, which consists of a 
non-racemic mixture of reagent enantiomers, is determined. In both cases, 
the specific rotations can be related to the respective quantities of 
reactants and yields of reactions, and the two mathematical equations may 
be solved simultaneously to give the absolute rotation of the analyte, 
from which the optical and hence enantiomeric purity can be ascertained. 
The main requirement for the success of the method is that the rotations 
of the residual mixtures of both the analyte and reagent enantiomers are 
fairly large, and thus the differences between the rate constants for each 
pair of reactions are correspondingly large in order to achieve an 
optical yield which is outside the range of experimental uncertainty, 
However, since the yield of each reaction is incorporated into the 
equations, the reactant is not necessarily required to be optically pure,
Other kinetic resolution techniques are based on employing enzyme systems 
[931, and depend on the availability of an enzyme which will react 
quantitatively with one enantiomer in the presence of a large excess of 
the other. The experimental procedures vary according to the 
determination, but often involves a volumetric determination of the 
amount of oxygen consumed or carbon dioxide evolved in the enzymatic 
reaction. Although the range of applications is limited by the problems 
which undoubtedly arise from finding a suitable stereospecific enzyme 
system, the technique is very sensitive and it is not unusual to reach 
limits of detection of less than 0,1% optical impurity.
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1.4.4 Differential Microcalorimetry
This technique, devised by Fauquey and Jacques in 1966 [94,951, is 
based on the phase relationship between the component enantiomers in an 
unkown mixture. Such a mixture can generally be classified as either a 
conglomerate, defined as an equimolar mixture of crystals of pure 
enantiomers, or a racemic compound, in which equal quantities of 
enantiomers are present in a well defined crystal lattice [961, and this 
determines the experimental procedures required to find the enantiomeric 
purity of the unknown mixture.
The analysis may be performed either directly or indirectly and involves 
measuring certain thermodynamic parameters with a differential scanning 
microcalorimeter. The enthalpy of fusion and the melting point of the 
pure racemic mixture are then compared to the temperature of termination 
of fusion of the unknown sample to yield the composition of the binary 
mixture. The direct method is generally employed for mixtures of 
enantiomers of intermediate purity and, since the precision is not high, 
is often used to monitor the progress of p resolution. The indirect 
method detects the presence of impurities which lower the melting point 
by forming a eutectic mixture with the nearly pure substance, and is only 
used for mixtures which are either of high enantiomeric purity or are 
very close to being racemic [97-993, However the method is unable to 
distinguish between whether the melting point is lowered due to the 
presence of an enantiomeric impurity in a nearly optically pure sample or 
whether it is due to a chemical impurity. The precision, however, is 
high, especially with high purity samples.
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In addition to the necessity for chemically pure samples, these methods 
also require that the compounds are thermally stable, and do not racemise 
at elevated temperatures,
1,4.5 Enantioselective Nuclear Magnetic Resonance Spectroscopy
This technique provides a means of measuring the optical purity of 
a substance without prior separation of the enantiomers or diastereomers. 
Such methods are based on the necessity for two variable parameters, one 
of which is structurally dependant but is unaffected by the concentration 
factors, and the other which, independently of structural considerations, 
varies with the concentrations of the species present. In nuclear 
magnetic resonance spectroscopy, these parameters correspond to the 
chemical shift, a structurally determined variable, and the integrated 
intensities of the resonances, which is indicative only of the relative 
concentrations present in the sample. The application of nuclear 
magnetic resonance spectroscopy to enantiomeric determinations is 
therefore based on obtaining a measurably nonequivalent, or anisochronous, 
set of signals due to corresponding groups in the two isomers. These 
signals should either be singlets or doublets and should not overlap or 
interfere with the signals due to any other part of the molecule.
There are several means by which such nonequivalence may be secured, the 
most obvious being by the formation of diastereomers [873, Since the 
analysis does not involve a separation, the ease of recovery of the 
enantiomers from the diastereomers need not be considered, and hence 
covalent derivatives are more often used. The nonequivalence may either 
arise from the enantiomeric portion of the diastereomers, or may be
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introduced by the derivatising reagent. Thus the analysis may be 
improved by the choice of derivatisation reagent,
The alternative to the formation of diastereomers prior to analysis is to 
place the enantiomeric mixture in a chiral environment, resulting in the 
occurence of diasteromeric interactions which may differ in energy 
sufficiently to cause peak splitting. In a very few cases 11003, the 
enantiomers themselves create the chiral environment, the homochiral 
interactions between the enantiomers differing significantly from the 
heterochiral interactions, thus enabling immediate analysis when bath 
enantiomers are present in a mixture of unequal amounts [101,1023.
In most cases however, the diastereomeric interactions have to be 
externally introduced into the system. In 1965, Eaban and Mislaw 
postulated that this could be achieved by the use of a chiral solvent 
[1033, and this was supported with experimental evidence by Pirkle C1043. 
It is interesting to note that it is not necessary for the chiral solvent 
to be optically pure, although the magnitude of the difference between the 
chemical shifts of the signals due to corresponding groups on each 
enantiomer is proportional to the optical purity of the solvent [1053,
The principal disadvantage of this method is that, even with solvents of 
high optical purity, the degree of separation between the signals from 
the two enantiomers is small, and often cannot be used for quantitative 
determinations.
An increasingly more popular approach is to use a chiral lanthanide shift 
reagents (LSR). A lanthanide shift reagent consists of a six coordinate
lanthanide metal complex, which, by expanding its sphere of coordination, 
accepts further ligands, thus forming a paramagnetic lanthanide complex 
with heteroatoms exhibiting some degree of Lewis basicity [106,1073. The 
mast common lanthanide shift reagents are based on europium [108,1093, 
and a review of the use of such shift reagents for the determination of 
the enantiomeric purity of a wide range of organic compounds is provided 
l>y Sullivan C1103. Although the magnitude of the enantiomeric differences 
in chemical shifts is much greater [1113, the mechanisms which give rise 
to the anisochronous signals of compounds in the presence of lanthanide 
shift reagents is similar to that which occurs with compounds in 
optically active solvents, and, as in the case of optically active 
solvents, it is not necessary that the shift reagent is optically pure,
but that again, the magnitude of the peak splitting is reduced by lower
purities. One limitation to the use of lanthanide shift reagents is that 
the relative shifting of the signals due to each enantiomer is difficult 
to predict, and, in cases where it is important to determine absolute 
concentrations of each enantiomer, standards, enriched in first one 
enantiomer then the other, would be required to establish the relative
peak order for each signal.
Determinations of optical, and hence enantiomeric purity of compounds are 
not limited to proton nuclear magnetic resonance, and the methods are, in 
general, equally applicable to 13C, iaF and 31 P.
1.4.6 Chiral Chromatographic Techniques
Since the technique of chromatography combines a separative stage 
with one of several detection systems and is also already widely used for
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low level drug analysis, it is ideally suited to the quantitative 
determination of enantiomers. Once a separation has been effected, using 
a suitable chromatographic system, then achiral detection of each 
enantiomer may be performed by classical means. As with most of the 
other techniques, the chromatographic resolution of enantiomers may be 
achieved either directly or indirectly, regardless of the type of 
chromatography employed. Direct analysis requires that the chirality of 
the solute molecule is recognised by the chromatographic sjrstem, either 
by a chiral stationary phase or by a chiral eluent in the case of liquid 
chromatography, while indirect analysis is again based on the formation 
of diastereomers prior to the chromatographic separation,
Until fairly recently, the majority of chromatographic resolutions have 
been performed indirectly, by the formation of diastereomeric derivatives 
which could then be separated using an achiral system, There are several 
disadvantages inherent in this approach, not least of which is that the 
quantitative discrimination between the enantiomers is dependant on the 
optical purity of the derivatislng reagent. It is also important to 
recognise that the diastereomers, once produced and separated, da not 
necessarily give identical detector responses,
There are two approaches to the direct chromatographic resolution of 
enantiomers, the most versatile of which is the use of chiral stationary 
phases (CSP>. Chiral separations on such phases are based on the 
formation of transient diastereomeric complexes between each enantiomer 
and an optically pure chiral selector bound to the stationary support, 
Energy differences between the two enantiomer-chiral stationary phase
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complexes cause differences in the retentions of each isomer and thus 
effect the separation. A second possibility is to include the chiral 
selector in the eluent, although this is limited to thin layer and liquid 
chromatographic systems. The mechanisms involved are similar, with the 
transient diastereomeric complexes farmed between the enantiomers and the 
mobile phase additive. The separation is achieved via the differential 
partition of the transient complexes between the mobile and stationary 
phases. In either case, there is evidence to show that calibration curves 
obtained with one enantiomer cannot necessarily be used to quantitate its 
antipode, and thus for any analysis the calibration should be performed 
with standards containing known concentrations of both enantiomers from 
which two separate curves are obtained.
1.4.7 Bnantioselective Radioimmunoassay
A relatively new and promising technique for the routine analysis of 
enantiomeric drugs and metabolites involves radioimmunoassay with 
enantiospecific antisera, This is based on utilising the natural 
enantioselectivity of a living system to raise antisera to one isomer 
which will be inactive towards the other, thus mimicking the body's 
inherent stereospecificity. Although the technique is not yet caramon 
practice, it has been successfully been used for several studies on drugs 
such as propranolol 11123, warfarin C1133 and an antimalerial agent [1143, 
The method does however suffer from similar problems of cost and 
difficulty in producing the antisera as does the achiral method, possibly 
to an even greater extent.
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1.5 Problems with Enantioselective Analysis
There are a number of problems inherent to enantioselective analysis, 
irrespective of the particular technique used, which are not applicable in 
achiral analysis, and may therefore tend to be easily overlooked. One 
such consideration is that, for those methods in which the enantiomers 
are reacted with an optically pure reagent to form diastereoraers, the 
purity of the derivatising reagent is of crucial importance to the 
quantitative results £1151. In addition to this, it is important to study 
the derivatisation reaction mechanism and conditions in detail since the 
derivatisation could cause partial racemisation of either the sample 
enantiomers or the derivatising reagent, particularly, for example, if the 
reaction proceeds through a trigonal planar intermediate. The reaction 
may also show some stereoselectivity in the rates of reaction, causing 
some kinetic resolution effects if the reaction is not allowed to proceed 
to completion, resulting in the enrichment of the mixture with the isomer 
with the fastest rate of reaction 11163. These factors could all lead to 
significant errors in the results of the determination, and thus must be 
fully evaluated prior to the analysis.
Another interesting potential source of error in chiral analysis is known 
as the enantiodifferentiating process El.173, in which a nan racemic 
mixture may, despite the absence of a chiral environment, become enriched 
in one enantiomer as a consequence of procedures such as solvent 
extraction, chemical reactions and achiral chromatography. This arises 
from dissymmetric intermolecular interactions between the two 
enantiomers, which are possibly concentration dependent.
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It is therefore important that the validation of any method, particularly 
if used for routine drug analysis, should be carried out both with known 
enantiomeric mixtures and also with the pure enantiomers, and that the 
standards used for such validation are of the highest optical purity, If 
the separate enantiomers are not available, or the purity is not 
sufficient, then the method should be validated by comparing the results 
with those obtained for the same analysis using a second technique which 
relies on different principles of resolution.
In addition to the points already mentioned, it is also important to 
consider the sample matrix when choosing the method of analysis. With 
techniques such as chromatography, impurities in the sample are not 
important providing they do not co-elute with the compound of interest, 
whereas far example with differential microcalorimetry, the presence of a 
chemical impurity would affect the results to such a degree as to render 
the technique unsuitable for anything other than chemically pure samples,
1,6 Sample Preparation
For any analysis of drugs in biological fluids, a certain amount of 
pretreatment is required to extract the drug from the sample matrix, and 
this is generally achieved by liquid extraction with an organic solvent. 
This technique involves several stages, the first of which is to adjust 
the pH of the sample to ensure that the drug is in an unionized form. An 
organic extraction solvent is agitated with the sample and partitioning 
of the drug between the aqueous and organic phases will occur. The 
majority of the unionized drug will exist in the organic phase, which can
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be separated from the aqueous layer and dried if required. For routine 
drug analysis, it is generally necessary to concentrate the samples prior 
to analysis, and this may be achieved by the evaporation of the organic 
solvent to dryness whereupon the sample residue may be redissolved in a 
much smaller volume of solvent.
There are several factors which must be investigated prior to the 
extraction of samples, the most important of which is the choice of an 
extraction solvent system, The partition of the drug between the aqueous 
and organic phases is controlled, by the relative polarities of the 
organic solvent system and the drug; a lipophilic drug will be readily 
extracted with a nonpolar solvent whereas a more polar drug will require 
a correspondingly more polar solvent, In general, since the majority of 
interfering impurities in the sample matrix are polar, the extraction 
system should be as nonpolar as is possible to extract the compound of 
interest,
Other passible extraction procedures are available, the most papular of 
which involves the use of solid phase cartridges, These are small 
cartridges containing a bonded phase on a solid silica support. The 
sample is drawn through the cartridge and the drug is adsorbed onto the 
phase, which is then sequentially washed with various solvents to elute 
the impurities, and finally eluted with a suitable solvent in a purified 
form, The separation is again a function of partition effects between 
the sample, the solid phase and the various solvents used.
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The choice of which extraction procedure to use depends largely on the 
analysis and the number and type of samples, Traditionally liquid-liquid 
extraction has been the method of immediate choice, but more recently 
solid phase extractions are becoming more popular and also more 
economically competitive.
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CHAPTER 2
CHROMATOGRAPHIC SEPARATIONS
2.1 Historical Aspects
Chromatography has been defined by IUPAC [118] as "a method used 
primarily for the separation of the components of a sample, in which the 
components are distributed between two phases, one of which is stationary 
while the other moves. The stationary phase may be a solid or a liquid 
supported on a solid or a gel, and may be packed in a column, spread as a 
layer or distributed as a film. The mobile phase may be either liquid ar 
gaseous".
The first chromatographic separations were made by Runge, who used the 
method for testing the composition of dyes and bleaches by spotting the 
mixtures onto a special paper, thus producing colour separations [119,1201 
in 1850, and also by Groppelsroder, who developed a system using strips 
of paper with one end dipped in aqueous solutions to separate coloured 
materials in solution [1211 in 1861, A more comprehensive description of 
the separation process followed much later, when Tswett used a glass 
column filled with a calcium carbonate adsorbent to separate plant 
pigments into distinctive green and yellow zones [122,1231 in 1906, He 
used the term chromatography to describe his separations, and defined the 
process by the statement "chromatography is a method in which the 
components of a mixture are separated on an adsorbent column in a 
flowing system".
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However, it was not until the early 1930's that adsorption chromatography 
began to attract more widespread interest, and was used for a number of 
separations [124,1253. Following this, a second type of chromatography, 
based on partition of the sample [between two liquids, was developed by 
Martin and Synge [126,1273. Columns of silica gel were initially used to 
support a water stationary phase, although in 1944, filter paper 
impregnated with the liquid stationary phase was used instead of the 
silica column [1283. A similar principle was later applied to separations 
involving gaseous mobile phases [1293, During this time, the technique of 
thin layer chromatography was introduced by Ismailov and Schraiber [1303, 
but the method was of little value until a more reliable mechanical means 
of producing reproducible thin layers was devised by Stahl [1313.
2.2 Theory
The theoretical aspects of chromatography were first studied by Wilson 
[1323, although prior to this an attempt had been made to establish 
several different principles of separation by Tiaelius and Claessan 
£133,1343. Much work was done to relate the column performance to 
factors such as the stationary phase particle size and the diffusion 
effects of the column £135,1363, cummulating in the development of a rate 
theory to describe the separation process by van Deemter in 1956 £1373,
Chromatography involves the separation of the components of a mixture 
by differences in the retention of each compound. Such differences are 
caused by differing partition coefficients for each compound. The 
partition coefficient is defined as the ratio between the concentration of
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the component in the stationary phase and that in the mobile phase, The 
separation depends therefore on the nature of the stationary phase, the 
mobile phase and the solute, and the interactions of each with the others. 
There are a number of equations which may be used to describe such 
interactions and relate their effect to the retention of the sample,
Possibly the mast important theoretical considerations for analytical 
purposes are the resolution and efficiency of a separation. The ideal 
chromatographic process is one in which the components of a sample form 
narrow bands which are completely resolved from one another, although in 
practice, this rarely happens.
The column efficiency is a measure of the rate at which the solute 
molecules spread out as they travel through the column, or across a 
thin layer chromatography plate, The efficiency, or number of theoretical 
plates, I, of a separation is determined by a comparison between the 
retention of a component, tF<, and its peak width, tw, or, as is more 
common, it's peak width at half the peak height, twi* (as shown in figure 
2.1), by:
I = 16 (trc/tw ):2 = 5.54<WW>*
However, it is sometimes better to determine the number of effective 
plates for the column, as this gives a snore accurate measure of the 
efficiency. The effective plate number is based on the corrected 
retention of the solute, tw', and therefore takes account of the retention 
of the unretained peak, to, since
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Thus, the effective plate number, Nett, is always less than the 
theoretical plate number, and is given by:
W e  f  f  =  5 , 5 4  <tR VtwMs)2
The effective plate number is a useful parameter for the comparison of 
efficiencies of similar columns with the same stationary phase, however 
it is more common to use the height equivalent to a theoretical plate, or 
plate height, H, for such comparisons, since this is independent of the 
length of the column, L:
H = L/N
Efficient separations are therefore characterised by sharp, narrow peaks 
giving a high plate number and a low plate height.
A general theory of factors contributing to band spreading was developed 
by Giddings [138] which assumes that the progress of molecules through 
the column is a succession of random stops and starts and that 
dispersion, and hence band broadening, increases with the number of 
transfer steps. The plate height, H, is used to express 
the resultant effect of the various band broadening processes via the van 
Deem ter equation:
t R‘ = t R-to
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H = A + (B/u) + CsU + CmU
where u is the average linear velocity.
The first term represents the eddy diffusion, and relates to the variable 
unequal paths of the molecules around the stationary phase or support 
particles. This is a function of the mean particle diameter, d;
A = Xd
where X is a coefficient reflecting the column geometry and uniformity of 
packing, The second term describes band broadening due to longitudinal 
diffusion, and is related to the degree of obstruction, or hindrance to 
diffusion of the column packing, K;
B = 2KDm
where Dm represents the solute diffusion in the mobile phase. This term 
is more important in gas chromatography since the diffusion coefficients 
of salutes in gases are much greater than those in liquids. The last 
terms describe the resistance to mass transfer effects. Those effects 
occurring at the solute-stationary phase interface are a function of the 
diffusion coefficient of the salute in the stationary phase, D®, and the. 
thickness of the film of stationary phase on the support, d®, and that 
caused by the resistance of the packing material particles to radial mass 
transfer is related to the particle diameter, d p ,  and the diffusion 
coefficient of the solute in the mobile phase, Dm:
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Cs = d:=:s /Ds- Cm — dp'"'1 /Dm
The average linear velocity, and hence the flow rate, must therefore be 
adjusted to compromise between each factor in order to obtain the optimum 
efficiency, and the variation of the plate height with the average linear 
velocity is shown in figure 2.2
Band broadening effects, particularly in liquid chromatography, are not 
limited to the column, and may occur throughout the rest of the system. 
Although the injection and detection system contribute, the major factor 
causing extra-column band spreading is the connecting tubing, with the 
broadening effects, av, related not only to the length of the tubing, but 
also to the radius [139,1403:
avs  a l r A
The resolution is a measure of the degree of separation of successive 
salute bands, and is given by the ratio of the separation of the peak 
maxima to the broadness of the peaks, or the mean of the peak widths:
R t;= : = 2 (treB" treA > /  (tw A  +  tw 1 3  >
Since resolution is also dependent on the relative retentions of each 
compound, and therefore the relative partition coefficients, It, a 
separation or selectivity factor, a, can be defined, where
a = Kb /Ka
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The Effect of Variation in the Mobile Phase Velocity 
on the Column Efficiency
Plate Height <H>
Figure 2,2
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However, as the partition coefficient for a given solute in a particular 
stationary phase is generally unknown, the capacity factor, k', which may 
be determined from the chromatogram, is more often used, thus
a = k * 7 W
The capacity factor is the ratio of the number of moles of solute in the 
stationary phase to that in the mobile phase, and for any component,
k '  =  < t R - t o ) / t o
The efficiency of the column also has an effect on the resolution of the 
separation, since less band spreading results in a smaller peak overlap, 
This relationship is summarised in the Purnell equation:
Ss = [1**74] [<a-l>/oc3 DteV dtk*')]
This clearly shows that the resolution can be improved either by altering 
the thermodynamics, which will in turn affect the selectivity and 
capacity factors, or by changing the column conditions to give a higher 
efficiency, The resolution can also be expressed as a function of the 
effective plate number, since
I* ft = [kVCl+kOFN
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Thus the Purnell equation becomes:
R s  =  CNb * / 4 3  [ < o £ - l ) / a l
Other factors which affect the resolution of a separation include the 
temperature, since all the parameters which control the efficiency of the 
column are temperature dependent, and also the capacity of the stationary 
phase in relation to the amount of sample introduced. This will have an 
indirect effect on both efficiency and resolution, since exceeding the 
capacity of the phase by sample overloading will result in poor peak 
shape and a possible modification of the retention times. The sample 
capacity is dependent an factors such as the surface area and available 
volume of the stationary phase as well as its chemical nature.
Although the theoretical considerations such as efficiency and resolution 
are common to all types of chromatography, each different technique 
requires different considerations. For example, in liquid chromatography 
there are a number of mechanisms by which a separation may be effected 
whereas this is not the case for gas chromatography. However, the latter 
often requires same form of derivatisatian prior to the analysis in order 
to increase the volatility of the sample, and there are a number of 
different reactions which may be used to achieve this,
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2,3 Chromatographic Techniques
A liquid chromatographic separation may be classified into several 
categories depending on the mechanism involved: for partition 
chromatography the stationary phase is a liquid, adsorption 
chromatography occurs with a solid stationary phase, for ion exchange 
chromatography the stationary phase carries a net charge and the 
separation involves the exchange of one ionic species for another and in 
exclusion chromatography the separation is achieved according to the 
different molecular sizes of the analytes. Of these different types, 
partition is the most common, and may be carried out in one of two 
modes; either reverse phase or normal phase depending on the polarities 
of the stationary and mobile phases. Reverse phase chromatography 
utilises a non polar stationary phase in conjunction with a polar eluent, 
whereas for normal phase separations, a polar stationary phase is used 
with a non polar eluent.
A typical high performance liquid chromatography system is shown in 
figure 2.3, The injection system ma.y either take the form of a manual 
loop injector or an autosampler, In each case a fixed volume loop is 
filled with the required injection volume of sample and, upon injection, 
the eluent flow is redirected through the loop and the sample carried 
onto the column. The type of detection used depends on the nature of the 
analyte and the concentration range of interest, Those most commonly <■ 
used are ultraviolet, fluorescent and electrochemical detectors, although 
others include mass spectrometric, refractive index, electron capture and 
infra red detectors.
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Basic Components of a Typical HPLC System
Figure 2.3
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There are significantly less modes of gas chromatography than liquid 
chromatography, and the separation is achieved either through gas liquid 
partition or gas solid adsorption, although use of the latter is less 
common. In addition to packed column gas chromatography, where the 
liquid phase is coated onto a solid support and packed into glass or 
stainless steel tubular columns, gas liquid chromatography may also be 
performed on capillary columns, where the inner surface of a long length 
of capillary tubing is coated with the liquid stationary phase, thereby 
increasing the efficiency.
The two main requirements for gas chromatography are that the stationary 
phase must be stable at elevated temperatures and that the samples are 
gaseous at the working temperature of the column. If the column 
temperature is too high the stationary phase will begin to bleed, or be 
stripped off the support resulting in the loss of performance of the 
column, Hence there are maximum operating temperatures for each column, 
and if the sample is not sufficiently volatile at temperatures below this, 
then derivatisation prior to analysis will be required,
There are a number of different reactions which may be used to increase 
the volatility of the sample, the three most commonly used being 
silylation, involving the replacement of an acidic hydrogen with an 
alkylsilyl group, acylation, which is used to derivatise alcohols, phenols 
and amines using, for example, trifluoroacetic anhydride, and alkylation, 
in which an alkyl group is added to an active functional group.
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As in liquid chromatography, there are a number of detectors which may 
be used in gas chromatography. The two types most commonly used are 
flame ionization detectors and electron capture detectors, although 
various other detection systems are also used and include katherametric, 
conductivity, flame photometric and nitrogen phosphorus detectors in 
addition to mass spectrometry, and again, the choice of which to use 
depends on the sample under analysis and the concentration range.
It can therefore be seen that, owing to the large number of variable 
parameters, chromatographic methods have a very wide range of 
applications, and it is due to such versatility that the technique of 
chromatography lends itself so readily to the analysis of optical 
isomers.
2.4 Separation of Enantiomers
As has previously been mentioned, the chromatographic analysis of 
enantiomeric compounds may be performed by one of two approaches; 
indirectly, via diastereomeric derivatisation prior to the analysis, or 
directly, using a chiral chromatographic system.
The idea of separating enantiomers by the formation of diastereomeric 
derivatives is not new, and was used before the development of 
chromatography for resolution techniques such as crystallisation. Since 
diastereomers are physically and chemically different, they are easily 
separable on achiral columns. However, in contrast to this, problems may 
arise in the derivatisation stage. The enantiomeric purity of the reagent
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is critical to the quantitative formation of the derivatives and, in 
addition to this, if partial raceraisation or kinetic fractionation occurs 
during the reaction, the product diastereomers will not necessarily be in 
the same ratio as the original enantiomers. Despite this, however, there 
have been a large number of successful applications of this approach to 
the separation of isomers, using both high performance liquid 
chromatography [141-1561 and gas liquid chromatography [157-1621, and 
also less commonly, thin layer chromatography [163,1641.
More recently, the use of chiral chromatographic systems for 
enantioselective analysis has became more prominent, generally involving 
the use of chiral stationary phases. The separation is then achieved by 
the formation of transient diastereomeric complexes between the 
enantiomers and a chiral selector which is bound to the silica support. 
Due to the different spatial arrangements of the composite atoms, the two 
diastereomeric complexes will have slightly different internal energies 
and stabilities, which will cause one enantiomer to be eluted in advance 
of the other, and hence the degree of separation is largely dependent on 
the magnitude of the energy difference between the two complexes. A 
similar effect may be achieved by adding the chiral selector to the 
mobile phase. Transient diastereomeric complexes are farmed between the 
optically pure mobile phase additive and the solute enantiomers, which 
can then be resolved on an achiral stationary phase.
Although the majority of work using this approach has taken place in the 
last twenty years, the first direct chromatographic resolution was 
reported in 1938, involving the partial resolution of an enantiomeric
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chromium complex on an adsorption column of powdered quartz [165]. This 
was fallowed by resolutions of racemic (±)-p-phenylene-bis-iminocamphor 
[166,167] and Trogers base [168] on an adsorption column containing solid 
(t)-lactose. Better separations were observed by Senoh [169] in 1951, 
with the use of paper chromatography to analyse amino acids. The paper 
was found to be chiral because of both the helicity of the cellulose and 
the glucose content of the paper. This work was extended by Dalgleish, 
who, by studying the effect of the structural variations on the resolution 
and retention of amino acids, was able to postulate a mechanism by which 
such stereoselectivity may occur [1701. He stated that three simultaneous 
interactions between the chiral selector and the enantiomers are 
necessary for chiral recognition, since any two could be equally well 
maintained by either enantiomer. Although this was not the first 
statement of the three point rule [171], it marked an important 
development, and was later to become one of the most crucial factors in 
the design of specific chiral stationary phases. The first practical 
application of this theory was in the separation of the enantiomers of 
dihydroxyphenylalanine, where models were used to show that a stationary 
phase based an 1-a.rginine would allow three interactions with the 1- 
isomer but only two with the d- isomer [172], This approach to the 
design of enantioselective stationary phases has now become universally 
accepted, and much work has been done to ascertain the mechanisms and 
sites of interactions between the solute enantiomers and the various 
phases. Notable in this area is the work of Pirkle, who has established 
a number of chiral stationary phases, and rationalised the separation 
mechanisms for each.
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The increased interest in chiral separations is reflected in the 
development of a large array of chiral stationary phases for high 
performance liquid chromatography, gas liquid chromatography and also 
thin layer chromatography. Since liquid chromatographic methods are more 
commonly used for routine analysis, this has led to a wider range of 
commercially available high performance liquid chromatography columns 
than either gas liquid chromatography columns or thin layer 
chromatography plates, although many separations have been achieved on 
specifically designed and synthesised phases by all three methods,
2.5 Enantioselective Stationary Phases for HPLC
C o m r o e n x a U -
The firstAchiral stationary phase for high performance liquid 
chromatography was introduced by Pirkle in 1981 [173], although 
separations using enantiomeric phases had been achieved prior to this, 
lore recently, a wide range of different chiral stationary phases have 
been developed, thus reversing the original problem of adapting the 
analyte to suit the phase, to one of selecting the best phase for a 
particular analysis. A selection of commercially available chiral 
stationary phases for high performance liquid chromatography is 
summarised in table 2.1 and the scope of such phases is the subject of a 
number of reviews £174-178], In spite of the increasing popularity of 
the commercially available phases, a considerable number of separations 
have been achieved on novel synthesised phases, designed to suit a 
specific analyte or range of analytes.
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Commercially Available Liquid Chromatographic Chiral Stationary Phases
PHASE TYPE
Chirace1 OA 
Chirace1 OB 
Chiracel OC 
Chirace1 OD 
Chirace1 OE 
Chirace1 OK 
Chiralpak OT 
Chiralpak OP 
Chiralpak WH 
Chiralpak WM 
Chiralpak ¥E 
Crownpak CR 
Enant i opac 
Resolvosil 
Jfucleosil 
Conbriotac 
LC-<R)"Urea 
Phenylglycine 
Leucine 
lapht hy1alani ne
Cellulose triacetate 
Cellulose tribenzoate 
Cellulose tris(phenylcarbamate)
Cellulose tris(3,5-dimethylphenylcarbamate)
Cellulose tribenzyl ether
Cellulose tricinnamate
Palytriphenylmethylmethacrylate
Poly <2-pyridyldiphenylraethylmethacrylate)
Proline copper complex
Amino acid copper complex
Crown ether 
oc-Acid glycoprotein 
Bovine serum albumin
Cellulose triacetate
<3,5-Dinitrobensoyl) phenylglycine 
<3,5-Dinitrobenzoyl) leucine
Table 2 . 1
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SUPPLIER
Daicel/
Baker
LKB
Hichrora
Hichrom
EDT
Supelco
Regis/
Baker/
lHichrom
Despite of the wide range of phases available, it is still necessary, in a 
number of cases, to derivatise the sample prior to the analysis. Such 
derivatisation is generally performed in order to reduce the polarity of 
the solute molecules, particularly for strong acids and bases, although it 
may also be used in order to introduce specific functional groups to 
facilitate the required number of interactions, Distinction should be 
made, however, between chiral derivatisation, leading to the formation of 
diastereomers, and achiral derivatisation, which serves only to alter the 
retention characteristics of a solute an a chiral stationary phase. As 
has previously been mentioned, the former approach may give rise to a 
number of problems when used for quantitative analysis, whereas the 
latter, since it is performed with achiral reagents, does not suffer from 
the same disadvantages.
With such a wide range of phases available, either commercially or by 
synthesis, some form of classification was required in order to 
rationalise the selection of a column for a particular analysis. In 
response to this, a system was devised by Wainer based on the mechanisms 
involved in the chiral resolution. Initially the system centred on four 
classes C1793, but this was later expanded to five [1803, However, in the 
latter scheme, the division between two of the categories, namely types 2 
and 3, do not appear to be well defined, and therefore, for the purposes 
of this discussion, the original classifications have been adapted.
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The stereoselectivity of phases of this type is dependent on 
specific polar interactions between the chiral selector and the salute 
enantiomers, A minimum of three interactions are required, and these may 
be hydrogen bonding, re-re interactions, steric effects and dipole dipole 
interactions [181,1821
The most common commercially available columns of this type are the 
Pirkle phases, which can be subdivided into two types; re-electron 
acceptors such as the dinitrobenzoyl derivatives of phenylglycine and 
leucine (see figure 2.4), and re-electron donors such as naphthylalanine. 
These phases can be used for a wide range of compounds, but the analytes 
often have to be derivatised prior to the analysis, both to provide 
suitable interaction sites and to reduce the polarity. In order to 
achieve good separations on a re-electron accepting phase the salute must 
contain a re-electron donating group, and conversely, a re-electron 
accepting group is necessary for analytes separated on a re-electron 
donating phase. Such reciprocity has been used, particularly by Pirkle, 
to develop a number of additional phases [183-1901.
The re-electron accepting phases are available in several forms, depending 
on whether the banding of the phase to the silica support is ionic or 
covalent, and each has markedly different properties. It is generally 
difficult to assess which of the four phases will give the best 
separation, and various studies have been made to compare the covalent 
and ionic versions of the same phase [1911 and the phenylglycine and 
leucine phases [192-1961. The Pirkle phases, particularly
2.5,1 Type 1 Phases
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Examples of a Type 1 HPLC Phase
3,5-Dinitrobensoyl Phenylglycine
3,5-Dinitrobenzoyl Leucine
Figure 2.4
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(3,5~dinitrobenzayl)-phenylglycine, have a wide range of applications 
[197-1993 including various chiral pharmaceuticals [200-2063 and 
enantiomeric polycyclic aromatic hydrocarbons and their metabolites [207- 
2113,
Other commercially available chiral stationary phases of this type 
include the Sumipax range, which, although used for several applications 
[212-2153, is overshadowed by the success of the Pirkle phases. This is 
also true for the LC-<5>-Urea phase marketed by Supelco.
Due in part to the ease of design of these phases, a large number of 
separations are carried out on novel, or specifically synthesised phases 
of this type, such as those based on hydantoin and arylalkylamlnes [2163, 
which were developed to be re-electron donors by the reciprocity 
principle. In addition to this, a number of other chiral selectors have 
been used as chiral stationary phases [217-2263, including those based on 
amide derivatives [227-2333 and urea derivatives [234-2363. A phase has 
also been recently developed incorporating both a re-acidic <3,5- 
dinitrobensoyl) phenylglycine group and a re-basic 6,7-dimethylnaphthyl 
group C2373 which may prove to be mare widely applicable than either of 
the two individual phases.
These types of phases have also been successfully used in conjunction 
with supercritical fluid chromatography [238-2423, whereupon the low 
viscosities of the supercritical fluids together with the correspondingly 
higher diffusion coefficients allow the technique to be run under mare 
optimal conditions than HPLC, thus improving the resolution and reducing
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the analysis time. Other attempts to improve the separations include 
using the chiral phase in series with a racemic or achiral column [2433, 
and performing chiral derivatisations prior to the analysis [244,2451, 
since diastereomers are more readily resolvable on a chiral phase than 
enantiomers.
2.5.2 Type 2 Phases
The mechanism proposed for chiral stationary phases of this type 
involves the entry of enantiomers into chiral cavities within the 
structure of the phase. Differences in the fit of the two enantiomers in 
the cavities together with the possibility of hydrogen bonding and steric 
interactions affect the stability of the inclusion complexes formed, and 
result in the stereoselective retention of the enantiomers.
Phases of this type can be subdivided into three main categories; 
cellulose or cellulose derivatives, cyclodextrins and synthetic polymers, 
and although each shares a common separation mechanism, the retention 
characteristics and range of applications of each is different.
The earliest phase of this type was cellulose, which has been used for a 
number of resolutions, particularly of polar compounds such as amino 
acids [246-2483. However, it was soon discovered that the derivatives 
have a higher resolving power, and are therefore more generally used.
The first derivative to be used was triacetylcellulose, a phase which in 
spite of having low separation factors, is applicable to many racemates 
[249-2523. This was then followed by the introduction of a wide range of 
derivatives including cellulose tribenzoate [253-2573,
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Cellulose Derivative HPLC Phases
cellulose tris(phenylcarbamate) C258-2603, cellulose tris(3,5- 
dimet hylphenylcarbamate) [261,2621 and a number of other similar phases 
[2631. The structures of the cellulose derivatives are shown in figure 
2.5. Separations on these phases may be effected with either polar or 
non polar eluents, although the samples may sometimes need to be 
derivatised to avoid strong acids or bases. The phases may also be 
prone to irreversible adsorbtion, and so biological samples should not be 
injected directly onto the column.
Cyclodextrins are cyclic oligoglucose molecules which have structures 
resembling open ended cones (see figure 2.6). The interior of the toroid 
is relatively nonpolar E2643, while both the larger and smaller ends are 
rimmed with secondary and primary hydroxyl groups respectively. 
Stereoselectivity is achieved through the formation of inclusion 
complexes, whereby the lipophilic part of the solute molecule fits into 
the cavity and the other substituents about the chiral centre undergo 
asymmetric interactions such as hydrogen bonding and steric interactions 
with the polar rim. There are a number of factors affecting the binding 
strength of the inclusion complexes [2651 but in general, the enantiomeric 
solute will form two complexes of different stabilities, and hence one 
isomer will be preferentially retained. There are three types of 
cyclodextrin used for chromatography, depending on the number of glucose 
units present, and hence the size of the cavity can be chosen to suit 
the solute requirements. The most popular is JJ-cyclodextrin, consisting 
of seven glucose units and tliis has been used for the resolution of a 
number of pharmaceuticals [266-2703 and other compounds C271-2753 
including metallocene enantiomers [2763. The other two cyclodextrins are
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Inclusion Complex Formation with a Cycladextrin HPLC Phase
Figure 2,6
or-cycladextrin, which, comprising of six glucose units, is the smallest 
and is mainly used for the separation of amino acid enantiomers 
[277,2783, and V-cyclodextrin, which, with eight glucose units, is only 
suitable for very large molecules. Cycladextrin phases can be used with 
mobile phases of any polarity, they are most commonly used in the 
reverse phase mode, and in fact, the formation of inclusion complexes is 
only possible in aqueous solutions. The retention is controlled by 
organic modifiers such as methanol and acetonitrile, the pH and ionic 
strength of buffers and temperature, Although inclusion complexing is 
the primary mechanism, interactions with the silica support, or the 
connecting spacer can also affect the resolution, particularly with less
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polar eluents, In addition to enantiomeric separations, many geometrical 
isomers are easily resolvable on cyclodextrin phases [279,280]
The most common synthetic polymer phases are based on polymethacrylates, 
Such phases are novel in that their chirality arises purely from the 
helicity of the polymer structure. Two phases of this type, (+)-poly 
(triphenylmethylmethacrylate) and <+)-poly (2-pyridyldiphenylmethyl 
methacrylate) are commercially available, and show good selectivity for 
many samples [281-2853, particularly those with a rigid nonplanar 
structure, although again, strong acids and bases should be avoided.
More recently, another phase, based on a crown ether chiral selector has 
become available, which falls into this category. This phase was first 
used by Cram and co workers in 1975 [2863, but did not find widespread 
application at that time. The phase is best suited to the resolution of 
amino acids [2873 and other compounds with a primary amino group close 
to the asymmetric centre. These phases are used in conjunction with an 
aqueous acidic eluent, and the retention is largely dependent on the 
hydraphobicity of the analyte, hydrophilic solutes being less strongly 
retained than hydrophobic ones.
2.5.3 Type 3 Phases
Separations of this type are based on the principle of ligand 
exchange chromatography and depend on the formation of diastereomeric 
ternary complexes involving a transition metal, a single enantiomer of a 
chiral molecule and the racemic analyte. Such phases were introduced by 
Davankov in the early 1970's [2883, who used a stationary phase of 1-
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praline immobilised onto chlaramethylpalystyrene loaded with either 
capper, sine, nickel or cadmium ions to separate various amino acid 
enantiomers, and later transferred to silica based columns by Giibits 
[2893.
Commercially available columns of this type include Chiralpak WH and 
Chiralpak WE (see figure 2.7).
The mast commonly used transition metal for ligand exchange is capper, 
and the selector ligands are generally amino acids. The analytes are 
limited to those which have polar functional groups with the correct 
spacing which can simultaneously act as ligands to form coordination 
complexes with the transition metal. Steric repulsion and additional 
interactions such as hydrogen bonding within the complex cause the 
diastereomers to differ in stability, thus effecting the separation, The 
retention and resolution of the analyte may be regulated by changes in 
the pH and the amount of organic modifier in the eluent, and increasing 
the temperature also improves the resolution.
Ligand exchange chromatography is generally only suited to the resolution 
of amino acids [290-2983, although separations of aminoalcohols and 2- 
hydroxy acid enantiomers have also been achieved [299,3003. There are 
several disadvantages to this technique, not least of which is the 
complexity of the mobile phase, which must contain small amounts of 
copper salts to prevent a nett loss of the ion from the stationary phase. 
In addition to this, chiral selectors only give good resolutions for a
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limited number of compounds, and closely related enantiomers may prove 
difficult to separate,
2.5,4 Type 4 Phases
The resolution mechanism on protein type phases is not fully 
understood, but is based on the stereoselective binding of enantiomeric 
compounds to plasma proteins, and is influenced by hydrophobic 
interactions, steric effects and interactions of the polar groups.
The first use of a protein based column for chromatographic separations 
was by Stewart and Doherty [3011, who used bovine serum albumin bound to 
agarose for the separation of tryptophan enantiomers. This was further 
developed by Allenmark, who succeeded in immobilising the protein on a 
silica support, thus improving the column stability [302], Similarly, 
Hermansson developed a phase based on a i-acid glycoprotein bound to a 
silica support [3033
Both phases are commercially available and are particularly suitable for 
the analysis of enantiomeric pharmaceuticals, most of which require no 
prior derivatisation, In general, albumin is the principle plasma binding 
protein for weakly acidic drugs, and is used for a number of resolutions 
[304-3063 particularly amino acids and their derivatives [307-3093. 
Conversely, cc-i-acid glycoprotein is the major binding protein for basic 
drugs, and is therefore widely applicable to the separation of a number 
of enantiomeric pharmaceuticals [310-3153 including amino alcohols [316- 
3183. A comparison of the enantioselectivity of both phases has been 
made, together with several other similar phases E3193
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Protein phases are compatible with aqueous mobile phases, but the 
separations are sensitive to changes in chromatographic conditions such 
as the pH and ionic strength of aqueous buffers, the concentration of 
organic modifier in the eluent and the temperature. Although the 
selectivity of such phases is excellent, the efficiencies are often poor, 
and, as the loading of the protein an the silica support is also lav/, the 
sample capacity is limited and the columns are easily overloaded.
2.6 Chiral Mobile Phases for HPLC
As an alternative to using chiral stationary phases, there exists, in 
liquid chromatography, the possibility of including the chiral selector in 
the mobile phase, thus allowing enantiomeric separations to be performed 
on achiral phases. Such mobile phase additives have the advantage that 
the chiral selector can be chosen from a wide range of suitable reagents, 
and easily changed if necessary to improve the resolution, a flexibility 
which is not readily achieved using a chiral stationary phase. In 
addition to this, a reversal of the elution order of the enantiomers can 
generally be obtained by the use of the optical antipode of the chosen 
selector.
The separation mechanisms involved in this approach are not so well 
defined as for resolutions on chiral stationary phases, but are thought 
to depend on the relative affinities of the chiral selector for the 
stationary phase and the solute enantiomers, In extreme cases, the 
selector may either be strongly adsorbed on the silica support, forming 
in effect a chiral stationary phase, or involved in the formation of
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diastereomeric complexes with the solute in the mobile phase, whereby the 
separation takes place as a normal liquid chromatographic separation of 
diastereomers. However, in practice, most separations fall between these 
two extremes, and a combination of these mechanisms occurs, giving a 
range of mixed retention modes.
The disadvantages of this technique are mainly centred on the detection 
system, since the choice of mobile phase additive may limit the range of 
detection methods which can be used, or vice versa, In some cases this 
may be overcome by the use of post column derivatisation to introduce for 
example, a fluorescent moiety into the salute complex. In addition to 
this, since the enantiomers are eluted from the column as diastereomeric 
complexes which, due to their different physical properties, may give 
different detector responses, individual calibration curves are required 
for each enantiomer. Following an from this, if the separations are 
performed on a preparative scale, problems may arise in isolating the 
optically pure solute enantiomers from the chiral selector.
One of the most commonly used methods for resolutions using chiral 
mobile phase additives is by ligand exchange chromatography. This was 
first used by LePage E3201 and Gil-Av E3213 to overcome the problems of 
producing ligand exchange chiral stationary phases experienced at that 
time, and was later the subject of a more detailed study by Davankov 
£3221. The formation of ternary transition metal complexes is similar to 
those achieved on a ligand exchange chiral stationary phase, with both 
the chiral selector ligand and the transition metal dissolved in the 
eluent, Such additives are generally used to resolve amino acids [323-
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3333, although various amines have also 3:>een resolved in this way [334- 
3363.
Chiral ion pair reagents can also be used as mobile phase additives to 
resolve oppositely charged racemates by normal phase chromatography.
This technique was first used by Pettersson and Schill for the resolution 
of amino alcohols using (-O-TO-camphorsulphonic acid as the chiral 
counter ion [3373, and although further work centred on the resolutions of 
amino alcohols [336,3393 and other compounds [340,3413 with 10- 
camphorsulphonic acid, other ion pair reagents were soon investigated, 
and quinnine and quinidine in particular were found to be suitable for 
resolving acids E342-3443. Improved results have also been achieved 
using N-benzoylcarbonyl-glycy1-proline (ZGP) C3453, Although the use of 
chiral counter ions has proved to be successful in a number of cases, 
such resolutions are not always easy to achieve, and are influenced by a 
number of factors. Of crucial importance is the water content of the 
mobile phase, with the recommended proportion being 80-90 ppm [3463. 
Concentrations above this impair the resolutions, but small amounts of 
water are necessary to deactivate the silica surface, which would 
otherwise adsorb the polar components too strongly. The surface 
properties of the polar silica are also important and it has been found 
that the hydrophilic properties of dial phases are best suited to 
resolutions of this type [3463. In addition to this, the capacity ratios 
of the enantiomers decrea.se with increasing counter ion concentrations, 
due to competition between the solute complexes and the counter ions for 
adsorption sites on the phase, and increasing the concentration of polar 
components in the eluent causes a decrease in the retention, and hence
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the resolution, of the enantiomers. It is interesting to note, however, 
that the optical purity of the ion pair reagent affects only the 
separation factor of the enantiomeric complexes, and therefore 
quantitative analysis can still be achieved in situations were the chiral 
counter ion is not completely pure [3473.
Enantiomeric resolutions can also be performed by the addition of 
inclusion complexing agents to the mobile phase, and in fact, one of the 
first resolutions involving the use of a chiral mobile phase additive was 
achieved using an eluent containing a chiral crown ether to separate 
racemic amino esters C3483. Recently, however, the majority of 
resolutions of this type use cyclodextrin as the inclusion complexing 
reagent with reverse phase chromatography conditions. These inclusion 
complexes are similar to those formed using a cyclodextrin stationary 
phase, but the retention mechanism is more complicated. In some cases, 
resolution is achieved by differences in the stability of the two 
complexes, Implying that the cyclodextrin is adsorbed onto the the 
achiral phase, while in others, the resolution is achieved by differences 
in the interactions between the achiral phase and the part of the solute 
enantiomer protruding from the cyclodextrin cavity [3493. As with the 
cyclodextrin stationary phases, ^-cyclodextrin is the most commonly used 
additive [350-3523, although several studies have compared the 
stereoselectivities of a~f j3~ and "tf-cycladextrins far the resolution of 
chiral barbiturates and norgestrel enantiomers [353,3543
Other mobile phase additive include those developed to undergo 
enantioselective hydrogen bond interactions with the chiral solute, Such
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selectors, particularly N-acetyl-L-valine-tert butylamide, may be used for 
normal phase separations [355-357], and are generally thought to be 
strongly adsorbed onto the silica surface. Resolutions of racemic drugs 
[358] and other compounds [3591 have also been achieved on achiral 
stationary phases using buffered eluents containing a t-acid glycoprotein.
2.7 Chiral GLC
The first successful gas chromatographic resolution with an optically 
active stationary phase was performed by Gil-Av in 1966 [3603, using 
glass capillary columns coated with N-trifluoroacetyl-L-isoleucine lauryl 
ester to separate racemic N-trifluoroacetyl-amina acid esters. Further 
work was done to establish a theoretical base for the separations [361- 
3643, and also to determine the structural features responsible for the 
stereoselective effects [365,3663, This knowledge, coupled with the need 
to increase resolution, efficiency and thermal stability led to the 
development of a number of new phases which were originally classified 
into three types [367,3683.
The dipeptide phases, introduced by Gil-Av and Feibush, are used mainly 
for highly volatile amino acid derivatives [369-3733. and derived from 
these are the diamide phases which contain two thermally stable amide 
functions around one asymmetric centre, thus giving greater 
stereospeclficity [374-3833, The third type of phase, the N,N-carbonyl- 
bis-(amino acid ester) phases, were originally developed to increase the 
probability of a three point interaction around the asymmetric centre of 
the phase and thereby improving the separations, and are sometimes 
incorrectly called ureide phases [384-3893. The general structures of
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each type of phase are shown in figure 2-8. More recently, a fourth type 
of enantiomeric stationary phase has been introduced which involves the 
use of chiral metal coordination compounds for the separation of 
enantiomers by stereoselective complexation [390,3913. Hence this 
technique is particularly suited to the resolution of those compounds 
which do not possess the appropriate functional groups capable of 
hydrogen bonding as required by the other phase types [392-4003.
Although there are a large number of possible phases for enantlospecific 
gas chromatographic analysis, the number of commercially available chiral 
stationary phases is limited, and mostly fall into the diamide category. 
The two most common optically active stationary phases are Chirasil-Val, 
based on L-valine-tert-butylamide, and XE-60-S-valine-S-phenylethylamide, 
both available from Chrompaek. Similarities exist between the structures 
of the two phases, as shown in figure 2.9, although XE-60-S-valine-S- 
phenylethylamide has two chiral centres compared to the single 
asymmetric centre in Chirasil-Val, and the separation mechanisms for both 
are based on hydrogen bonding of the solute enantiomers about the chiral 
centre of the phase, Although Chirasil-Val has a slightly higher maximum 
operating temperature than XE-60-S-valine-S-phenylethylamide, each phase 
has an extensive range of applications. Both have been used to separate 
amino acids [401-4073, carboxylic acids [408-4103 and alcohols and dials 
[411-4153, Chirasil-Val has also been used to separate a range of other 
compounds [416-4223 such as tocainide [423-4253 and mephenytoin C4263, 
while XE-60-S-valine-S-phenylethylaraide has been used for various 
resolutions [427-4283 including aminoalcohols [429-4323, chiral ketones 
[433,4343 and panthenol [4353, A comparison between the two phases is
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given with respect to the resolution of the enantiomers of putrescine and 
cadaverine analogues as their N-perfluoroacyl derivatives [4363
Two other chiral gas chromatographic stationary phases are Supelco SP300, 
a phase based on n-lauryl-L-valine-tert-butylamide available from Supelco 
Inc. as bath a liquid phase and a column packing, and RSL-007 which is 
based on L-valine-tert-butylamide and available from Alltech Associates 
Inc.. Although neither phase has found common use, RSL-007 has been used 
for the resolution of fungicide enantiomers in a comparison with 
Chirasil-Val [4-373 and the interactions of SP300 have been studied by 
Feibush [4383 prior to its use for enantiomeric separations [439,4403.
Recently, a new range of stationary phases have become available, 
involving chiral selectors based on cyclodextrin derivatives. The 
separation mechanism of these phases is still the subject of debate as to 
whether inclusion complexes are formed in a similar fashion to those 
achieved in liquid chromatography [4413 or whether the separations are 
effected by dipole dipole interactions C4423. Although it was previously 
thought that an aqueous medium was required for inclusion complex 
formation, the polar solvent of the liquid phase may also provide 
sufficient energy differences to facilitate the formation of the 
complexes, and the mechanism may be determined by the structure of the 
solute. Despite the low operating temperatures of these phases, they have 
been successfully used far a number of applications C443-4473, and are 
likely to become more popular.
It is also interesting to note that, in a similar fashion to liquid 
chromatography, an attempt has been made to include the chiral selector 
in with the gaseous mobile phase C4481.
2,8 Chiral TLC
Mention must also be made of the technique of thin layer chromatography 
since, although the popularity of this approach is limited, almost 
certainly due to the difficulties in both quantitation and automation, 
there are a number of advantages, One such point is that thin layer 
chromatography can be used as a. rapid and simple means of checking the 
enantiomeric purity of a compound, but more importantly, thin layer 
chromatography may be used to provide a relatively inexpensive 
preliminary assessment of a separation for high performance liquid 
chromatography on a similar phase.
The only commercially available thin layer chiral stationary phase, 
Chiralplate, is based on the principle of ligand exchange chromatography, 
with the chiral selector, (2S,4R,2,RS)-4~hydroxy-l-(2-hydroxydodecyl> 
proline, coated onto a silica support and impregnated with copper ions. 
The plates have been used extensively for the separation of amino acids 
[449-4511, and resolutions have also been achieved for penicillamine 
[452,453], 3,4-dihydroxyphenylalanine C4543 and chiral dipeptides [4553. 
Such applications are the subject of a recent review by Gunther [4563,
Other chiral stationary phases for thin layer chromatography include a 
|3-cyclodextrin phase, used for the resolution of a number of optical,
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geometrical and structural isomers £4571, and a Pirkle type
3,5-dinitrobenzoyl phenylglycine phase [458], the enantioselectivity of 
which is tested using 2,2,2-trifluaro-l- (9-anthryl)ethanol.
Despite the emphasis on the use of chiral stationary phases, there is no 
reason to assume that enantioselective thin layer chromatography could 
not also be performed using chiral mobile phase additives in a similar 
fashion to high performance liquid chromatography,
Thus, there is an extensive range of techniques by which the 
chromatographic analysis of enantiomers may, in theory, be achieved. 
However, stereoselective separations, in practice, are not generally easily 
accomplished, and are often time consuming and expensive. The 
sensitivity of the resolution to minor fluctuations in chromatographic 
conditions and the complexity of any necessary pre-column derivatisation, 
whether chiral or not, makes the application of such techniques to the 
routine analysis of large numbers of samples more difficult still.
2.9 Chiral Detection
However, a more recent development has led to the possibility of 
performing quantitative analysis of enantiomers without chromatographic 
separation, This approach is based on the use of an ultra-violet 
detector in series with a micropolarimeter. While the ultra-violet, or 
other achiral detector, measures the total concentration of analyte, the 
polarimeter measures the sum of the laevorotatory and dextrorotatory 
isomers. By a comparison of the two, the concentrations of each
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enantiomer can be established. The sample preparation and analysis can 
be carried out as if for an achiral determination, thus eliminating many 
of the aforementioned problems. Since the ChiraMonitor micropolarimeter 
has only recently become commercially available, there are few reported 
applications as yet [459-4633, although this approach is likely to become 
more popular in time, with the only limiting factor being the sensitivity 
of the detector.
2.10 Model Compounds
However the primary aim of this work was to develop methods for the 
enantioselective analysis of a number of cardiovascular drugs such as 
verapamil, propranolol and other beta adrenoceptor blocking agents, Such 
drugs are used in the treatment of angina, hypertension and arrhythmias, 
and are generally marketed and administered as racemic mixtures. The 
structures of the compounds chosen for this study are shown in figures
2.10 and 2,1 1 .
All beta blockers have at least one asymmetric centre in their molecular 
structures and evidence exists to show that their activity is highly 
stereoselective. In the case of propranolol, it has been found that the 
(S)-(-)-Q) isomer is largely responsible for the receptor antagonist 
properties [213 although in other aspects, such as their local anaesthetic 
activity, both isomers have a similar potency which is generally greater 
than that of the racemic compound. In addition to this, the <E) form is 
preferentially metabolised in man leading to 30-60% higher plasma levels 
of the mare active (S) form after oral
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administration [464,4653. Similar results have also been found for 
pronethalol, another adrenoceptive J3-receptor antagonist, where the (-> 
isomer has been shown to be 40 times as active as the (+) isomer [4663.
Verapamil is a calcium channel antagonist which is again administered as 
a racemic mixture, in which the (1) isomer is 3-10 times more active than 
the (d) form [243. It has also been found that stereoselective first pass 
metabolism preferentially reduces the plasma levels of the more active 
(1) verapamil following oral administration, thus increasing the 
bioavailability of (d) verapamil [303.
Verapamil enantiomers, together with those of pronethalol and metoprolol, 
have been successfully resolved by HPLC on a cyclodextrin column without 
prior derivatisation [2703, but better separations have been achieved for 
these and other J3 blockers using an al-acid glycoprotein phase [3173 
although in some cases this requires the formation of oxasalidone 
derivatives [4673. Propranolol has been resolved on a cellulose tris(3,5- 
diraethyIpheny1-carbamate) phase
without derivatisation E4683 and on a <3,5-dinitobensoyl)-phenylglycine 
column as an amide or an oxasolidone derivative [469,4703, The 
oxazolidone have also been resolved by capillary GLC using an XE-60-L- 
valine- (E)-oc-phenylethylamide phase [4313.
Other enantioselective separations have been achieved through the use of 
both mobile phase additives [3393 and chiral derivatising reagents, with 
the derivatives resolved by either HPLC [471-4733 or TLC [4743.
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In addition to the aforeiaentioed cardiovascular drugs, it was occasionally 
found necessary to use other model compounds to assess the column 
performance or when repeating other published work. In particular, 
enantiomeric resolution of the antihistaminic drug, chlorpheniramine was 
attempted together with the separation of the geometric isomers of 
clomiphene, an anti-oestrogen drug.
CHAPTER 3
MATERIALS AID METHODS
3.1 Reagents
3.1.1 Model Compounds
Racemic atenolol, alprenolol, oxprenolol, practolol and propranolol 
were obtained, mainly as salts, from ICI Pharmaceutical Division, Alderly Edge. 
The (+) and <-) isomers of propranolol (Inderal) and pronethalol (Aldelin) 
were obtained from the same source, Racemic metoprolol tartrate was obtained 
from Geigy Pharmaceuticals, Macclesfield, Cheshire, and racemic verapamil 
hydrochloride was a gift from Dr. G. Mould, St. Lukes Hospital, Guildford,
Chlorpheniramine maleate was received as a racemic mixture from Dr. Stewart, 
University of Georgia, Athens, Clomiphene was supplied as a mixture of the 
cis and trans isomers from Sigma Chemical Company Ltd, Poole, Dorset.
3.1.2 Derivatising and Ion Pairing Reagents
Acetic anhydride was obtained from BDH. Ltd., Poole, Dorset, as was 
trifluoraacetic anhydride. Heptafluorobutyric anhydride was supplied by Sigma. 
Both 1-naphthoyl chloride and 2-naphthoyl chloride were obtained from Aldrich 
Chemical Company Ltd., Gillingham, Dorset. Pyridine was used in several 
derivatisation procedures and was supplied by BDH Ltd.
The ion pair reagent, (+)-10-camphorsulphonic acid, was obtained from Sigma.
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3.1.3 General Reagents
Of the compounds used to test column performance, phenol, o-cresol, 
1-naphthol and ra-nitroaniline were obtained from Chemistry Stores, University 
of Surrey, m-dinitrobenzene was obtained from BDH Ltd., and 1,1,1-trifluoro-l- 
(9-anthryl)ethanol was supplied by Aldrich.
Sodium dihydrogen orthophosphate, disodiura hydrogen orthophosphate and 
orthophosphoric acid were obtained from BDH Ltd. as was triethylamine, while 
glacial acetic acid was supplied by lay and Baker, Manchester. Hydrochloric 
acid was obtained from FSA, Loughborough and sodium hydroxide was purchased 
from Sigma.
Standard solutions of buffers at pH 4 and 7 were used to calibrate the pH 
meter and were supplied by BDH Ltd,
3.2 Solvents
3,2,1 Mobile Phase Solvents
HPLC grade methanol and acetonitrile were obtained from FSA, 
HiPerSolv grade dichloromethane, propan-l-ol, propan-2-ol, butan-l-ol and 
hexane were from BDH Ltd. Ethanol and pentan-l-ol were also from BDH Ltd. 
and of AnalaR grade. Water was generally glass distilled using a Jencons 4 
Plus auto still (Jencons Ltd,, Leighton Buzzard, Beds,), although in some cases 
purer water was obtained by reverse osmosis (Elga, High Wycombe, Bucks.)
All HPLC mobile phases were thoroughly degassed prior to use, This was 
achieved by ultrasonication of the eluent in a sonic bath (Mettler Electronics, 
California) for approximately 10 minutes.
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3.2.2 General Solvents
Heptane and chloroform HiPerSolv and ether and cyclohexane AnalaR 
were obtained from BDH Ltd. Laboratory grade ethyl acetate and butanone were 
obtained from the same source as was pentan-2-ol and n-butyl acetate. HPLC 
grade acetone was supplied by FSA and toluene was received from May and 
Baker. The hydrocarbons C©, Ci o, Cis, C14. and Ci s were all purchased from 
Sigma.
3.3 Equipment
3,3,1 General Laboratory Equipment
Accurate weighing of stardards were carried out on a Sartorius 
2024IP five place balance (Sartorius Ltd,, Belmont Surrey), while general 
weighings were made on an Ohaus Brainweigh B1500D top pan balance (Ghaus 
Europe Ltd., Cambridge), Quantitative liquid transfers were achieved using 
Gilson Pipetteman P5000, P1000, P200 and P20 pipettes (Gilson Medical 
Electronics, Yilliers-le-Bel, France)
Mixing of samples was normally carried out using a whirlimixer (FSA), while 
shaking for solvent extraction was either done on a home made horizontal 
shaker or a multitube vortexer (Scientific Manufacturing Industries, 
California). Centrifugation was generally performed at 2000rpm at subambient 
temperatures using a Mistral 6L centrifuge (MSE(Fisons), Crawley, Sussex). A 
heating block (Grants Instruments Ltd,, Cambridge) was used to achieve the 
elevated temperatures required for some derivatisation procedures.
Evaporation of organic extraction solvents was carried out using a home made 
solvent evaporator where the glass test tubes are individually supported on a 
thermostatically controlled heating block and the contents subjected to a 
steady steam of dry oxygen free nitrogen.
Where buffers were used, the pH values were measured and adjusted using an 
Orion glass electrode (Orion Research Inc., Boston) connected to a PTI-15 
digital pH meter (EDT Instruments Ltd., Dover, Kent). While measuring pH
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values, a magnetic stirrer (Voss Instruments Ltd., Maldan, Essex) was used to 
gently agitate the solution.
Ultraviolet scans of the model compounds were carried out using a Perkin Elmer 
Lambda 5 scanning spectrophotometer (Perkin Elmer Ltd., Beaconsfield, Bucks.). 
Fluorescent scans were similarly achieved using a Perkin Elmer LS-5 scanning 
fluorimeter.
Disposable round bottomed borosilicate glass test tubes and screw capped tubes 
were supplied by Corning, lew York, together with teflon lined caps. Flat 
bottomed 5ml glass tubes were obtained from LIP (Shipley, Yorkshire)
3.3.2 Chromatography Equipment
The initial work was carried out using Beckman 110 pumps (Beckman 
RIIC Ltd., High Wycombe, Bucks.), although the latter part of the study involved 
the use of a Severn Analytical SA6410B dual piston pump (Severn Analytical, 
Shefford, Beds,).
Sample injection was achieved by the use of a Rheodyne 7120 sample injection 
valve (Rheodyne Inc., Berkeley, California) together with a Hamilton HPLC 
syringe (Hamilton, Bonaduz, Switzerland). Typical injection loop volumes were 
20/jtl, 50/j.I and lOQpl.
Ultraviolet detection was carried out using either a Pye Unicam LC-UV (Pye 
Unicam Ltd,, Cambridge) an LDC Spectromonitor III (Laboratory Data Control, 
Stone, Staffs) or a Cecil CE212 detector (Cecil Instruments, Cambridge), all of 
which were variable wavelength detectors, Fluorescent detection was achieved 
using a Schoefel FS970 fluorimeter (Kratos Ltd., Manchester)
The detector signal was generally recorded using a CR650 or CR652 chart 
recorder <JJ Lloyd Instruments Ltd., Southampton), although in some cases a 
Spectra Physics SP4270 computing integrator was used (Spectra Physics, San 
Jose, California). In addition, an Axxiom Chromatography Data System (Quadrant 
Scientific Ltd,, Gloucester) was also used for a short time.
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GLC was carried out using either a Perkin Elmer Sigma 3B or a Perkin Elmer 
8320 gas chromatograph. In both cases sample injection was achieved using a 
1/jlI type B syringe (Scientific Glass Engineering, Milton Keynes) and flame 
ionization detection was used. All gases were supplied by BOC, London, with 
the exception of air which was generated by a Jun Air compressor.
3.4 Stationary Phases
A variety of different stationary phases were used for this study, including a 
25cm LiChrosorb DIOL column, obtained from HPLC Technology, Macclesfield, 
Cheshire and Spherisorb ODS-1 columns, supplied by Anaehem, Luton, Beds,
Of the chiral HPLC columns, a 25cm j3-cyclodextrin phase, Cyclobond i, was 
supplied by Technicol Ltd., Stockport, Cheshire, while the Pirkle type 3,5- 
dinitrobenzoyl phenylglycine phases were obtained in both the ionic and 
covalently bound forms from Hichrom, Reading, Berks, In addition, one 25cm 
Chirasil 1 ionic 3,5-dinitrobenzoyl phenylglycine cartridge was donated 
together with the cartridge holder and fittings, from Alltech Associates, 
Carnforth, Lancs. All HPLC columns were approximately 4.6mm internal diameter.
Two GLC capillary columns were used in this study; a 50m BP1 bonded phase 
column with an internal diameter of 0.33mm supplied by Scientific Glass 
Engineering, and a Chirasil-L-Val 25m column supplied by Chrompack,
Hiddelburg, Netherlands. The chiral capillary column had a film thickness of 
0,13pm and an internal diameter of 0,22mm.
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3.5 Test Conditions
Each column, both GLC and HPLC, was tested upon arrival under the 
manufacturers stated conditions to verify the claimed efficiency. A set of 
standard conditions were then established to enable the column performance to 
be monitored throughout its use. Due to the wide variety of columns used, no 
single set of conditions could be established to suit all phases and so 
individual test conditions were found for each phase,
In each case the efficiency is calculated for the last eluted peak. Althaug'h 
no absolute values for the minimum efficiency of each column were set, the 
performance was frequently monitored for significant drops in efficiency, 
whereupon the column was replaced.
LiChrosorb DIOL
Test Mixture: m-dinitrobenzene and toluene in heptane 
Eluent: 1% pentan-2-ol in hexane @2.0 ml/rain
Detection: UV 254nm
Spherisorb S5 ODS 1
Test Mixture: acetone, phenol, o-cresol and 1-naphthol in eluent 
Eluent: 60% methanol in water @ 1.0 ml/min
Detection: UV 254nm
Cyclobond 1
Test Mixture: m-nitraaniline in eluent
Eluent: 50% methanol in water @1.0 ml/min
Detection: UV 254nm
3,5-Dinitrobenzoyl Phenylglycine (ionic and covalent)
Test Mixture: 1,1,1-trifluoro-1-(9-anthryl) ethanol in eluent 
Eluent: 10% propan-2-ol in hexane @0,6 ml/min
Detector: UV 254nm
/
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Chirasi1-L-Val
Test Mixture: derivatised amino acids as supplied by Chrompack
Oven Temp. : 140"C isothermal
Carrier: He, 10 psi
Detection: FID
3.6 Derivatisation Procedures
3.6.1 Formation of Acyl Derivatives for GLC
Several different derivatisation reactions were carried out in an 
attempt to increase the volatility of the sample. Heptafluorobutyryl, 
trifluoroacetyl and acetyl derivatives were each formed by using the 
appropriate acid anhydride derivatising reagent within a common reaction 
procedure, as outlined below:
A known amount of the sample was dissolved in 100-2Q0jul of a solvent such as 
n-hexane or dichloromethane. A similar volume of the derivatising reagent was 
added and the mixture heated to between 50-100 °C for 30 minutes, The excess 
reagents were then evaporated under nitrogen, and the residue dissolved in a 
suitable solvent.
On several occasions pyridine was added to the reaction mixture together with 
the derivatising reagent in order to act as a catalyst for the reaction, and in 
some cases the reaction had to be stopped by the addition of a volume of water 
following the heating.
3.6.2 Formation of laphthamide Derivatives
laphthamide derivatives of the beta blockers were formed in order 
to reduce the polarity of the sample molecules and also to provide additional 
sites for possible interactions with the 3,5-dinitrobenzoyl phenylglycine HPLC 
stationary phase. Although an acid anhydride would normally have been the 
first choice of derivatising reagent, since any excess anhydride is relatively 
easy to remove, in this case, due to the availability of reagents, 1-naphthoyl
-  102 -
chloride was used to derivatise the samples according to the procedure 
described below:
A fixed volume of a 2M sodium hydroxide solution was added to 2G0pl of an 
aqueous or methanolic solution of the sample, and a suitable volume of the 
derivatising reagent was added. The reaction mixture was vortexed for 2 
minutes then the derivatives were extracted by vortex mixing for a further 2 
minutes with a appropriate solvent such as chloroform. The samples were 
centrifuged for 5 minutes at 2000rpm and a known volume of the organic 
extract was transferred to a fresh tube and taken to dryness under nitrogen. 
The residue was then dissolved in a suitable solvent.
In several cases, pyridine was added to the reaction mixture in an attempt to 
increase the rate and yield of the reaction, since it acts as a scavnger for 
the excess hydrochloric acid produced by the reaction. Additionally, a 
methanolic solution of 2-naphthoyl chloride was occasionally substituted for 
1-naphthoyl chloride as the derivatising reagent.
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CHAPTER 4
RESULTS AID DISCUSSIGI
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4.1 Achiral Method Development and Validation for Verapamil
4.1.1 Introduction
Literature surveys have shown that, while there are numerous methods 
available for the determination of ? . . . drugs, the published
methodology for verapamil is limited, with most methods describing 
procedures involving a back extraction into sulphuric acid. Attempts 
were therefore made to establish a simple HPLC method for the analysis 
of verapamil in human plasma, involving the minimum amount of sample 
preparation work,
Verapamil, 5- <<3,4-dimethoxyphenethyl)methylamino)-2- (3,4- 
dimethoxypheny 1 )-2-isapropylvaleronitrile, is a drug which inhibits the 
slow inward transmembrane calcium currents and has anti-anginal, anti- 
arrhythmic and anti-hypertensive effects. The important metabolic 
reactions are N-dealkylation, giving mainly nor verapamil, and 0- 
demethylation, Depending on the dose, the mean plasma concentrations 
range between 30 ng/ml and 500 ng/ml.
4.1.2 Chromatography
The initial column selection was based not only on a study of the 
molecular structure, but also on economic and safety considerations. 
Columns used far routine assays should, wherever passible, be both robust 
and compatable with the organic solvents which present the minimum 
hazard to the health and safety of the analyst, To this end, a reversed 
phase actadecyl silica column was chosen, and thus a polar mobile phase 
was required.
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Since verapamil is a basic drug, an aqueous buffer, modified with an 
organic solvent, was selected as the eluent. In this way the retention of 
the solute could be controlled by variation in either the pH of the buffer 
or the eluent composition, A system was therefore set up consisting of a 
12.5cm Spherisorb S50DS1 column and an aqueous phosphate buffer-organic 
modifier mobile phase at a flow rate of 1.0 ml/rain.
A UV detection system was used to monitor the solute elution for the 
initial development work, and the UV absorption scan of verapamil is 
given in figure 4.1.1. This shows three maxima, at 204, 228 and 277 nra 
respectively, with that at 228nm chosen for detection since, although it 
is not the most intense, it avoids the difficulties caused by impurities 
in solvents at low wavelengths, Standard solutions of verapamil in 
methanol with concentrations between 20-200 pg/ml were used for the 
retention studies, of which 20 pi was injected with a Rheodyne sample 
injection valve.
Retention studies were carried out to determine the optimum 
chromatographic conditions and the initial investigations involved 
varying the nature and concentrations of the organic modifier in a 0,11, 
pH 3 phosphate buffer mobile phase, Methanol and acetonitrile
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The UV Absorption Scan of Verapamil in Methanol
Figure 4.1.1
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were chosen for this, and their percentage composition in the eluent 
varied between 40 and 80. For each eluent the salute retention was 
measured and the capacity factor (as defined in Chap 2) was calculated, 
producing the results shown in figure 4.1,2.
Further studies were performed to determine the effect of the pH on the 
retention, using a 70% acetonitrile in buffer eluent. Attempts were 
initially made using a 0.1M phosphate buffer, but at these concentrations 
it was found that the- addition of acetonitrile caused a precipitation of 
the buffer at pH values above 5. Consequently the concentration of the 
buffer was reduced to 0.0111 to enable the effect to be examined over the 
wider pH range of the column, that is, in the case of ODS columns, 
between 3 and 7.5, The results are shown in figure 4.1,3 and highlight an 
additional way of controlling the solute retention, namely by varying the 
ionic strength of the buffer. Hence this trend was also investigated, 
keeping the composition constant at 70% acetonitrile and the pH constant 
at 3. The results are shown in figure 4.1.4.
Although the retention time of the solute can be selected by the choice 
of chromatographic conditions, there are several important factors which 
must be considered. For any routine assay, while it is desirable to keep 
the retention times as short as passible, the solute must not only be 
well resolved from the solvent peak but must also allow for the elution 
of the polar interferences in plasma extracts, which normally follow 
immediately after the solvent peak. Hence, in general, the aim is to find 
a system which will give a capacity factor of between 3 and 5. Goad 
peak shape is dependant upon maintaining the maximum difference between
The Variation of the Retention of Verapamil with 
Eluent Composition
Capacity Ratio (k’)
% Organic Modifier
Figure 4.1.2 Column: 12.5cm Spherisorb ODS1 
Eluent: Organic modifier in 0.1 M 
phosphate buffer, pH 3.0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20 ul 
Detector: UV 228nm
Capacity Ratio (k’)
The Variation of the Retention of Verapamil with
the pH of the Buffer
pH of Buffer
Figure 4.1.3 Column: 12.5cm Spherisorb ODS1 
Eiuent: 70% acetonitrile in 
phosphate buffer,
Flow Rate: 1.0 ml/min 
Injection Volume: 20 ul 
Detector: UV 228nm
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Capacity Ratio (k1)
The Variation of the Retention of Verapamil with
the Ionic Strength of Buffer
Buffer Concentration (M)
Figure 4.1.4 Column: 12.5cm Spherisorb ODS1 
Eluent: 70% acetonitrile in
phosphate buffer, pH 3.0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20 ul 
Detector: UV 228nm
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the nature of the stationary phase and that of the mobile phase, and thus 
it was desirable to keep the percentage of water in the mobile phase as 
high as possible. It can be seen from the results in figure 4,1.2 that, 
for a given capacity factor value, the percentage of methanol required is 
higher than that of acetonitrile and hence the latter was considered 
preferable. From this an eluent of 70% acetonitrile in buffer was chosen.
As can be seen from figure 4.1.3, increasing the pH of the buffer causes 
an increase in the retention of the solute, This is the expected trend, 
since verapamil is a basic drug and is therefore ionisable. In its 
unionised form, verapamil is fairly non polar, and thus has a high 
affinity for the non polar C-i© stationary phase leading to long 
retentions. However, at a low pH, the molecule exists in its ionised 
form, which, due to its increased polarity, is less corapatable in the non 
polar environment of the stationary phase and more soluble in the polar 
eluent, resulting in shorter retention times,
A similar trend is also true of the ionic strength of the buffer where 
increasing the concentration decreases the retention of the solute. Since 
the extent of ionization of the solute depends only on the pH of the 
eluent and the pKa value of verapamil, the retention should be the same 
with each strength of buffer investigated. However, as the buffer is 
adjusted to the set pH and not the eluent, the pH of the weaker buffer 
may be more affected by the addition of acetonitrile than the stronger 
buffer. Hence the differences in retention may be caused more by a 
variation in pH than ionic strength, although other explanations based on 
the nature of the buffer are also possible,
In summary, it was established that, in order to attain a suitable 
retention time an a 12.5cm Spherisorb S50DS1 column, an eluent of 70% 
acetonitrile in aqueous phosphate buffer was selected. The ionic strength 
of the buffer was set at 0.1M and the pH at 3.0. At a flow rate of 1.0 
ml/min, these conditions resulted in a capacity factor of 3.0 and a 
retention time of about 4 minutes.
4.1.3 Extraction Procedure
Having determined the chromatographic conditions, the next stage of 
the method development work was to find a suitable proceedure to extract 
verapamil from an aqueous biological matrix. Investigations were 
therefore carried out to find a liquid liquid extraction method which 
would give good recoveries,
The initial considerations involved the choice of extraction solvent and 
so experiments were carried out to compare the recoveries of a range of 
solvents using an aqueous verapamil solution as a model for plasma, A 
set volume of each solvent was used to extract a 1 ml aliquot of an 
alkaline verapamil solution <150pg/ml> by vortex mixing for 30s. A 
standard volume of each solvent was then taken to dryness under nitrogen 
and redissolved in 500 pi acetonitrile. Recoveries were assessed by the 
comparison of chromatographic peak heights with a recovery standard 
using the previously described system. The results are shown in table
4.1.1.
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A Comparison of the Recovery of Verapamil with Different 
Extraction Solvents
SOLVEIT PEAK HEIGHT <mm) % RECOVERY
Stock Solution 129 -
Butanone 47 36. 4
Heptane 135 104.4
Ether 122 94,4
Cyclohexane 101 78. 1
Diehloromethane 136 105.2
Ethyl Acetate 67 51.8
Trichloromethane 104 80.5
Hexane 135 104.4
Table 4.1,1 Column: 12.5cm Spherisorb ODS1
Eluent: 70% Acetonitrile in 0.IM Phosphate 
Buffer pH 3,0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20pl 
Detector: UV 228nm
The Effect of pH on the Recovery of Verapamil with Ether
pH OF PLASM PEAK HEIGHT (ram) % RECOVERY
: Solution 237 _
3 192 81. 1
4 216 91.2
5 221 93.3
6 240 101.4
7 220 92.9
8 218 92, 1
9 224 94,6
10 218 92. 1
11 231 97.6
12(NaOH) 220 92,9
Table 4.1.2 Column: 12.5cm Spherisorb 0DS1
Eluent: 70% Acetonitrile in 0.11 Phosphate 
Buffer pH 3.0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20p,l 
Detector: UV 228nm
Although recovery is the most important factor when selecting a solvent, 
a number of other physical properties must also be taken into account. 
Ideally, the solvent chosen should be less dense than water, and hence 
plasma, and be fairly volatile, to facilitate easy drying down for sample 
concentration, It is also desirable to choose the most non polar solvent 
passible, since this will extract the minimum amount of the plasma 
interferences, which tend to be polar. From this, ether was chosen as 
the extracting solvent,
As with the retention studies, the pH of the plasma may have an effect on 
the recovery of verapamil into the organic solvent. At low pH values, 
verapamil exists in its ionised form which, being more polar, will be 
more soluble in the aqueous plasma phase than the organic phase, and thus 
will not be extracted. Hence it may be important to maintain the pH 
above a certain value in order to achieve good recoveries. This effect 
was investigated by taking 1 ml aliquots of spiked plasma and ajusting 
the pH of each tube with buffers to give a pH range between 3 and 12.
The verapamil was then extracted with ether by vortex mixing for 30s, 
centrifuging for 5 mins, transferring the supernatant to fresh tube and 
evaporating the solvent under nitrogen. The residues were reconstituted 
in 500 pi of eluent and the recoveries for each pH value calculated on 
the basis of peak height comparison by reference to a recovery standard. 
The results, shown in table 4.1.2, indicate that the pH of the plasma does 
not affect the recovery of verapamil to any great extent, although it was 
noticed that the extracts were cleaner at pH values above 9, possibly 
implying that at least some of the impurities in the plasma were acidic
in nature. All further extractions were therefore performed with the 
addition of a sodium hydroxide solution to the plasma prior to the 
extraction.
Having developed the basis of the above method the next stage was to 
produce some standard curves covering the range of expected plasma 
levels, in this case between 10 and 100 ng/ml. At these levels it was 
thought that the UV detector used so far, would not be sufficiently 
sensitive, and so was exchanged for a fluorimeter, The excitation 
wavelengths for the fluorescence of a compound are the same as the UV 
absorption wavelengths, and because fluorimetry is a more selective 
detection technique, it was now possible, in this case, to use the more 
intense, lower maxima of the three shown in figure 4,1,1. Hence an 
excitation wavelength of 203nm was used in conjunction with a 32Gnm 
emmission cut off filter,
Pooled plasma was spiked with a methanolic verapamil solution to give a 
range of plasma standard of 0-100 ng/ml. Each standard was made 
alkaline by the addition of 1 ml of 10% sodium hydroxide solution, and 
the verapamil extracted with with 10 ml of ether by vortex mixing for 30 
s and centrifuging for 5 minutes at 1000 rpm. The ether layer was 
decanted off and dried down under nitrogen and the residue redissolved 
in 1 ml of eluent. The standards were injected on to the previously 
described chromatographic system with an injection volume of 100 pi, and 
a standard curve was constructed from the resultant peak heights (see 
figure 4.1.5).
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A Standard Curve for Verapamil After an
Ether Extraction
Peak Height (mm)
Verapamil Concentration (ng/ml)
Figure 4.1.5 Column: 12.5 cm Spherisorb ODS1 
Eluent: 70% acetonitrile in
phosphate buffer, pH 3.0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20 ul 
Detector: Fluorimetric, ex 203 nm
Since the standard curve is not linear, and the blank plasma standard 
also gave a peak at the verapamil retention, the extraction praceedure is 
obviously not entirely satisfactory. An unextracted standard curve, run 
over a similar range to that used for the extraction gave a more linear 
response indicating that the problem lies more with the extraction than 
with the chromatography, A volume of ether similar to that used for the 
extraction was evaporated under nitrogen and the residue redissolved and 
injected onto the chromatography system. The interfering peak was 
present in this sample and so is likely to originate from the ether.
It was therefore necessary to reconsider other extraction solvents, and 
the possibility of back extraction into 0.1 1 hydrochloric acid was also 
explored in an attempt to eliminate the interferences. In addition to 
ether, heptane and 1,5% pentanol in hexane were also investigated, and in 
each case, back extraction into acid significantly reduced the recovery to 
unacceptable levels, A sample of each extraction solvent was dried down 
under nitrogen and tested for interferences, and this again confirmed 
that the ether used contained a coeluting impurity, as did the hexane. 
Although it may have been possible to purify the ether by the process of 
redistillation, heptane contained no such interfering impurities and in 
addition gave reasonable recoveries, and was therefore used far all 
further extractions.
Hence a second standard curve was generated using heptane as the 
extraction solvent following the previously described procedure, the 
results of which are shown in figure 4.1.6. This gave a linear response 
(r=0.9991) with detection limits of around 10 ng/ml, although this was
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largely due to the unusually high background noise levels of the detector 
at this time. Such noise levels have not been evident in previous assays 
and may be due to the deterioration of the deuterium lamp, and therefore 
lower detection limits may be expected in future runs.
In conclusion, a summary of the method of extraction of verapamil from 
plasma is as follows:
1 ml aliquots of plasma were made alkaline with 0.1M sodium hydroxide,
10 ml of heptane was added to extract the verapamil, and the tubes 
vortexed for 30s and centrifuged for 5 minutes at 1000 rpm, 9 ml of 
each heptane layer was taken to dryness in clean tubes, then redissolved 
in a suitable volume of eluent,
4.1.4 Validation
The validation of this assay centred mainly an finding an 
appropriate internal standard and assessing the day to day precision of 
the method.
There are several factors which are important in selecting a suitable 
internal standard. Ideally the compound chosen for the internal standard 
should be fairly similar in structure to the sample compound, and elute 
close to the sample peak under the chosen chromatographic conditions. It 
is also important to ensure that, not only is the internal standard 
extracted under the predetermined procedure, but that the recoveries of 
both the internal standard and the sample are similar,
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A Standard Curve for Verapamil After a
Heptane Extraction
Peak Height (mm)
Verapamil Concentration (ng/ml)
Figure 4.1.6 Column: 12.5 cm Spherisorb ODS1 
Eluent: 70% acetonitrile in
phosphate buffer, pH 3.0 
Flow Rate: 1.0 ml/min 
Injection Volume: 20 ul 
Detector: Fluorimetric, ex 203 nm
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Several compounds were investigated for their suitability as internal 
standards and it was decided to use propranolol, which elutes just before 
verapamil on the chromatographic system described above. Propranolol 
also has the advantage that it is rarely administered in conjunction with 
verapamil, and so is unlikely to be present in patient plasma samples.
Experiments were carried out to ascertain the retention of propranolol in 
relation to verapamil, and to determine the comparative detector response. 
Since the two peaks of interest elute fairly close together, the mobile 
phase was adjusted to 35% 0.11 phosphate buffer, pH 3,0 : 65% acetonitrile 
to give a better separation. Under these conditions the retention times 
of verapamil and propranolol were found to be 414 and 3 mins respectively 
at a flow rate of 1.0 ml/min. The optimum concentraion for the internal 
standard should result in a peak height of approximately half that of the 
top standard, and in this case was found to be 10 ng/ml.
The percentage recovery of both verapamil and propranolol was assessed 
by extracting a number of samples containing the drug and the internal 
standard and comparing the peak heights of the resulting chromatograms 
with those obtained from similar recovery standards. Taking into account 
the quantifiable lasses in the extraction proceedure, both verapamil and 
propranolol gave recoveries of about 75% at 100 ng/ml.
The next stage was to perform a six day four level validation, On each 
of six different days, a standard curve was constructed by extracting 1ml 
aliquots of plasma, spiked to give a range of verapamil concentrations 
(100 - 5ng/ml), and a constant propranolol concentration (lOng/ml). The
standard curve was then used to determine the verapamil concentration of 
four blind spike samples.
A comparison of the results obtained at each spike level on the six days 
was made in order to assess the day to day precision of the method, and 
the results are shown in table 4,1,3:
As can be seen, the coefficients of variation range between 4.6% at the 
60 ng/ml level and 8,6% at the 8 ng/ml level with the correlation 
coefficients of each standard curve being greater than 0.99. Although 
these results are acceptable in themselves, it should also be noted that 
the plasma aliquots for bath the blind spikes and the standards were 
spiked on a day to day basis, and therefore the results also reflect the 
precision and accuracy of the spiking procedure. These values may be 
improved by preparing batches of spiked plasma at each concentrations 
prior to the commencement of the validation study, thus producing the 
required number of identical standards and blind spikes,
4.1.5 Conclusion
In conclusion, a summary of the method of analysis of verapamil in 
plasma is as follows:
1 ml of plasma was dispensed into a clean screw capped tube and 100 pi 
of a 100 ng/ml propranolol solution was added. The plasma was made 
alkaline by the addition of 0.11 sodium hydroxide. 10 mis of heptane was 
added to extract the verapamil, and the mixture vortexed for 30s and 
centrifuged for 5 minutes at 1000 rpm. 9 ml of the heptane layer was 
transferred to a clean tube and taken to dryness in clean tubes under
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Validation Results fo r Verapamil
STANDARD CURVE SPIICE LEVEL <ng/ml)
DAY K SLOPE 60 35 15 8
1 0.9976 0. 0217 61. 1 32.7 '17. 1 10,2
2 0,9974 0. 0196 58.5 30.7 16.8 9.4
3 0,9962 0, 0229 61.6 36.8 16, 0 8.4
4 0.9943 0, 0205 64.6 37. 1 15.9 8.7
5 0.9974 0.0193 57.8 35.8 14.5 -
6 0.9967 0.0209 57.4 33.3 15. 5 9, 3
IEAI 60, 4 34.5 15.9 9,2
S, D. 2.79 2.63 0.94 0.78
C, V. 4.6% 7.6% 5.9% 8.6%
Table 4.1.1 Column: 12.5cm Spherisorb QDSi
Eluent: 65% Acetonitrile in 0. IM Phosphate 
Buffer pH 3.0 
Flow Rate: 1.0 ral/min 
Injection Volume: 20pl 
Detector: Fluorimetric, X«>s=203nm
oxygen free nitrogen. The residue was then redissolved in a suitable 
volume of eluent.
The chromatographic system consisted of a 12.5 cm Spherisorb 50DS column 
with an eluent of 65% acetonitrile 35% O.lKt phosphate buffer adjusted to 
pH 3.0, at a flow rate of 1.0 ml/min. A fluorescence detector was used, 
set to an excitation wavelength of 203 nm and a 320 nm cut off filter.
The resulting chromatograms were recorded using a chart recorder.
Although enantiomeric resolution was neither achieved or expected with 
this system, it was hoped to be able to transfer the method to a reverse 
phase chiral column, such as cyclodextrin, to achieve separations at a 
later stage,
A r\oo-^vs
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4.2 Enantiomeric Resolution by Ion P a ir Chromatography
4.2.1 Introduction
The use of chiral additives in the mobile phase provides, in theory, 
the easiest and cheapest method of achieving enantiomeric resolutions by 
HPLC, by removing the need for costly and sometimes delicate chiral 
stationary phases. Of the various types of additives available for such 
use, chiral ion pair reagents are particularly suited to ionic or 
ionisable compounds, and in particular 10~campharsulphonic acid has been 
used by Pettersson and Schill for the separation of aminoalcohol 
enantiomers E337L
Attempts were therefore made to evaluate this approach with respect to 
the resolution of alprenolol and other beta blacking drugs, Initial 
efforts were centreed on repeating the work of Pettersson and Schill and 
involved the use of a normal phase dial column in conjunction with an 
eluent of 0.5% pentanol in dichloromethane containing 5.4ml (+>—10— 
camphorsulphanic acid. However, as this proved to be unsuccessful, with 
the solute being retained on the column, more detailed retention studies 
were undertaken,
4.2.2 Retention Studies
The chromatographic system consisted of a 25 cm LlChrosarb DIOL column 
in conjunction with a dichloromethane eluent containing small
concentrations of an alcoholic polar modifier. A variable wavelength UV 
detection system was used to monitor the solute elution, set to 271 nm, 
corresponding to the absorption maximum of alprenolol as shown in figure
4.2.1. A 250 pg/ml alprenolol solution was used for this work, of which 
20 pi was injected using a Rheodyne sample injection valve.
The initial investigation involved varying the nature and concentration 
of the alcoholic polar modifier and measuring the retention or capacity 
factor and the efficiency with each different mobile phase, The results, 
as shown in table 4.2.1, follow the expected trend of increasing capacity 
factors with decreasing polarity of the eluent, since alprenolol is a 
basic drug and is therefore more readily partitioned into a more polar 
mobile phase. It can also be seen that the efficiencies improve as the 
eluent becomes progressively more non polar, and this is consistent with 
the increase in retention times.
Since the alprenolol peaks were becoming broader, due to the increased 
retention times with less polar eluents, the effect of adding small 
quantities of glacial acetic acid to the mobile phase was studied. An 
eluent of 1% propanol in dichloromethane was used and the acetic acid 
content was varied between 0 and 0.3%. The results, as shown in table
4.2.2, indicate that the addition of acetic acid causes a decrease in 
retention accompanied by an increase in the efficiency.
The acetic acid lowers the pH of the eluent which forces the alprenolol 
to exist in a charged form which should be more strongly retained on the 
polar stationary phase. However the increased polarity of the acidic
UV Absorption Scan of Alprenolol in Methanol
Figure 4.2.1
The Effect of Variation in the Polar Modifier on the Retention
of Alprenolol on a lorm al Phase Column
Polar Modifier k* I
5% Methanol 0
3.3% Methanol 0. 33 554
2.5% Methanol 0. 83 342
2% Ethanol 1.8 554
2% Propanol 2. 0 798
Table 4.2.1 Column: 25cm LiChrosorb DIOL
Eluent: Diehloromethane: polar modifier 
Flow Rate: 3.0 ml/min 
Detection: UV 271 nm 
Injection Volume: 20 pi
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% Acetic Acid k‘ N
The Effect of the Addition of G lad a l Acetic Acid on the
Retention of Alprenolol on a Normal Phase Column
0 6.6 320
0.2 2.6 554
0,3 2.2 630
Table 4.2.2 Column: 25cm LiChrosorb DIOL
Eluent: 1% Propanol in dichloromethane 
Flow Rate: 3,0 ml/min 
Detection: UV 271 nm 
Injection Volume: 20 pi
The Effect of Variation in the Polar Modifier on the Retention of 
Alprenolol with Eluents Containing Glacial Acetic Acid
Polar Modifier k1 I
1% Propanol 2.2 630
1% Butanol 2.2 296
0.5% Butanol 4,5 262
1% 2-Pentanol 2 < 2 253
0.5% i-Pentanol 2. 4 266
0.5% 2-Pentanol 2.6 278
Table 2.3 Column: 25cm LiChrosorb DIOL
Eluent: Diehloromethane: polar modifier 
Flow Rate: 3,0 ml/min 
Detection: UV 271 nm 
Injection Volume: 20 pi
mobile phase more than compensates for this, and hence the capacity 
factors are reduced.
As this effect widens the range of alcoholic polar modifiers which can be 
studied, capacity factors and efficiencies were again measured for a 
range of mobile phases, each containing 0.3% glacial acetic acid. The 
results are given in table 4.2.3
In contrast to the results in table 4.2.1, there seems to be no noticable 
trend between the polarity of the modifier and the retention. This could 
possibly be due to column deterioration since the experiments were 
performed over a relatively long period of time. However, subgroups 
within the table, such as the pentanol series, indicate that, as the 
polarity decreases, the capacity factors and the efficiencies increase.
Since the efficiencies are low, attempts were made to monitor the effect 
of variations in flow rate on both retention and efficiency on a number 
of different eluent systems.
The results given in figure 4.2.2 show that while increasing the flow rate 
from 1.0 ml/min to 3.0 ml/min increases the capacity factor, the 
efficiency is reduced with each of the solvent systems used. This can be 
explained by the van Deemter equation (Chap. 2), relating flow dependant 
band broadening effects to the plate height or efficiency of the 
separations. As the flow rate increases the mass transfer 
characteristics become more important and hence the efficiency is
The Effect of Variations in Flow Rate on the Capacity 
Ratio and Efficiency of the Diol Phase
Efficiency (N)
Flow Rate (ml/min)
Capacity Factor (k‘)
5
-------A  .....
_____ ____ ___
Flow Rate (ml/min)
1 % Butanol 0,5% Butanol 1 % Pentan-2-ol
- - Q -  • A -
0.5% Pentan-2-ol 0.5%Pentan-1-ol
Figure 4.2.2 Column: 25 cm LiChrosorb DIOL
Eluent: dichloromethane : polar modifier 
Detection: UV 271 nm 
Injection Volume: 20 ul
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decreased. It was therefore decided that all further work should be 
performed using a flow rate of 1.0 ml/min.
The next stage of the study involves an investigation of the effect of 
the addition of the (+)~10~camphorsulphonic acid ion pair reagent as a 
chir^al mobile phase additive, From the previous results, a 0.5% butanol 
in dichloromethane system containing 0,3% glacial acetic acid was chosen, 
and run at a flow rate of 1.0 ml/min. Samples of alprenolol were 
injected, and the peaks compared to those obtained with a similar eluent 
containing 6ml <+)~10~camphorsulphonic acid (see figure 4.2.3). In 
addition to this, the experiment was repeated using eluents which did not 
contain any acetic acid (figure 4.2.5). The results for this experiment 
are given in table 4.2.4.
If ion pairing had occurred between the (+)-10-camphorsulphonic acid and 
the alprenolol, the ion pair complex would be more lipophilic than the 
unpaired alprenolol and would thus be expected to be less retained on 
the polar DI0L stationary phase, Since the capacity factors are 
significantly reduced by the addition of the (f)-lO-camphorsulphonic acid 
ion pair reagent with both eluent systems, ie with and without acetic 
acid in the mobile phase, this would appear to indicate that an ion pair 
had, in fact, been formed between the alprenolol and the campharsulphonlc 
acid, However neither eluent system gave any hint of chiral resolution.
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The Effect of the Addition of Ion Pair Reagent on the 
Retention of Alprenolal
Eluent k' I
0.5% Butanol 3,16 289
0.5% Butanol + CSA 2.17 184
0.5% Butanol + Acid 2.00 371
0.5% Butanol + Acid + CSA 1.20 382
Table 4.2,4 Column: 25cm LiChrosorb DIOL
Eluent: Dichloromethane: polar modifier 
Flow Rate: 1.0 ml/min 
Detection: UY 271 nm 
Injection Volume: 20 pi
The Effect of the <+)-10-Camphorsulphonlc Acid Mobile Phase 
Additive on the Resolution of Alprenolol with Acidic Eluents
I
Figure 4.2.3 Column: 25cm LiChrosorb DIQL
Eluent A: 0.5% butanol, 0.3% acetic acid in 
dichloromethane 
B: 0.5% butanol, 0.3% acetic acid in
dichloromethane containing 6mM (+)-10- 
camphorsulphonic acid 
Flow Rate: 3.0 ml/min 
Detection; UV 271 nm 
Injection Volume; 20 pi
3k- VteSutC- oLa~m52- -Vcd
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The Effect of the (-l-)-lO-Camphorsulphonic Acid Mobile Phase
Additive on the Resolution of Alprenolol
Figure 4,2.4 Column: 25cm LiChrosorb DIOL
Eluent A: 0.5% butanol in dichloromethane
B: 0.5% butanol in dichloromethane containing 
6mM <+)-10-camphorsulphonic acid 
Flow Rate: 3.0 ml/min 
Detection: UV 271 nm 
Injection Volume: 20 jyil
4.2.3 Discussion
The results for this section of work are, in general, very disappointing. 
Although the retention studies followed the trends expected for a normal 
phase system, the addition of the camphor sulphonic acid did not result 
in any indication of enantioselective resolution.
The rationale behind this approach to chiral separations is that 
diastereomeric ion pairs are farmed between the single counter ion 
enantiomer and each of the solute enantiomers, and that these ion pairs 
have structural differences which allow them to be differentially 
distributed between the two phases and are thus resolved. Although the 
mechanism of chromatography is not completely clear, it is known that 
there must be at least three points of interaction between the solute and 
the counter ion to produce ion pairs with sufficient structural 
differences to effect such a separation. In this case, the three 
interactions are thought to be electastatic interaction between the amino 
and acid groups, hydrogen bonding between the hydroxyl group of the 
salute and the carbonyl group of the counter ion and steric interactions 
between the two ring systems.
As has been previously discussed, there are a number of factors affecting 
such resolutions, the most important of which is the water content of the 
mobile phase. Low concentrations of water in the eluent adversly 
modifies the degree of resolution, possibly due to competition between the 
water and the salute for hydrogen bonding sites an the counter ion. 
Attempts were therefore made to repeat the final experiment using eluents
which had been dried over a molecular sieve prior to use, but this 
resulted in the solute being retained an the column. Work by Petersson 
[3463 suggests that a water concentration of around 80 ppm creates an 
ideal compromise between the detrimental effects of water on 
stereoselectivity and its necessity for the controlled elution of the 
solute. However, without more specialised techniques, it was impossible 
to monitor the water concentration of eluents in this study to such a 
degree, and thus the fine control required for optimum resolutions was 
unattainable.
The effect of the acetic acid in the eluent is more complicated. 
Essentially, the acetic acid provides a means of controlling the retention 
3:>y lowering the pH of the eluent and ionising the solute enantiomers, 
thus promoting the ion pair formation. However, in addition to this, 
there will also be competition between the acetic acid and the 
camphorsulphonic acid for the formation of ion pairs with, the alprenolol 
isomers, although in practice, this effect will be relatively small since 
the camphorsulphonic acid is the stonger of the two.
The resolution of the enantiomers is also dependent on the optical purity 
of the camphorsulphonic acid, V7ith ion pair resolution, any optical 
impurities in the chiral counter ion decrease the separation between the 
diastereomers rather than affecting the quantitive results. The <+)-10- 
camphorsulphonic acid used in this study was of unknown age and optical 
purity, and this, together with the previous points and the gradual 
deterioration of the column efficiency could all help to account for the 
lack of positive results.
4.3.1 Introduction
The aim of this section of work was to provide an evaluation of a 
GLC approach to enantioselective resolution using a chiral stationary 
phase. The first commercially available chiral GLC column was a diamide 
phase based on valine hert butylamlde, known as Chirasil Val, and since 
this was also the most readily available capillary column at the time, it 
was chosen for this study.
Although the phase has been widely used to separate enantiomeric amino 
acid derivatives and other small molecules, it's application to the 
resolution of other compounds is limited. This study therefore centres 
on the evaluation of this phase with respect to the enantiomeric 
resolution of amino alcohols such as propranolol, metoprolol and 
alprenolol.
4.3.2 Experimental
The column chosen was a 25m x 0.22mm i.d. fused silica capillary 
column coated with Chirasil-L-Val with a film thickness of 0.12 pm and 
the initial work involved setting and optimising the GC parameters to 
give the best column performance. The column efficiency is related to 
the linear gas velocity by the van Deemter equation and thus the inlet 
pressure must be adjusted to give the optimum linear velocity for the 
carrier gas used. The linear velocity can be calculated by relating the 
column length to the elution time of an unretained compound such as a
4.3 Enantiomeric Resolutioin Using A Chiral GLC S ta tionary  Phase
solvent or methane. For a helium carrier, the ideal velocity is between 
15 - 25 cm/s and thus for a 25m column, the elution time should be 2 - 3 
mires. Hence the inlet pressure for this system was set at 12 psi, giving 
a retention time of 2.3 mins for dichloromethane at a temperature of 140° 
C,
A sample of the test mixture, as supplied by the manufacturer, was 
injected to verify the performance (see figure 4.3.1). The test sample 
was a mixture of four derivatised amino acids; alanine, leucine, aspartic 
acid and methionine and the efficiency, calculated from the last eluted 
peak, was found to be approximately 79,000 plates. This compared 
favorably with the 82,000 plates claimed on the test report.
The column was retested at regular intervals and it was interesting to 
note that the retention times of the peak increased considerably after a 
short period of time (see figure 4.3.2), This increase however, was 
achieved without any noticable reduction in the efficiency.
The next stage of this work was to attempt to separate the enantiomers 
of several small molecules such as bromobutane, butan-2-ol and pentan-2- 
ol, neither of which require derivatisation to improve their volatility. 
Although this was only a limited experiment, the initial results seemed 
to indicate that some resolution had taken place albeit with low 
separation factors (see figure 4,3.3). Such low values would be expected 
with the short resolution times, and would be difficult to improve at 
normal GLC working temperatures. However, further studies
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The Initial Testing of the Chirasil Val Column
rOt inf- • •
Column: 25ra Chirasil-L-Val 
Oven Temp: 140 CC Isothermal 
Carrier: Helium 10 psi 
Detection: FID
Sample: Amino Acid Test Mixture
1. D-Alanine
2. L-Alanine
3. D-Leucine
4. L-Leucine
5. D-Aspartic Acid
6. L-Aspartic Acid
7. D-Methionine
8. L-Methionine
(X| LU
-J
Figure 4.3,1 
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Further Testing of the C h irasil Val Column
Column: 25m Chirasil-L-Val 
Oven Temp: 140°C Isothermal 
Carrier: Helium 10 psi 
Detection: FID
Sample: Amino Acid Test Mixture
1. D~Alanine
2. L~Alanine
3. D-Leucine
4. L-Leucine
5. D-Aspartic Acid
6. L-Aspartic Acid
^ 7. D-Methionine
in
4rf
t-i-
12 3 A 5 6
Figure 4.3.2
Resolution of 2-Br'omobutane and 2-Butanol
■nco
•N
Column; 25m Chirasil-L-Val 
Oven Temp: 140*C Isothermal 
Carrier: Helium 12 psir <T» 
r -
Detection: FID ,-,J
Sample; 1. 2-Butanol
2. 2-Bromobutane
cc•s>
o
otxt 00
Figure 4.3.3
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revealed that the two peaks for each injection were not similar in size 
as would be expected for a racemic mixture, and hence, in the absence of 
enantiomerically pure samples, it was impossible to determine whether 
chiral resolution had occurred or whether the peak splitting was caused 
by other factors.
In order to analyse larger compounds like the arainoalcohols by GLC, some 
form of derivatisation is required to increase the volatility of the 
samples. Although the beta blockers may be derivatised in a number of 
different ways, acylation may be achieved by a relatively quick and easy 
procedure and so was the preferred method for this study.
Initially, heptafluorobutyryl derivatives of propranolol, metoprolol and 
alprenolol were formed according to the procedure described in chapter $3 
Injections of each sample were made, and the preliminary results showed 
two peaks for both propranolol and metoprolol (see figure 4.3.4). In both 
cases the peaks were smaller than expected, even taking the 1/60 split 
ratio into account, but this may have been caused by sample losses in the 
derivatisation procedure, No peaks, other than the solvent peak, were 
observed for the alprenolol injection, leading to the assumption that the 
derivative had either not been formed or was retained on the column.
The experiment was then repeated with fresh heptafluorobytyryl 
derivatives and similar results achieved. However, similar injections, 
made after the derivatives had been stared at 4*C
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overnight, showed no peaks at all. This appeared to indicate that the 
derivatives were not stable
Since it has been suggested that the concentration of derivatising 
reagent could have a large effect on the stability of the derivatives 
[4243, experiments were performed to vary the amount of 
heptafluorobutyric anhydride used in the derivatisation of both 
propranolol and metoprolol in order to assess the storage stability. 
However, on injection none of the derivatised samples were eluted from 
the column within 1 hour.
After several unsuccessful attempts to repeat the initial experiments, 
further efforts were centred on finding a more volatile derivative, To 
this end trifluoroacetyl derivatives were investigated, as were acetyl 
derivatives. However, in neither case were any of the samples eluted 
form the column at any temperature.
One possible explanation for this is that the derivatives were not formed 
under the reaction conditions used. This was investigated by replacing 
the chiral column with a non polar BP1 phase. Propranolol, metoprolol, 
alprenolol, atenolol, practolol and oxprenolol were all derivatised with 
trifluoroacetic anhydride by an identical procedure to that used 
previously, and injected onto the BP1 column, which was run with a 
temperatur'e program of 110 °C for 2 mins then 5Vmin to 220 °C and held 
for 15 mins. With the exception of practolol, peaks were observed for 
all the compounds, although calculations showed that in each case the 
elution temperature was in excess of 200°C.
-  148 -
Having verified the formation of the derivative, a comparison between the 
two phases was made. For each column, a range of hydrocarbons was 
injected, together with a selection of other compounds, under standard 
conditions of a 130 *C isothermal oven temperature with a helium carrier 
at 10 psi. The capacity factors for each phase, as shown in table 4.3.1, 
indicate that the Chirasil Val phase is significantly more polar than the 
BP1 phase.
A Comparison of Capacity Ratios for Different Samples
Between the Chirasil Val Phase and the BP1 Phase
Compound Chirasil Val BP1
C© 0. 11 1. 02
Cl O 0. 17 3.23
Cl a 0.27 9.75
Butanone 0. 17 0.23
Butanol 0. 16 0.36
Pyridene 0.20 0.70
Benzene 0, 19 0.72
Diehloromethane 0. 18 0.71
Table 4,3.1 Oven Temp: 130eC
Helium Pressure: 10 psi 
Detection: FID
In theory, resolutions of the beta blockers should be passible with 
the Chirasil Val column since there are sufficient interactions between 
the phase and the derivative samples, The mast probable interactions 
include hydrogen bonding between the tert butylamide carbonyl of the 
phase and the hydroxyl group of the salute, and also between the amide 
carbonyl of the derivative and the second amide hydrogen on the phase. 
The third interaction is likely to be a steric hindrance by the isopropyl 
group on the selector which will block the approach of the solute on one 
side.
However, the initial results from this study showing the resolution of 
the enantiomers of propranolol and raetoprolol, although encouraging, 
appear to be inconsistent with the remainder of the study, In both 
cases, the peaks have very long retention times and, in consequence, are 
very broad. The lack of peaks when attempts were made to repeat the 
work could possibly be explained by reference to the regular testing of 
the column with the test mixture, whereby it was noticed that, prior to 
repeating the propranolol and metoprolol derivatives, the retention times 
of the test mixture increased considerably, from 10,9 mins to 14.0 mins 
for D-methionine. Although this was not accompanied by a significant 
decrease in efficiency, a similar increase in the retention of the 
propranolol and metoprolol enantiomers could possibly cause sufficient 
band broadening as to reduce such small peaks to a non detectable level,
Mare significant conclusions can be drawn from a comparison between the 
chiral phase and the BP1 phase and, in general, McReynolds constants are
4,3.3 Discussion
used to provide an assessment of the polarity of different phases. 
Although there are more, the first five constants are the mast important 
and these are given for benzene, representing the aromatic and 
unsaturated compounds, 1-butanol, representing the alcohols, 2-pentanone 
for the carbonyls, nitrapropane for the other polar compounds and 
pyridene, representing the heterocyclics. McReynolds constants are 
determined by measuring the Kovats indices for each of the five 
compounds on the phase of interest under standard conditions, and 
subtracting the corresponding Kovats indices for the same samples as 
determined on a non polar, squalane phase. The McReynolds constants for 
Chirasil Val and the BP1 phase are given in table 4.3.2. Other systems 
have expanded this approach, one of the most useful being the CP Index. 
Under this system, the sum of the first five McReynolds constants for the 
phase of interest is compared to that of the most polar phase, QV275, 
glvig a ratio of between 0, for non polar squalane, and 100 for the 
highly polar phase, A comparison between the BP1 and the chiral phase 
shows that the chiral phase is the most polar with both systems,
This result can be used to relate the expected retention of the 
derivatives on the chiral phase to that achieved on the BP1 phase by 
assessing the polarity of the samples. Although derivatisation of the 
aminoalcohols reduces their polarity significantly, they still retain 
enough of their polar characteristics to be more strongly retained on the 
more polar chiral phase. From the work done with the BP1 phase, it was 
found temperatures in excess of 200°C were required to elute the 
derivatives within a reasonable length of time. However, the maximum 
operating temperature of Chirasil Val is 200 °C and the column suffers
A Comparison of the MeReynolds Constants and CP
Indices for Chirasil L Val and the BP 1 Phase.
IcReynoldis Constants
Phase 1 2 3 4 5 I CP
Squalane 0 0 0 0 0 0 0
BP1 15 53 44 64 41 217 5. 14
Chirasil-L-Val 24 264- 102 130 107 627 14.86
GV275 629 827 763 1106 849 4219 100
Table 4.3,2:
from a high bleed at temperatures above 170 °C. This implies that at the 
lower temperatures the retention of the derivatives will be very long, 
and again, the peak broadening effects of increased retention may make 
detection of the peaks of interest difficult.
It was therefore concluded that this approach was not easily applied to 
the enantiomeric separation of beta blockers, and any further work must 
first overcome the problem of finding a procedure to give more volatile, 
less polar derivatives, or alternatively find ways to improve the thermal 
stability of the phase.
4.4 Enantiomeric Resolution Using a Cycladextrin HPLC Phase
4.4.1 .Introduction
The use of chiral stationary phases for the resolution of
enantiomers by HPLC is becoming increasingly more common, and of the
wide range of stationary phases available, the cycladextrin phase is 
possibly the most versatile, being compatable with the polar eluents used 
in reverse phase chromatography and generally requiring no prior sample 
derivatisation. As such, the column initially appeared to be the most 
suatable choice for the resolution of the polar beta blacking drugs.
As has previously been described, cyclodextrins have a toroidal 
configuration, the size of which is dependent upon the number of glucose
units in the structure. Since resolutions are achieved through inclusion 
complexing, the size of the cyclodextrin cavity must be comparable to 
that of the compounds to be separated. For this study, a Cyclobond I, or 
J3 cyclodextrin column was selected as its seven glucose units provide the 
most appropriate sized cavity for the aromatic systems of the amino 
alcohols.
The aim of this section of work was not only to develop enantioselective 
methods for the analysis of beta blockers, but also to assess the 
suitability of the phase with respect to other compounds.
An assessment of the column performance was made on receipt of the 
column by measuring the efficiency of the phase under the recommended 
test conditions using a sample solution of m-nitroani 1 ine, see figure
4.4.1. The efficincy was found to be considerably below that claimed in 
the manufacturers specifications, and although efforts were made to 
improve this, by checking that there was no dead volume throughout the 
HPLC system, no significant increases were achieved
As it was initially thought that the cause of this problem was a fault in 
this particular column, a second was obtained. The results from this 
second column, however, mirrored those of the first. Communication with 
the suppliers revealed that the mass transfer characteristics of the 
cyclodextrin phase were relatively poor and an improvement in efficiency 
could possibly be achieved by a reduction in both the injection volume 
and also the sample concentration
An investigation was therefore carried out to measure the efficiency for 
injection volumes between 1 and 10 pi under the standard test conditions, 
the results of which are shown in figure 4.4.2. This shows that the 
efficiency may be increased to 11000 plates by injecting Ipl of a 500 
ng/ml solution, although further improvements were not achieved by 
additional reductions in the sample concentration.
While such measures succeeded in increasing the efficiency of the 
separation to a more acceptable value, very low injection volumes are
4.4.2 Testing the Column
Testing the Cyclobond Column
H---------------------------------------------- 1
5 0
Figure 4.4.1 Column: Cyclobond I
Eluent: 50% mehtanol in water 
Flow Rate: 1 ml/rain 
Detection: UV 254nm 
Sample: m-nitroaniline 
Injection Volume: Ipl
The Effect of Variations in Injection Volume on 
the Efficiency of the Cyclobond Phase
Efficiency (N)
Injection Volume (ul)
Figure 4.4.2 Column: 25cm Cyclobond 1
Eluent: 50% methanol in water 
Flow Rate: 1.0 ml/min 
Detection: UV 254nm 
Sample: m-nitroaniline
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not readily suited to quantitative analysis unless specialised injection 
valves are used, since syringe injections into a larger loop is not 
sufficiently precise without the presence of an internal standard. Band 
broadening effects will also occur when the small sample volume is loaded 
into the loop of a Rheodyne type valve unless the injection is made 
immediately; a requirement which cannot be achieved when injecting using 
an autosampler. It also has been found that the relationship between the 
sample concentration and the retention time is not constant and that low 
amounts of injected sample cause retention time increases. More 
importantly, small injection volumes have the effect of increasing the 
limit of detection, particularly if more concentrated samples cannot be 
used.
4.4.3 Resolution of Propranolol
As the main aim of this section of work was to evaluate the 
Cyclobond with respect to the enantiomeric resolution of beta blocking 
drugs, propranolol was selected as a suitable model compound along with 
verapamil. A system was set up using the Cyclobond I column in 
conjunction with a UV detection system. Following the manufacturers 
advice, a 50% methanol in water eluent was chosen as a starting point, 
and injections were made of both propranolol and verapamil. As this 
choice of mobile phase gave no hint of separation for either propranolol 
or verapamil, retention studies were carried out to determine whether 
resolution could be achieved with different mobile phase compositions.
The percentage of methanol was varied between 40 and 90% and the 
capacity factors calculated for both compounds. The results, as shown in 
figure 4.4.3, show that the capacity factors decrease as the percentage of
The Effect of Eluent Composition on the Retention 
of Propranolol and Verapamil on Cyclobond I
30 40 50 60 70 80 90 100
% Methanol
Figure 4.4.3 Column: 25cm Cyclobond I 
Eluent: methanol in water 
Flow Rate: 1.0 mi/min 
Detection: UV 254nm
of organic modifier in the eluent increases, but at no time was there any 
indication that enantioselective resolutions could be achieved under these 
conditions.
The mobile phase was then changed to a buffered system using 1% aqueous 
trlethylamine adjusted to pH 4.1 with glacial acetic acid, and an eluent 
of 25% methanol in buffer was used far the next stage of this 
investigation.
Injections of propranolol were made, and the initial results appeared 
promising, with the chromatogram showing a distinct shoulder on the peak 
of interest, see figure 4.4.4. This was at first thought to be due to 
some degree of enantioselective resolution occurring, but further attempts 
to Improve the separation by reducing the injection volume only resulted 
in the shoulder changing it's position from the leading to the tailing 
edge of the propranolol peak. Additional information was obtained by 
collecting fractions of eluent from the split peak and reanalysing each 
fraction separately. Five fractions were collected over the peak of 
interest and each was dried down under nitrogen, reconstituted in a 
suitable volume of eluent and reinjected. For each fraction, the retention 
and peak shape was found to be identical indicating that the shoulder and 
main peak were caused by the same solute, and optical resolution had not 
occurred.
The split peaks are therefore likely to have been caused by column 
overloading since, if too much analyte is injected, either by injecting a 
concentrated solution or using too large an injection volume, it is
Resolution of Propranolol on a Cyclobond I Column
Figure 4.4.4 Column: Cyclobond I
Eluent: 25% methanol in 1% triethylamine 
acetate buffer, pH 4.1 
Flow Rate: 1.0 ml/min 
Detection: UV 288nra 
Injection Volume: 10 pi
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possible that not all of the sample molecules will be able to form 
inclusion complexes within the cyclodextrin cavities. In this case, the 
remainder of the solute would be retained on the column by a different 
mechanism, such as adsorption onto the silica support, and therefore have 
a slightly different retention time to the included sample, thus giving 
rise to split peaks. Since the column efficiency is fairly low, the 
smaller of the two peaks is manifested as a shoulder an the larger peak. 
As the capacity of the column for inclusion complexing is likely to 
constant, the position of the shoulder depends upon the total amount of 
sample; for less concentrated solutions, inclusion complexing is the major 
interaction and that retained by other mechanisms gives rise to the 
shoulder, while for high concentration samples, the majority of the sample 
is retained by the additional mechanism and inclusion complexing becomes 
the secondary interaction causing the shoulder.
The study was then transferred to a new Cyclobond I phase and further 
investigations continued, The new column was, however, tested prior to 
use as previously described and found to give no improvement in 
efficiency over those tested earlier. Using an eluent of 25% methanol in 
buffer, injections were made of all the amino alcohols under 
investigation, including verapamil, Although peaks were observed for all 
the compounds, the retentions of which are shown in table 4.4.1, none of 
them showed any sign of resolution.
Attempts were then made to resolve the enantiomers by derivatising each 
compound prior to analysis. Samples of all the amino alcohols,
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The Retentions of Under!vatised Amina Alcohols 
Sample k'
Metoprolol 1.92
Atenolol 0.23
Propranolol 2.31
Verapamil 5.54
Alprenolol 1. 08
Oxprenolol 0.54
Practolol 0.31
Table 4.4.1: Column: 25cm Cyclobond I
Eluent: 25% methanol in 1% triethylamine 
acetate buffer, pH 4.1 
Injection Volume: 10 pi 
Detection: UV 230 nm
including verapamil, were derivatised by the previously described 
proceedure to form acetyl and trifluoroacetyl derivatives. Two mobile 
phase systems were used; 75% methanol in water and 60% methanol in 
water, and injections of the two derivatives of each compound were made 
with both eluents, The retentions far- each derivative were measured for 
all the compounds and it was found that, with the exception of verapamil,
for each eluent system all the acetyl derivatives shared a common 
retention time, as was likewise the case far all the trifluoroacetyl 
derivatives. In addition to this it was found that, for each eluent, the 
trifluoroacetyl derivatives were more strongly retained than the acetyl 
derivatives. The occurrence of a common retention time for each 
derivative, although unexpected, may possibly be explained by considering 
the nature and configuration of the inclusion complex formed between the 
solute and the cyclodextrin. Since all the amino alcohols under 
investigation have different aromatic ring systems attached to a common 
side chain (see figure 2.11), if the aromatic ring system was included in 
the cyclodextrin cavity, then the retention times far each salute would 
differ, as was the case for the underivatised compounds. Although this 
is the accepted configuration of the inclusion complex, it does not 
account far the results obtained, which can be more readily explained by 
considering that the aliphatic side chain is included into the 
cyclodextrin cavity in preference to the aromatic system. This 
postulation is more feasible in the case of the trifluoroacetyl 
derivatives, since it is known that chlorine atoms have a strong affinity 
for the cyclodextrin cavity and therefore the same is likely to be true 
for fluorine atoms. However, this does not follow for the acetyl 
derivatives, and it can only be supposed that the reduction in polarity 
of the derivatives, together with a possible size criteria make this 
configuration more stable than if the aromatic portion was included.
In addition to this, it was found that several of the trifluoroacetyl 
derivatives showed signs of possible enantiomeric separation, with split 
peaks achieved for atenolol, propranolol and alprenolol. The experiment
was repeated using freshly prepared trifluoroacetyl derivatives and 
injection volumes varied to ascertain whether the peak splitting could be 
caused by column overloading, as was previously the case. The fresh 
derivatives were also found to give split peaks and the chromatograms 
for each compound were similar to those obtained previously, regardless 
of the injection volume used. Since the two peaks for each compound were 
of comparable size, it therefore seems likely that they are caused by 
chiral resolution, although further work to verify this by using single 
enantiomers was prevented both by time considerations and by a drop in 
the efficiency of the Cyclobond column.
It was interesting to note that no such resolution was achieved with the 
acetyl derivatives, possibly since they were not so strongly included 
within the cycladextrin cavity.
4.4.4 Resolution of Chlorpheniramine
Since the column had failed to resolve any of the previously 
mentioned compounds without prior derivatisation, it was decided to 
attempt to resolve a different sample compound using a published method 
in order to obtain some assessment of the column performance in 
comparison to similar columns used elsewhere. Chlorpheniramine, an 
antihistaminic drug whose structure is shown in figure 2.10, has been 
resolved on the Cyclobond I phase by Armstrong and co workers [2703 
using an eluent of 15% acetonitrile in 1% triethylamine acetate buffer, pH
4.1,
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A similar system was therefore set up and found to be successful in 
partially resolving the sample enantiomers, although the peaks were not 
fully resolved (see figure 4.4.5). Further retention studies were carried 
out, initially investigating the effects of the mobile phase composition 
on both the capacity ratios and separation factor of the peaks,
The percentage of organic modifier in the eluent was varied between 5 and 
20% at a flow rate of 0,6 ml/min, and the results are shown in table 4.4.2
These results show that the Cyclobond column behaves in a similar way to 
a standard reverse phase ODS column, with the increase in organic 
modifier causing a decrease in the retention of the compound. As would 
also be expected the separation of the partially resolved peaks decreases 
as the percentage of acetonitrile increases. The degree of resolution is 
dependent on the retention time, since the more rapidly the compound is 
eluted through the column, the less time there is for the subtle 
interactions, necessary for enantioselective resolutions, to be manifested.
The effect of the mobile phase pH on the retention and resolution of the 
solute was also investigated over the range 4 to 7 and it was found that, 
as the pH was increased, the retention of the compound increased, and the 
separation factor decreased. In addition, the effect of flow rates on the 
resolution was investigated, since it had been suggested that the 
efficiency of the separation could be significantly increased by using 
lower flow rates [4751, Two eluent systems were used: 15% acetonitrile in 
buffer pH 4.1 and 10% acetonitrile in buffer, pH 4.1, and flow rates were 
varied between 1.0 and 0,4- ml/min. The capacity and separation factors
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The Resolution of Chlorpheniramine
H-----------------------------------------------------------1
15 0
Figure 4.4.5 Column: Cyclobond I
Eluent: 10% Acetonitrile in 1%
trlethylamine acetate buffer, pH 
Flow Rate: 1.0 ml/min 
Detection: UV 261 nm 
Injection Volume: 10 pi
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The Effect of Mobile Phase Composition on the Resolution of 
Chlorpheniramine
% Acetonitrile k * t k'^ a
20 1.25 - 1. 0
15 2.20 2.34 '1. 064
10 4.83 5. 19 1. 074
5 10.54 11,40 1. 082
Table 4.4.2: Column: 25cm Cyclobond I
Eluent: Acetonitrile in 1% trlethylamine 
acetate buffer, pH 4.1 
Injection Volume: 10 pi 
Detection: UV 261 nm
were calculated and the results shown in table 4.4.3.
Since the two peaks were only partially resolved, it was not possible to 
assess the efficiency of the separations, and therefore only the 
separation factors were calculated. These show only minor variations and 
do not fall into any particular pattern, and do not give any indication 
of changes in efficiency, However, visual comparisons and calculations 
based on projected peak shapes appear to show that the flow rate makes
The Effect of Flow Sate on the Resolution of Chlorpheniramine
Eluent Flow Rate k* -i k'a a
15% CHs.CN 1.0 2.25 2.42 1.0 76
15% CHaCI 0,6 2.29 2.43 1. 061
10% CHs.CN 0. 6 4, 75 5,10 1. 074
10% CHs.CN 0,4 4. 75 5. 10 1. 074
Table 4.4.3: Column: 25cm Cyclobond I
Eluent: Acetonitrile in 1% triethylamine 
acetate buffer, pH 4,1 
Injection Volume: 10 pi 
Detection: UV 261 nm
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little difference to the efficiency of the separations or to the degree of 
resolution.
In conclusion, this section of work shows that at least partial 
enantioselective resolutions are possible for some compounds.lt is 
interesting to compare the results obtained in this section with those 
reported for the published method. Although the efficiency of the column 
was considered to be particularly low, a separation factor of 1.074 was 
achieved using an eluent of 15% acetonitrile in 1% triethylamine acetate 
buffer, pH 4.1, whereas under similar conditions, the separation factor 
reported by Armstrong and co workers was 1.070. These results however, 
do not take peak shape into consideration, and therefore the degree of 
resolution; that is, whether the peaks are baseline separated or only 
partially resolved, cannot be ascertained without a study of the 
chromatograms. Since no chromatograms were shown in the published 
report, further comparisons were not possible
4.4.5 Resolution of Clomiphene
In addition to enantioselective analysis, the cyclodextrin phases are 
ideally suited to the resolution of structural isomers, since the 
inclusion complex formation is a spatially dependent interaction.
Although such isomers have differing physical properties, they are often 
not sufficiently different to facilitate easy resolution by conventional 
reverse phase columns.
Clomiphene, an anti-oestrogen drug whose structure is shown in figure 
2.10, is a compound which exhibits such geometric isomerism, existing in
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cis- and trans- forms, and was therefore selected for this investigation. 
A system was set up using a methanol trlethylamine acetate buffer mobile 
phase and retention studies were carried out. Initial investigations 
involved varying the mobile phase composition to determine the effect on 
both retention and resolution of the enantiomers, The composition was 
varied between 40 and 70% methanol in 1% trlethylamine acetate buffer, pH
4,1, at a flow rate of 1.0 ml/min and the results are shown in table 
4.4.4.
Good resolutions of cis- and trans-cloraiphene were achieved using this 
system (see figure 4.4.6) and both peaks were well separated with a 
methanol concentration of up to 60%, and again, as the percentage of 
organic modifier in the eluent increased, the retention and resolution of 
cloraiphene decreased.
The effect of varying the buffer pH was also investigated by selecting a 
50% methanol in 1% triethylamine acetate buffer eluent system and varjring 
the buffer pH between 4 and 7. The results, given in table 4.4^, show 
that the resolution of the isomers decrease as the pH of the mobile phase 
increases. This is in marked contrast to the expected trend which would 
indicate that as the pH increases, the retention of a basic compound 
increases, and in general, the resolution increases in accordance with 
retention increases. In this case the increase in retention with pH is 
observed but it is accompanied by a decrease in the separation factor. 
This can be explained by considering the interactions between the 
cyclodextrin and the solute when an inclusion complex is formed. The 
retention behaviour of each isomer is determined not only by the
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Clomiphene
% Methanol k' t k ' & oc
The Effect of Mobile Phase Composition on the Resolution of
40
50
60
70
2.21
1.21
0.32
0.23
5.54 
3. 00 
0.79
2.51
2.48
2.46
1 .0 0
Table 4.4..Z: Column: 25cm Cyclobond I
Eluent: methanol in 1% triethylamine 
acetate buffer, pH 4,1 
Injection Volume: 10 pi 
Detection: UV 245 nm
Resolution of Cis and Trans Clomiphene on the Cyclobond Phase
Figure 4.4.6 Column: Cyclobond I
Eluent: 50% methanol in 1% trlethylamine 
acetate buffer, pH 6.0 
Flow Rate: 1.0 ml/min 
Detection: UV 245nm 
Injection Volume: 10 pi
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inclusion of the salute but also by hydrogen bonding interactions with 
the primary and secondary hydroxyl groups positioned at the opening of 
the cyclodextrin cavity. Since both clomiphene and chlorpheniramine are 
basic compounds containing a tertiary amine group in their structures, in 
a law pH environment they exist in an ionised form, with a proton on the 
nitrogen atom available for hydrogen bonding with a hydroxyl group if 
the structure of the isomer permits. However, at a higher pH, the 
compounds exist in a free base form, and although they are retained in 
the lipophilic cyclodextrin cavity longer, the scape for hydrogen bonding 
with the cyclodextrin hydroxyls Is limited, and therefore the differences 
in retention between the two isomers lessens, ultimately becoming 
insufficient to resolve the two peaks.
Since previous attempts to resolve the isomers of clomiphene on a reverse 
phase ODS column had been unsuccessful, this section of work highlights 
the suitability of the cyclodextrin phase for separations of this type.
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The Effect of pH on the Resolution of Clomiphene
Eluent pH k* , k ’s oc
4 1.21 3.00 2.48
5 0.96 2.11 2.20
6 1.68 3.21 1.91
7 3.25 5,71 1.76
&
Table 4.4.2-!: Column: 25cm Cyclobond I
Eluent: 50% methanol in 1% triethylamine 
acetate buffer 
Injection Volume: 10 pi 
Detection: UV 245 nm
It was initially hoped that this phase would provide the basis of a 
relatively simple method to resolve the enantiomers of beta blockers 
under reverse phase conditions. Although the success of this section of 
work was limited in this respect, there are still a number of interesting 
points which can be drawn from it.
The inability to resave the enantiomers of propranolol and the other 
amino alcohols, in spite of being disappointing, was not altogether 
unexpected, since Armstrong and co workers [2701 had found it necessary 
to use two 25cm Cyclobond I columns in series in order to increase the 
efficiency sufficiently to resolve the two isomers of metopralol and 
propranolol.
The resolution of same of the amino alcohols as trifluoroacetyl 
derivatives should ideally have been studied further, had not the column 
efficiency dropped to below an unacceptable level. As far as possible, 
samples of single enantiomers should be derivatised to form similar 
derivatives and chromatographed, to ensure that the split peak obtained 
for the racemic mixture is caused by the resolution of the enantiomers of 
each compound.
4.4.6 Discussion
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Other types of derivatives could also have been studied to ascertain 
whether separations could be achieved for the remainder of the beta 
blockers, and in addition, as many different aminaalcahols as passible 
should be reacted to form each type of derivative and injected in an 
attempt to characterise the mechanism of stereoselective resolution and 
investigate the orientation of the solute within the cyclodextrin.
Comparisons can also be made between the resolutions of chlorpheniramine 
and clomiphene. Only partial resolutions of chlorphenirame can be 
achieved with conditions of 5% acetonitrile in buffer, whereas clomiphene 
isomers can still be separated with eluents of 70% acetonitrile in buffer 
and pH values of up to 7. Further information an the variation of 
retention and resolution of these compounds with the pH of the mobile 
phase could be obtained by selecting a range of compounds with different 
hydrogen bonding capabilities and investigating the effect of eluent pH 
an each.
It can therefore be concluded that, although the Cyclobond I phase did 
not produce the desired separation, such resolutions were more readily 
achieved by the formation of a trifluoroacetyl derivative prior to 
chromatographic analysis. It must be noted, however that if precolumn 
derivatisation reactions are necessary, one of the main advantages of the 
phase is lost.
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4.5 Enantiomeric Separations Using a "Pirkle'" Type Phase
4.5.1 Introduction
Literature studies have showed that, of all the commercially 
available chiral stationary phases, the "Pirkle" columns have the widest 
range of applications, and hence it was selected to investigate the 
possibility of achieving enantiomeric resolution of the beta blocking 
drugs,
There are, however, a number of "Pirkle" type columns, differing both in 
the chiral selector and in the type of banding between the selector and 
the silica support, and therefore factors such as the type of sample and 
mobile phase must be considered in making a selection. Since the beta 
blockers are re electron donors, they will be resolved best on a phase 
which is a re electron acceptor, and thus the 3,5-dinitrobenzoyl 
phenylglycine phase was selected. These are available with either an 
ionic or a covalent bond between the chiral selector and the silica 
support and the choice between the two is dependent on the type of 
mobile phase required for the separation; ionic phases can only be used 
with eluents of low polarity while covalently bonded phases may be used 
with solvents of any polarity, including water.
Such phases work on the basis of having a minimum of three points of 
interaction between the salute and the phase, and if such interaction 
sites are not present in the sample, a derivatisation reaction can be 
performed to add a suitable group to the molecule. However there are a
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number of disadvantages inherent with derivatisation reactions, not least 
of which is the increase in sample preparation time and also in 
unavoidable sample losses.
4.5.2 Resolution of Propranolol
The primary aim of this study centred on developing a method for 
enantiomeric separations without the need for derivatisation, and once 
again propranolol and verapamil were chosen to be the model compounds. 
Initial attempts to resolve the enantiomers using the suggested eluent of 
10% isopropanol in hexane were found to be unsuccessful, with both 
compounds being retained on the column for over an hour, and so further 
retention studies were carried out. A covalent phase was chosen for this 
work in order that the mobile phase could be varied between 100% 
methanol and 100% hexane, and a system was set up using methanol : 
isopropanol : hexane eluents and UV detection. Injections of both 
compounds were made and the capacity ratios and any sign of chiral 
separations were noted for each eluent system (see table 4.5.1).
With methanol and methanol : isopropanol mobile phases, both propranolol 
and verapamil were eluted with the solvent peak, but in no case was there 
any evidence of enantiomeric resolution for either compound with any of 
the eluent systems investigated, although as the polarity of the solvent 
decreased so the retentions increased until with 10% isopropanol in 
hexane, the compounds were retained on the column. This was due to both 
the polarity of the solute molecules and
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The Variation of the Retention of Propranolol with
Mobile Phase Composition
Eluent k ‘ (Prapranolol) k'(Verapamil)
1:2:2 0. 100 1. 08
4:3:3 0.83 1.50
C
O
}—
i 1. 83 2.33
8:1:1 3. 00 4. 00
18:1:1 5.25 7.38
Table 4.5.1 Column: 25 cm <R)~3,5-dinitrobenzoyl phenylglycine 
Eluent: hexane:isopropanol:methanol 
Flow Rate: 1,0 ml/rain
Detection: UV, verapamil-232nm, propranolol~288nm 
Injection Volume: 20 pi
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possibly to a lack of sufficient suitable functional groups to interact 
with the phase. Since the aminoalcohols are highly polar molecules, as 
is the phase itself, they are not readily eluted from the column, with 
eluents of law polarity. Yet increasing the polarity of the mobile phase 
causes the solutes to be eluted too rapidly for enantioseparation to 
occur.
Molecular models of both the phase and the solutes were used to identify 
the possible interaction sites and establish whether they are sufficient 
to permit chiral separation in the absence of polarity considerations.
For the purpose of this exercise, the 3,5 dinitrobenzayl phenylglycine was 
considered to preferentially reside in the conformation in which the 
amide hydrogen is in the plane of, and trans to the amide carbonyl 
oxygen.
The possible interactions of propranolol are shown in figure 4.5.1 and 
indicate that chiral selectivity should be possible since the solute 
molecule has the required three interactions, spaced about both chiral 
centres. Once the solute is immobilised on the phase, differences in 
steric hindrances between the isomers will weaken the interactions far 
one enantiomer, allowing chiral resolution. However, similar studies show 
that verapamil is unlikely to be resolved on the 3,5-dinitrobenzoyl 
phenylglycine phase since there is only one point of interaction between 
the solute and the phase, namely the re-re interaction between the 
activated aromatic group of verapamil and the deactivated dinitrobenzayl 
group of the phase,
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Since the previous section of work had proved to be unsuccessful, 
some form of derivatisation of the samples was deemed to be necessary.
As the point of performing a derivatisation reaction was to introduce a 
functional group which would provide a suitable site for interaction with 
the phase when necessary, the choice of derivative was critical.
Successful resolutions have been achieved for a number of amines C4763 
and aryl aminoalkanes [477] on this phase by the formation of their a- 
naphthamide derivatives and hence a similar approach was taken with the 
beta blockers. The formation of naphthamide derivatives from the 
secondary amine solute (see figure 4.5,2) not only reduces the polarity, 
but the re basic naphthyl ring system is able to form strong re-re 
interactions with the re acidic 3,5-dinitrobenzoyl group,
This approach was eventually found to be very successful and resolutions 
have been achieved for five of the seven compounds of interest (see 
figure 4.5,3 and figure 4.5.9a-g). However, the initial attempts involved 
the use of an ionic phase which gave no separations at all, and it proved 
necessary to transfer the method to a covalently bound column of the 
same phase before suitable chiral separations were attained. Such 
covalent columns have been found to be considerably more robust and also 
give significantly higher efficiencies when tested with 2,2,2-trifluoro-l- 
(9-anthryl) ethanol under standard conditions, in this case 21700 plates 
for the covalent column compared to 9000 plates for the ionic phase (see 
figure 4.5.4). Thus all further work was carried out using covalent 
phenylglycine columns.
4.5.3 Resolution of Propranolol Naphtkamide
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Resolution of Propranolol as the laphthamide Derivative 
on a 3,5-Dinitrobenzoylphenylglyclne Phase
O'
'o
■H
K>
V
v
n
Figure 4.5.3 Column: covalent <R>-3,5-dinitrabensoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20pl
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Test Chromatograms for the <R>-3,5-Dinitrobenzoyl 
Phenylglycine Phase
30
Covalent Phenylglycine Column
30 . 0
Figure 4.5.4 Column: <R)-3,5-dinitrobenzoylphenylglycine
Eluent: 10% isopropanol in hexane
Flow Rate: 2.0 ml/min
Detection: UV 280 nm
Injection Volume: 20pl
Sample: 2,2,2-trifluoro-1-(9-anthryl) ethanol
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The influence of the mobile phase composition on both retention and 
separation was investigated using samples of propranolol derivative. The 
mobile phase was varied between 8% and 20% isopropanol in hexane, and 
the retention times and separation factors for each eluent showed the 
expected trend that increasing the polarity of the mobile phase has the 
effect of decreasing the retention, and also the resolution of the two 
enantiomers (see table 4.5,2),
An attempt to assess the effect of the stucture of the analyte on the 
retention and separation of the enantiomers was made by derivatising 
samples of each of the other beta blockers and subjecting them to 
analysis with a mobile phase of 10% isopropanol in hexane. Wherever 
possible the individual enantiomers of each compound were also 
derivatised and chromatographed, to ascertain that the two peaks were 
definitely due to the two isomers, and in each case the (+)- isomer 
eluted before the <->- isomer (see figure 4,5,9d~g>. Although the 
derivatives of practolol and atenolol were retained on the column, the 
retention times and separation factors of the others are shown in table 
4.5.3.
From a study of the molecular structures, shown as their l~naphthamide 
derivatives in figure 4,5.5., several trends can be established. Both 
propranolol and pronethalol molecules contain two naphthyl groups, either 
of which could potentially form the transient re-re bonds with the 3,5- 
dinitrobenzoyl group. However, in the case of propranolol, the 
naphthamide system is the least re-basic of the two, owing to the electron 
withdrawing power of the carbonyl group, and thus the
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The Effects of Variations in Mobile Phase Composition on the 
Resolution of Propranolol laphthamide Derivatives on a Covalent 
<R) 3,5-Dinitrobenzoyl phenylglycine Phase
% Isopropanol ki* fcs' a
8 25,32 27.40 '1. 082
10 20.51 22.20 1. 082
12 17.71 18.91 1. 068
14 14.20 15. 11 1. 064
16 12.20 12.89 1. 057
20 9.95 10.36 1. 041
Table 4.5,2 Column: covalent (R)-3,5-dinitrobenzoyl
phenylglycine 
Eluent: isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nra 
Injection Volume: 20/il
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Retention of Aminoalcohols as their 1~ Naphthamide Derivatives 
on a Covalent (R) 3,5-Dinitrobenzoylphenylglycine Phase
Analyte ki' ka* oc
Propranolol 22. 06 23.88 1. 082
Pronethalol 12.75 13.67 1. 072
Oxprenolol 16. 00 17. 00 1. 063
Alprenolol ooo 7.40 1. 058
Metoprolol 16.92 17.83 1. 054
Table 4.5.3 Column: covalent <R)-3,5~dinltrobensoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20jil
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Structures of l-Iaphthamide Derivatives
ATENOLOL
OHi
0-C H2-CH-CH2 - N-CH (CH, )2
r  V
ch2-cg.\ih2
PRACTOLOL
0-CH2*CH-CH2-N-CH(CH3L
V
OXPRENOLOL
OHI
0-CH2-CH-CH2-N-CH(CH352 
q Y 0-CH2-CH V-o
ch2 A / \foYo1
ALPRENOLOL
OH
g-CH 2-C H -C H 2-M-CH(CH3)2
f o i o l
PROPRANOLOL metoprolol
0-CH2-CH-CH2-N-CH{CH3).
PRONETHALOL
Figure 4.5.5
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interaction occurs at the opposite end of the molecule, This is also 
likely to be true for pronethalol, since again the carbonyl group is more 
electron withdrawing than a hydroxyl. The differences in retention and 
resolution between the two probably arises from differences in the 
aminoalcohol chain length. With the aromatic end secured by re-re 
interactions, the longer chain length of propranolol may enable the other 
functional groups to approach in closer proximity and thus form stronger 
hydrogen bonds than would be possible for pronethalol, In addition to 
this the re-re interactions are likely to be stronger for propranolol.
Since none of the other beta blockers have a second naphthyl system in 
their molecular structures, the re-re interaction between the solute and 
phase occurs at the naphthamide group, The difference in retention and 
resolution between oxprenolol and alprenolol is more interesting since to 
all intents and purposes the major interactions of re-re and hydrogen 
bonding should be similar for each. The difference between the two 
structures lies in the substituted phenyl groups; that of oxprenolol being 
more electron deficient than that of alprenolol. For this to affect the 
retention and resolution the phenyl group must also be involved in the 
phase-solute interactions, although it is not yet clear in what way. It 
was also interesting to note that the two compounds, atenolol and 
practolol, which were not eluted under these conditions both had amide 
groups on the phenyl ring, but it is difficult to assess whether the long 
retention is due to the formation of different interactions or whether, in 
fact, the derivatisation has not been successful.
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A further investigation of the effect of structural differences in the 
solute was carried out by altering the derivatising reagent. Two similar 
samples of propranolol were derivatised, one with 1-naphthoyl chloride 
and the other with 2-naphthoyl chloride, as shown in figure 4.5.6. When 
chromatographed under standard conditions the results were as shown in 
table 4.5.4. The increase in both retention and resolution of the 2- 
naphthamlde derivative is possibly more due to the different orientation 
of the 2-naphthamide ring system causing less steric hindrance between 
the solute-phase complex than to differences in any of the primary 
interactions.
Retention of Propranolol Naphthamide Derivatives on a Covalent 
<R) 3,5-Dinitrobenzoylphenylglycine Phase
Derivative ki 1 ks' a
1-Naphtharaide 17.4 18.2 1,046
2-Naphthamide 25.8 27.4 1.062
Table 4.5,4 Column: (R)-3,5-dinitrobenzoylphenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20pl
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Standard Curves for Propranolol as its Naphthamide 
Derivative on a 3,5-Dinitrobenzoylphenylglycine Phase
Peak Area
3,000,000
2,500,000 --
A
2 ,000,000
1,500,000 --
1,000,000
500,000 --
P
/
/
/
/
/
/
/ff s  (+) Propranolol y=-23133 +  4181x, r=0.9993
y j T  - a -
A ' /  (-) Propranolol y=-68544 +  5486x, r=0.9970
j s r
A-------- +■
100 200 300 400
Standard Concentration (ug)
500
Figure 4.5.7 Column: (R)-3,5-dinitrobenzoylphenylglycine 
Eluent: 10% Isopropanol in hexane 
Flow Rate: 1.0 ml/min 
Detection: UV 288 nm
Although several stages of the derivatisation proceedure were 
investigated , the unavailability of a pure unextracted naphthamide 
standard made an assessment of the yield or recovery of the method a 
difficult task. However, several standard curves were assayed over the 
range 1-0.01 mg/ml propranolol, and in each case the correlation 
caeficients were not less than 0.99 (see figure 4.5.7), leading to the 
assumption that the derivatisation proceedure was, at least, uniformly 
quantitative over this range. Problems with the method occurred at 
concentrations below this range due to an interference which swamped the 
detector response to the enantiomeric derivative. This may have been 
caused by the use of Teflon lined screw caps during derivatisation, since 
Teflon is known to affect the reaction (478), or alternatively the 
interference may be due to the excess derivatising reagent. This could 
possibly be overcame by either solid phase extraction or column switching 
techniques when the method is put into routine use for monitoring 
enantiomeric plasma levels.
4,5.4 Computer Modelling
In an attempt to assess whether computer modelling facilities could 
be used as a tool to predict the ability of a phase to resolve a given 
compound, computer modelling studies were carried out by Dr D. Lewis,
Dept, of Biochemistry, University of Surrey, with a view to comparing the 
computer predictions to the experimental data.
Representative structures were set up for both enantiomers of the 
naphthamide derivatives of each amino alcohol, and each structure was
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8b
modelled against that of the (R)-3,5-dinitrobenzoyl phenylglycine chiral 
selector, as shown in figure 4.5.8. Interactions, such as hydrogen 
bonding, ti-ju interactions and steric hindrances, between the two 
molecules were assessed, and the total interaction energy, a H, was 
calculated for the most stable of all possible conformations far each 
solute-phase pair. This process was repeated for all of the beta blacker 
enantiomers and the results are shown in table 4.5.5.
The values far a H provide a measure of the stability of the solute-phase 
complex and the more negative the number, the more stable the complex.
If such computer predictions are to be successful, it must therefore 
follow that the more stable the solute-phase complex, the longer it is 
retained on the column far any given conditions. Thus the degree of 
resolution between two enantiomers can be ascertained by calculating the 
difference, A(AH), between their interaction energies since this is 
indicative of the difference in retention of each isomer, and the relative 
elution order of the isomers predicted.
In order to test the validity of this prognosis, it is necessary to 
compare the interaction energy values with the experimental results.
Such a comparison, is given in table 4.5.6 and highlights a number of 
discrepancies between the predicted and experimental results,
It is difficult to rank the compounds into an elution order using the AH 
values since a number of the enantiomers overlap, but it can be seen that 
atenolol should have a retention similar to propranolol and that 
practolol should be eluted between oxprnolol and metoprolol, whereas in
- 197 -
Interaction Energies Between (R)3,5 Dinitrobenzayl Phenylglyine 
and the Enantiomeric Amino Alcohol Naphthamides
Analyte a H<-> AH<+> A(AH)
(kcal/raole) (kcal/raale) (kcal/mole)
Propranolol -24.483 -12.089 12.394
Metaprolol -8.263 -11.257 2,994
Atenolol -19.557 -17.281 2.276
Pranethalol -16.031 -14.784 1.247
Practolol -13.770 -13.029 0.741
Alprenolol -18.446 -18.549 0. 103
Oxprenalol -15.099 -15.022 0. 077
Table 4.5.5
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practice, neither was eluted from the column within an hour. Metoprolol, 
which has the least negative values, implying that the solute-phase 
complexes are the least stable, is actually the second most retained 
compound, and in contrast, alprenolol is the least retained compound yet 
has one of the most stable interaction energies.
Comparisons of resolutions are no more successful, with the energy values 
showing that alprenolol and oxprenolol are unlikely to be separated, 
whereas experimentally they are reasonably well resolved. Likewise, 
metoprolol is the least well resolved, yet has the second largest 
difference between the enantiomers. It is impassible to judge whether the' 
predictions of the elution order of individual enantiomers is correct 
since this was determined experimentally in only two cases, both of v/hich 
agreed with the energy values.
Hence, as a means of predicting whether or not a separation can be 
achieved for individual compounds on a given phase, computer modelling 
appears to be largely unsuccessful and neither can it be used to predict 
the separation of an unknown compound by reference to a known 
separation. The reasons for this lack of success are based primarily on 
the simplicity of the models used.
While the interactions between the stationary phase and each salute 
enantiomer can be accurately calculated from such molecular models there 
are a number of other important factors in liquid chromatographic 
separations. As has been illustrated throughout the whole of this study, 
the nature of the mobile phase is of paramount importance to a
separation, and resolution can be achieved or lost through the choice of 
mobile phase. A chromatographic resolution is a result of a competition 
between the solute-stationary phase interactions and solute-mobile phase 
interactions and therefore it is not sufficient to make predictions based 
on only one of these, Although one enantiomer may farm a significantly 
more stable solute-stationary phase complex than the other, the increase 
in retention that this should produce may be counteracted by the same 
enantiomer forming a more stable solute-mobile phase complex than the 
other.
Other factors which should be taken into account when attempting to 
predict the success of a separation include the nature of the linkage 
between the chiral selector and the silica support, the nature of the 
residual silanol groups on the silica support and the phase loading.
Although such a simple modelling system is not well suited to liquid 
chromatography systems, it may be more successfully applied to gas 
chromatographic separations. In this case the nature of the mobile phase 
is not varied and separations are achieved solely though solute- 
stationary phase interactions and temperature effects. As this is more 
akin to the model system used by the computer, the predicted values and 
experimental results should be more closely correlated.
'This section of work shows that computer based molecular modelling 
systems have the potential to predict the separation of enantiomeric 
compounds on a given phase, thus aiding the selection of the best phase 
to resolve the compound of interest. However it is important to be able 
to model all the experimental condition in far more detail than at 
present. The complexity of such a system could make it easier and even 
mare economical to find the best phase for each particular separation by 
an experimental trial and error approach.
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Resolution of Alprenolol as the Naphthamide Derivative
on a 3,5~Dinitrobenzoylphenylglycine Phase
Figure 4.5.9a Column: covalent <R)-3,5-dinitrobenzoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20p.l
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Resolution of Gxprenolol as the Naphthamide Derivative
on a 3,5-Dinitrobensoylphenylglycine Phase
K<
in in 
c-i o
I’l
M.
\A
/ V J  \
Figure 4.5.9b Column: covalent (R)-3,5~dlnitrobensoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20pl
Resolution of Metoprolol as the laphthamide Derivative
on a 3,5-Dinitrobenzoylphenylglycine Phase
CM M3in o
M3 N 
CM C-
A A
I A-.. \
V
Figure 4.5.9c Column: covalent <R)-3,5-dinitrabensoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20pl
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<+> Propranolol as the Naphthamide Derivative 
on a 3,5-Dinitrobenzoylphenylglycine Phase
Figure 4,5.9d Column: covalent (R)-3,5-dinitrobenzoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2,0 ml/min 
Detection: UV 280 nm 
Injection Volume: 20pl
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<-) Propranolol as the Naphthamide Derivative 
on a 3,5-Dinitrobenzaylphenylglycine Phase
Figure 4.5.9e Column: covalent (R)-3,5-dinitrobenzoyl
phenylglycine 
Eluent: 10% Isopropanol in hexane 
Flow Rate: 2.0 ml/rain 
Detection: UV 280 nm 
Injection Volume: 20pl
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<-) Pronethalol as the laphthamide Derivative 
on a 3,5-Dinitrobensoylphenylglycine Phase
Figure 4.5,9f Column: covalent <R)-3,5~dinitrobenzayl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flow Rate: 2.0 ml/min 
Detection: UV 280 nra 
Injection Volume: 20pl
- 208 -
<+> Pronethalol as the faphthamide Derivative
on a 3,5-Dinitrobenzoylphenylglycine Phase
Figure 4-.5.9g Column: covalent (R)-3,5-dinitrobenzoyl
phenylglycine 
Eluent: 10% isopropanol in hexane 
Flaw Rate: 2.0 ml/rain 
Detection: UV 280 nm 
Injection Volume: 20pi
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4.6 Enantiomeric Resolutions Using an oti Acid Glycoprotein Phase
4.6.1 Introduction
In a final attempt to achieve enantiomeric resolutions of the beta 
blockers without performing a precolumn derivatisation reaction, an ah 
acid glycoprotein (AGP) phase was obtained, Since protein phases of this 
type attempt to mimic the in-vivo stereoselective binding processes, such 
phases should theoretically be capable of resolving numerous enantiomeric 
drugs. Unfortunately, initial phases of this type had low capacities and 
short lifetimes unless treated with the greatest of care. However, these 
columns have now been improved by a patented process by which the AGP 
is bonded to the silica support [311], thus Increasing the phase 
stability.
The columns are used almost exclusively with mobile phases of aqueous 
phosphate buffers with the addition of small amounts of organic modifiers 
such as methanol, ethanol, propanol, isopropanol and acetonitrile, and is 
stable within a pH range of 3.0 to 7.5, The suggested buffer 
concentrations are between 0,011 and 0.035M and the
4.6.2 Retention Studies
Initially a system was set up with the AGP column and an eluent of 
10% acetonitrile in 0.011 phosphate buffer, pH 7.0, using a UV detector 
set at 225 ni. Injections were made of 0.01 mg/ml solutions of a number 
of beta blockers and verapamil. This approach proved to be very 
successful, giving baseline resolutions of both verapamil and oxprenolol.
-  2 1 0  -
R e t e n t i o n  s t u d i e s  w e r e  t h e n  c a r r i e d  o u t  t o  i n v e s t i g a t e  t h e  e f f e c t  o f  
c h a n g e s  i n  m o b i l e  p h a s e  c o m p o s i t i o n  o n  r e t e n t i o n  a n d  r e s o l u t i o n ,  T h e  
e l u e n t s  w e r e  v a r i e d  b e t w e e n  1 0 0 %  0 . 0 1 1  p h o s p h a t e  b u f f e r  p H  7 , 0  a n d  5 %  o f  
e i t h e r  a c e t o n i t r i l e  o r  i s o p r o p a n o l  i n  a  s i m i l a r  b u f f e r ,  a n d  w i t h i n  t h i s  
v a r i a t i o n ,  s e p a r a t i o n s  w e r e  a c h i e v e d  f o r  a l l  t h e  c o m p o u n d s  u n d e r  
i n v e s t i g a t i o n  w i t h  t h e  e x c e p t i o n  o f  p r a c t o l o l  ( s e e  f i g u r e  4 . 6 . 1 a - f > .
T h e  c h a n g e s  i n  r e t e n t i o n  a n d  r e s o l u t i o n  c a u s e d  b y  v a r i a t i o n s  i n  t h e  
m o b i l e  p h a s e  c a n  b e  s e e n  b y  c o n s i d e r i n g  t w o  c o m p o u n d s  f o r  s i m p l i c i t y ,  
f o r  e x a m p l e  a t e n o l o l  a n d  m e t o p r o l o l ,  T h e  c a p a c i t y  a n d  s e p a r a t i o n  f a c t o r s  
f o r  t h e s e  a r e  s h o w n  i n  t a b l e  4 . 6 . 1  a n d  i n d i c a t e  t h a t  d e c r e a s i n g  t h e  
a m o u n t  o f  o r g a n i c  m o d i f i e r  c a u s e s '  r e t e n t i o n  i n c r e a s e s  a n d  a l s o  i m p r o v e s  
t h e  r e s o l u t i o n .  T h e r e  a r e  n o  c l e a r  d i f f e r e n c e s  b e t w e e n  u s i n g  a c e t o n i t r i l e  
o r  i s o p r o p a n o l  a s  t h e  o r g a n i c  m o d i f i e r ,  a n d  t a b l e  4 . 6 . 2  s h o w s  a  
c o m p a r i s o n  o f  e a c h  m o d i f i e r  i n  a n  e l u e n t  a t  a  c o n c e n t r a t i o n  o f  5 %  i n  
b u f f e r .  T h i s  i n d i c a t e s  t h a t  w h i l e  t h e  u s e  o f  i s o p r o p a n o l  i n  p r e f e r e n c e  t o  
a c e t o n i t r i l e  i n c r e a s e s  t h e  r e t e n t i o n  f o r  p r a c t o l o l  a n d  a t e n o l o l ,  i t  h a s  
t h e  o p p o s i t e  e f f e c t  f o r  m e t o p r o l o l  a n d  o x p r e n o l o l .  S u c h  e f f e c t s  a r e  
l i k e l y  t o  b e  d u e  t o  d i f f e r e n c e s  i n  t h e  h y d r o g e n  b a n d i n g  a b i l i t y  o f  t h e  
t w o  s o l v e n t s .
F u r t h e r  s t u d i e s  o n  t h e  e f f e c t  o f  b u f f e r  p H  a n d  c o n c e n t r a t i o n  o n  
r e s o l u t i o n  w e r e  p r e v e n t e d  b y  a  d e t e r i o r a t i o n  i n  t h e  c o l u m n  c o n d i t i o n ,  
r e s u l t i n g  i n  p e a k  s p l i t t i n g  a n d  n o r  w a s  i t  p a s s i b l e  t o  d e t e r m i n e  t h e  
e l u t i o n  o r d e r  o f  t h e  e n a n t i o m e r s  o f  t h e  a n a l y t e s .  A l t h o u g h  t h i s  m a y  h a v e  
b e e n  d u e  t o  i n c o r r e c t  t r e a t m e n t  o f  t h e  p h a s e ,  i t  s t i l l  g i v e s  r i s e  t o  
u n c e r t a i n t i e s  c o n c e r n i n g  t h e  s t a b i l i t y  o f  t h e  p h a s e .  I n  s p i t e  o f  t h i s
R e t e n t i o n  S t u d i e s  f o r  A t e n o l o l  a n d  M e t o p r o l o l  o n  a n  
o h  A c i d  G l y c o p r o t e i n  P h a s e
A t e n o l o l  M e t o p r o l o l
E l u e n t k* i k ' a a k '  i k ' a : oc
1 0 %  CHaCN 1 . 8 0 - - 2 . 3 - -
5 %  CHaCN 1 . 9 - - 2 .  9 3 .  1 1 .  07
1 0 0 %  B u f f e r 3 . 4 4 3 . 8 9 1 .  1 3 9 . 5 1 2 . 2 1 . 2 8
5 %  I P A 2 . 3 3 - - 2 . 7 - -
T a b l e  4 . 6 . 1  C o l u m n :  A G P
E l u e n t :  O r g a n i c  M o d i f i e r  i n  0 . 0 1 M  p h o s p h a t e  b u f f e r  
p H  7 . 0  
F l o w  R a t e :  0 . 9  m l / m i n  
I n j e c t i o n .  V o l u m e :  2 0  p i  
D e t e c t i o n :  U V  2 2 5  n m
A c e t o n i t r i l e  I s o p r o p a n o l
The Effect of Variations in the Organic Modifier on the
Retention and Resolution of the Amino Alcohols
A n a l y t e 1 c '  i k ’  s o c k '  i k '  2  a
A t e n o l o l 1 . 9 - - 2 . 3 3 -
M e t o p r o l o l 2 . 9 3 ,  1 1 ,  0 7 2 . 7 -
P r a c t o l o l 2 .  0 - - 2 ,  1 -
O x p r e n o l o l 4 6 .  0 6 7 .  0 1 . 4 - 7 1 7 . 8 2 0 . 6  1 . 1 6
T a b l e  4 , 6 . 1  C o l u m n :  A G P
E l u e n t :  5 %  O r g a n i c  M o d i f i e r  i n  0 .  0 1 M  p h o s p h a t e  b u f f e r  
p H  7 .  0  
F l o w  R a t e :  0 . 9  m l / m i n  
I n j e c t i o n  V o l u m e :  2 0  p i  
D e t e c t i o n :  U V  2 2 5  n m
h o w e v e r ,  t h e  r e s u l t s  a c h i e v e d  w i t h  t h i s  p h a s e  a r e  t h e  m a s t  p r o m i s i n g  o f  
t h e  e n t i r e  s t u d y ,  a n d  i n d i c a t e  t h a t  e n a n t i o s e l e c t i v e  r e s o l u t i o n s  a r e  
p o s s i b l e  w i t h o u t  t h e  n e e d  f o r  p r e c o l u m n  d e r i v a t i s a t i o n  p r o v i d e d  t h e  
c o r r e c t  c h o i c e  o f  c h r o m a t o g r a p h i c  c o n d i t i o n s  i s  m a d e .
T h e  m a j o r  p r o b l e m  w i t h  t h e  s e p a r a t i o n s  a c h i e v e d  i n  t h i s  i n v e s t i g a t i o n  
d o e s  n o t  i n  f a c t  l i e  w i t h  t h e  r e s o l u t i o n  o f  t h e  e n a n t i o m e r s  b u t  r a t h e r  
w i t h  t h e  e f f i c i e n c y  o f  t h e  s e p a r a t i o n ,  A l t h o u g h  n o t  t e s t e d  w i t h  a  
s t a n d a r d  t e s t  m i x t u r e ,  t h e  e f f i c i e n c y  o f  t h e  c o l u m n  i s  f a i r l y  l a w ,  a n d  t h e  
s a m p l e  p e a k s  a r e  g e n e r a l l y  m u c h  b r o a d e r  t h a n  i s  c o n s i d e r e d  i d e a l .  T h i s  
c o u l d  h a v e  a  m a j o r  i m p a c t  o n  t h e  d e t e c t i o n  l i m i t s  o f  a n y  a s s a y  r u n  o n  
t h i s  p h a s e  s i n c e ,  a s  t h e  c o n c e n t r a t i o n  i s  r e d u c e d ,  t h e  b r o a d  p e a k s  w i l l  
r a p i d l y  b e c o m e  i n d i s t i n g u i s h a b l e  f r o m  t h e  b a s e l i n e .  U n l e s s  t h i s  c a n  b e  
o v e r c o m e  b y  t h e  u s e  o f  m o b i l e  p h a s e  a d d i t i v e s  o r  p H  c o n t r o l ,  t h e  
a p p l i c a t i o n  o f  t h e  p h a s e  t o  p h a r m a c o l o g i c a l  a n a l y s i s ,  w h e r e  t h e  s a m p l e  
c o n c e n t r a t i o n  i s  g e n e r a l l y  v e r y  l o w ,  i s  l i m i t e d .
I n  a d d i t i o n  t o  t h i s ,  t h e  i n j e c t i o n  o f  b i o l o g i c a l  e x t r a c t s  o n t o  t h e  c o l u m n  
c o u l d  f u r t h e r  r e d u c e  t h e  c o l u m n  l i f e t i n e  u n l e s s  e x t e n s i v e  c l e a n  u p  
p r o c e d u r e s  w e r e  u s e d .  U n f o r t u n a t e l y ,  t h e  c o l u m n  d e g r a d a t i o n  p r e v e n t e d  t h e  
i n v e s t i g a t i o n  o f  a n a l y t e s  e x t r a c t e d  f r o m  p l a s m a ,
Resolution of Atenolol on an oh Acid Glycoprotein Phase
i i
F i g u r e  4 . 6 . 1 a  C o l u m n :  A G P
E l u e n t :  Q . 0 1 M  p h o s p h a t e  b u f f e r ,  p H  7 . 0  
F l o v /  R a t e :  0 . 9  m l / m i n  
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CHAPTER 5
D I S C U S S I O N
I n  s p i t e  o f  a n  o b v i o u s  n e e d  f o r  d e v e l o p i n g  m e t h o d o l o g y  f o r  
e n a n t i o s e l e c t i v e  r e s o l u t i o n s  f o r  a  w i d e  r a n g e  o f  c h i r a l  c o m p o u n d s ,  t h e r e  
i s  s t i l l  m u c h  w o r k  t o  b e  d o n e  b e f o r e  s u c h  a n a l y s i s  i s  c a r r i e d  o u t  i n  
r o u t i n e  d r u g  m o n i t o r i n g  a n d  b i o a v a i l a b i l i t y  s t u d i e s .
A l t h o u g h  s e p a r a t i o n s  w e r e  a c h i e v e d  w i t h  a  n u m b e r  o f  t h e  d i f f e r e n t  
a p p r o a c h e s  t a k e n  i n  t h i s  s t u d y ,  i t  i s  u n f o r t u n a t e l y  s t i l l  t h e  c a s e  t h a t  
t h e  c h o i c e  o f  p h a s e  m u s t  b e  c a r e f u l l y  t a i l o r e d  t o  t h e  c o m p o u n d  o f  
i n t e r e s t  a n d  t h e  t y p e  o f  a n a l y s i s  r e q u i r e d ,  s i n c e  a s  y e t  t h e r e  i s  n o t h i n g  
e v e n  r e m o t e l y  r e s e m b l i n g  a  u n i v e r s a l l y  a p p l i c a b l e  p h a s e
O f  a l l  t h e  m e t h o d s  i n v e s t i g a t e d  i n  t h i s  s t u d y ,  t h e  A G P  c o l u m n  p r o v i d e s  
t h e  b e s t  r e s o l u t i o n s  a n d ,  i n  t h e  c a s e  o f  t h e  b e t a  b l o c k e r s ,  d o e s  n o t  
r e q u i r e  a n y  f o r m  o f  p r e c o l u m n  d e r i v a t i s a t i o n .  H o w e v e r  t h e  e f f i c i e n c y  i s  
l a w ,  l e a d i n g  t o  b r o a d  p e a k s  w h i c h  w i l l  u l t i m a t e l y  l i m i t  t h e  d e t e c t i o n  
s e n s i t i v i t y ,  a n d  t h e  c o s t  o f  t h e  c o l u m n  i s  h i g h  i n  c o m p a r i s o n  t o  m o s t  o f  
t h e  o t h e r  c o m m e r c i a l l y  a v a i l a b l e  p h a s e s .  T h e  c o l u m n  l i f e t i m e  h a s  s t i l l  
n o t  b e e n  r e l i a b l y  d e t e r m i n e d ,  e s p e c i a l l y  w h e n  d e a l i n g  w i t h  r e l a t i v e l y  
d i r t y  s a m p l e s ,  s u c h  a s  p l a s m a  e x t r a c t s ,  o n  a  r o u t i n e  b a s i s ,  a n d  t h i s  m a y  
b e  a n o t h e r  d r a w b a c k  t o  t h e  w i d e s p r e a d  u s e  o f  t h i s  p h a s e .
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T h e  3 , 5 - d i n i t r o b e n z o y l p h e n y l g l y c i n e  p h a s e  a l s o  g a v e  g o o d  s e p a r a t i o n s  f o r  
t h e  b e t a  b l o c k e r s ,  a l t h o u g h  n o t  w i t h o u t  t h e  p r i o r  f o r m a t i o n  o f  a  s u i t a b l e
d e r i v a t i v e .  S u c h  d e r i v a t i s a t i o n s  s e r v e  t o  i n c r e a s e  t h e  t i m e ,  c o s t  a n d  
p r e c i s i o n  o f  t h e  a s s a y  a n d  c o u l d  a f f e c t  t h e  r e l a t i v e  p r o p o r t i o n s  o f  e a c h  
e n a n t i o m e r  b y  a l l o w i n g  i n t e r c a n v e r s i o n  t o  o c c u r .  T h e  d e t e c t i o n  l i m i t s  
a c h i e v e d  f o r  t h e  r e s o l u t i o n  o f  t h e  b e t a  b l o c k e r s  b y  t h e  f o r m a t i o n  o f  
n a p h t h a m i d e  d e r i v a t i v e s  w e r e  a l s o  a d v e r s l y  a f f e c t e d  b y  a n  i m p u r i t y ,  
p r o b a b l y  i n t r o d u c e d  b y  t h e  d e r i v a t i s a t i o n  p r o c e s s .
T h e  c y c l o d e x t r i n  p h a s e  s t i l l  r e m a i n s  o n e  o f  t h e  b e s t  a p p r o a c h e s  t o  c h i r a l  
r e s o l u t i o n  i f  o n l y  t h e  e f f i c i e n c y  a n d  m a s s  t r a n s f e r  c h a r a c t e r i s t i c s  c o u l d  
b e  i m p r o v e d  t o  a  m o r e  a c c e p t a b l e  l e v e l .  T h e  r e l a t i v e l y  l o w  c o s t  o f  t h e  
p h a s e ,  t o g e t h e r  w i t h  i t s  c o r a p a t a b i l i t y  w i t h  r e v e r s e  p h a s e  s o l v e n t s  w o u l d  
m a k e  t h e  c o l u m n  a t t r a c t i v e  f o r  r o u t i n e  a n a l y s i s ,  p a r t i c u l a r l y  s i n c e  
p r e c o l u m n  d e r i v a t i s a t i o n ,  a l t h o u g h  s u c c e s s f u l l y  u s e d  i n  t h i s  s t u d y ,  s h o u l d  
n o t  g e n e r a l l y  b e  n e c e s s a r y ,
T h e  C h i r a s i l - V a l  G L C  p h a s e  i s  l i m i t e d  i n  i t s  a p p l i c a t i o n  b y  i t s  m a x i m u m  
o p e r a t i n g  t e m p e r a t u r e .  E v e n  a c c e p t i n g  t h a t  s o m e  f o r m  o f  d e r i v a t i s a t i o n  
i s  n e c e s s a r y  f o r  g a s  c h r o m a t o g r a p h y ,  i t  i s  s t i l l  d i f f i c u l t  t o  i n c r e a s e  t h e  
v o l a t i l i t y  o f  l a r g e  m o l e c u l e s  l i k e  t h e  b e t a  b l o c k e r s  t o  s u c h  a n  e x t e n t  a s  
t o  e l u t e  t h e m  f r o m  a  p o l a r  p h a s e  a t  t e m p e r a t u r e s  l e s s  t h a n  2 0 0 ’ C ,  I t  
m u s t  h o w e v e r  b e  a p p r e c i a t e d  t h a t ,  w h i l e  n o t  s u i t a b l e  f o r  s u c h  l a r g e  
c o m p o u n d s ,  t h e  c o l u m n  g a v e  e x c e l l e n t  r e s o l u t i o n s  o f  t h e  s m a l l e r  a m i n o  
a c i d s  i n  t h e  t e s t  m i x t u r e ,  w h i c h  w e r e  d e r i v a t i s e d  p r i m a r i l y  t o  r e d u c e  
t h e i r  p o l a r i t y .
O f  a l l  t h e  m e t h o d s  i n v e s t i g a t e d ,  t h e  u s e  o f  a  ( + ) ~ 1 0 ~ c a r a p h o r s u l p h o n i c  
a c i d  m o b i l e  p h a s e  a d d i t i v e  p r o v e d  t o  b e  t h e  l e a s t  s u c c e s s f u l ,  a n d  n o
r e s o l u t i o n s  w e r e  a c h i e v e d  u s i n g  t h i s  a p p r o a c h .  W h i l e  i n  t h e o r y  t h e  
m e t h o d  i s  r e l a t i v e l y  e a s y  a n d  i n e x p e n s i v e ,  s i m p l y  u s i n g  a n  a c h i r a l ,  
n o r m a l  p h a s e  c o l u m n ,  s e p a r a t i o n s  a r e  s i n g u l a r l y  d i f f i c u l t  t o  a c h i e v e  s i n c e  
t h e  f a c t o r s  w h i c h  c o n t r o l  t h e  r e t e n t i o n  a r e  d i f f i c u l t  t o  r e g u l a t e  
e f f e c t i v e l y .
A l t h o u g h  t h i s  w o r k  d e a l s  w i t h  a  s e l e c t i o n  f r o m  t h e  r a n g e  o f  a v a i l a b l e  
m e t h o d o l o g y ,  t h e  s c o p e  o f  t h i s  s t u d y  i s  s u c h  t h a t  m a n y  h a v e  b e e n  o m i t t e d .  
T h e  n u m b e r  o f  c o m m e r c i a l l y  a v a i l a b l e  H P L C  c o l u m n s  i s  r a p i d l y  i n c r e a s i n g ,  
a n d  w h i l e  t h e  g e n e r a l  c l a s s i f i c a t i o n  i n t o  V a i n e r ’ s  p r e d e f i n e d  f o u r  g r o u p s  
i s  s t i l l  a p p l i c a b l e ,  t h e  v a r i e t y  w i t h i n  e a c h  t y p e  i s  e x t e n s i v e .
A d d i t i o n a l  G L C  c o l u m n s  a r e  n o w  o n  t h e  m a r k e t ,  i n c l u d i n g  t h e  r a n g e  b a s e d  
o n  d e r i v a t i s e d  c y c l a d e x t r i n ,  a l t h o u g h  a s  y e t ,  s i g n i f i c a n t  i n c r e a s e s  i n  t h e  
m a x i m u m  o p e r a t i n g  t e m p e r a t u r e s  h a v e  n o t  b e e n  a c h i e v e d .
T h e  u s e  o f  m o b i l e  p h a s e  a d d i t i v e s  m a y  y e t  p r o v e  t o  b e  a  r e a l i s t i c  
a p p r o a c h  a n d  w o u l d  m e r i t  f u r t h e r  i n v e s t i g a t i o n .  T h e  r a n g e  o f  p a s s i b l e  
a d d i t i v e s  i s  e x t e n s i v e  a n d  i n c l u d e s  m a n y  o f  t h e  c h i r a l  s e l e c t o r s  u s e d  a s  
p h a s e s  i n  H P L C ,  s u c h  a s  c y c l o d e x t r i n ,  3 , 5 - d i n i t r o b e n s o y l  p h e n y l g l y c i n e  a n d  
A G P .  I n  a d d i t i o n  t o  a c h i e v i n g  a  r e s o l u t i o n ,  t h i s  a p p r o a c h  c a n  a l s o  b e  
u s e d  t o  o b t a i n  f u r t h e r  i n f o r m a t i o n  o n  t h e  s e p a r a t i o n  m e c h a n i s m  b y  
v a r y i n g  f a c t o r s  s u c h  a s  t h e  a d d i t i v e  c o n c e n t r a t i o n ,  w h i c h  a r e  f i x e d  
p a r a m e t e r s  w h e n  u s i n g  a  s i m i l a r  H P L C  p h a s e .
T h e  t y p e  o f  a n a l y s i s  a l s o  h a s  a  b e a r i n g  o n  t h e  c h o i c e  o f  m e t h o d < I f  t h e  
a n a l y s i s  i s  b e i n g  p e r f o r m e d  t o  c h e c k  t h e  e n a n t i o m e r i c  p u r i t y  o f  a  
c o m p o u n d ,  t h e n  i t  b e c o m e s  i m p o r t a n t  t o  b e  a b l e  t o  c o n t r o l  t h e  e l u t i o n
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o r d e r  o f  t h e  e n a n t i o m e r s .  I f  t h e  s a m p l e  c o n s i s t s  o f  a  s m a l l  a m o u n t  o f  
o n e  e n a n t i o m e r  i n  t h e  p r e s e n c e  o f  a n  e x c e s s  o f  t h e  o t h e r ,  t h e n  t h e  f o r m e r  
w i l l  b e  m e a s u r a b l e  o n l y  i f  i t  e l u t e s  f i r s t .  I f  t h i s  i s  n o t  t h e  c a s e ,  t h e n  
t h e  s m a l l e r  p e a k  w i l l  b e  s w a m p e d  b y  t h e  t a i l i n g  o f  t h e  l a r g e r  p e a k .
C h i r a l  s e l e c t o r s  w h i c h  c o n s i s t  o f  s i n g l e  e n a n t i o m e r s ,  s u c h  a s  t h e  " P i r k l e "  
p h a s e s  a n d  C h i r a s i l - V a l ,  c a n  b e  o b t a i n e d  a s  e i t h e r  e n a n t i o m e r  w h i c h  
a l l o w s  t h e  e l u t i o n  o r d e r  t o  b e  r e v e r s e d ,  w h e r e a s  w i t h  c y c l o d e x t r i n  o r  
p r o t e i n  p h a s e s  t h i s  r e v e r s a l  i s  n o t  p a s s i b l e .
T h i s  v a s t  v a r i a t i o n  h i g h l i g h t s  t h e  u s e f u l n e s s  o f  a  s y s t e m  w h i c h  c o u l d  b e  
u s e d  t o  p r e d i c t  t h e  s u c c e s s  o f  e a c h  a p p r o a c h  f o r  t h e  r e s o l u t i o n  o f  a  
g i v e n  c o m p o u n d ,  w i t h o u t  t h e  n e e d  t o  t r y  e a c h  m e t h o d  o r  p h a s e  
e x p e r i m e n t a l l y .  O n c e  t h e  c o m p o u n d  o f  i n t e r e s t  h a d  b e e n  s p e c i f i e d ,  s u c h  a  
s y s t e m  w o u l d  i d e a l l y  i d e n t i f y  o n e  o r  t w o  c h i r a l  s e l e c t o r s  w h i c h  w o u l d  
p r o v i d e  t h e  b e s t  r e s o l u t i o n s .  T h i s  w o u l d  r e d u c e  t h e  t i m e  s p e n t  i n  m e t h o d  
d e v e l o p m e n t  s t u d i e s  a n d  a l s o  a l l e v i a t e  t h e  c o s t  o f  o b t a i n i n g  a  n u m b e r  o f  
e x p e n s i v e  p h a s e s  w h i c h  m a y  n o t  b e  s u i t e d  t o  t h e  r e s o l u t i o n .
I t  w a s  f o r  t h i s  r e a s o n  t h a t  c o m p u t e r  m o d e l l i n g  s t u d i e s  w e r e  c a r r i e d  o u t  
a n d  c o m p a r e d  w i t h  t h e  e x p e r i m e n t a l l y  d e t e r m i n e d  r e s u l t s .  I t  w a s  h o p e d  
t h a t ,  i f  s u c c e s s f u l ,  a  d a t a  b a s e  c o n t a i n i n g  m o d e l s  o f  a  n u m b e r  o f  c h i r a l  
s e l e c t o r s  c o u l d  b e  e s t a b l i s h e d  a n d ,  a s  a n d  w h e n  n e c e s s a r y ,  i n d i v i d u a l  
r a c e m i c  c o m p o u n d s  c o u l d  b e  m o d e l l e d  a g a i n s t  e a c h  s e l e c t o r  t o  a s c e r t a i n  
w h i c h  p h a s e  w o u l d  p r o v i d e  s u f f i c i e n t  s i t e s  o f  i n t e r a c t i o n  t o  e n a b l e  
c h i r a l  r e s o l u t i o n  t o  o c c u r .  H o w e v e r ,  t h e  i n v e s t i g a t i o n  s h o w e d  t h a t  t h i s  
s i m p l i s t i c  a p p r o a c h  d i d  n o t  c o r r e l a t e  w i t h  t h e  e x p e r i m e n t a l  f i n d i n g s  a n d ,  
e v e n  u s i n g  t h i s  s y s t e m ,  t h e  l e n g t h  o f  t i m e  r e q u i r e d  t o  s e t  u p  e a c h
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m o l e c u l a r  m o d e l  i s  e x t e n s i v e .  T h i s  m a k e s  t h e  i d e a  o f  e s t a b l i s h i n g  a  m o r e  
r e a l i s t i c  s y s t e m ,  i n c l u d i n g  f a c t o r s  s u c h  a s  t h e  m o b i l e  p h a s e  a n d  s i l i c a  
s u p p o r t  f o r  e a c h  p h a s e  m o r e  c o s t l y  a n d  t i m e  c o n s u m i n g  t h a n  p e r f o r m i n g  
e x p e r i m e n t a l  m e t h o d  d e v e l o p m e n t  s t u d i e s ,  p a r t i c u l a r l y  s i n c e  t h e  p r o t e i n  
p h a s e s  s u c h  a s  A G P  w o u l d  b e  c o n s i d e r a b l y  m o r e  d i f f i c u l t  t o  m o d e l  t h a n  
t h e  s i m p l e  3 , 5 - d i n i t o b e n z o y l p h e n y l g l y c i n e  m o l e c u l e .
T h e  f u t u r e  t r e n d s  i n  c h i r a l  s e p a r a t i o n s  a r e  d i f f i c u l t  t o  p r e d i c t ;  t h e  
r a n g e  o f  c o m m e r c i a l l y  a v a i l a b l e  c o l u m n s ,  b o t h  f o r  H P L C  a n d  G L C ,  i s  
c o n t i n u a l l y  i n c r e a s i n g ,  w i t h  a  n u m b e r  o f  p h a s e s  b e i n g  t a i l o r e d  t o  v e r y  
s p e c i f i c  s a m p l e  t y p e s .  W h i l e  t h i s  i s  a c c e p t a b l e  i n  c a s e s  w h e r e  
l a b o r a t o r i e s  r e g u l a r l y  p e r f o r m  a n a l y s i s  o n  a  l i m i t e d  n u m b e r  o f  s a m p l e  
t y p e s ,  w h e r e  w i d e r  r a n g e s  o f  s a m p l e s  a r e  h a n d l e d ,  i t  d o e s  n o t  h e l p  t h e  
p r o b l e m  o f  w h i c h  p h a s e  t o  u s e .  T h i s  r a t i o n a l e  a l s o  h a s  a  n u m b e r  o f  
f i n a n c i a l  i m p l i c a t i o n s ,  s i n c e  v e r y  s p e c i f i c  c o l u m n s  c a n  o n l y  e x p e c t  t o  
a c h i e v e  l i m i t e d  s a l e s  f i g u r e s  a n d  t h e r e f o r e  t h e  c o s t  t o  t h e  c u s t o m e r  
r e m a i n s  h i g h .  I f  a  m o r e  u n i v e r s a l  p h a s e  c o u l d  b e  f o u n d ,  e q u i v a l e n t  f o r  
e x a m p l e ,  t o  t h e  a c h i r a l  O D S  c o l u m n s ,  t h e  d e v e l o p m e n t  c o s t s  c o u l d  t h e n  b e  
s h a r e d  o v e r  a  m u c h  w i d e r  m a r k e t ,  t h u s  l o w e r i n g  t h e  p r i c e  o f  i n d i v i d u a l  
c o l u m n s .
T h e  u s e  o f  c o l u m n  s w i t c h i n g  t e c h n i q u e s  f o r  H P L C  m a y  a l s o  b e c o m e  m o r e  
w i d e s p r e a d ,  i n v o l v i n g  b o t h  c h i r a l  a n d  a c h i r a l  c o l u m n s .  T h e  s a m p l e  i s  
i n i t i a l l y  i n j e c t e d  o n t o  a n  a c h i r a l  c o l u m n  w h i c h  s e p a r a t e s  t h e  c o m p o u n d  o f  
i n t e r e s t  f r o m  a n y  o t h e r  i m p u r i t i e s  a n d  a u t o m a t e d  s w i t c h i n g  m e c h a n i s m s  
d i v e r t  t h e  e l u e n t  f l o w  t o  a  c h i r a l  p h a s e  a t  t h e  p o i n t  o x  e l u t i o n  o f  t h e  
s o l u t e .  I n  t h i s  w a y  t h e  m o r e  e x p e n s i v e  c h i r a l  c o l u m n  i s  o n l y  u s e d  t o
s e p a r a t e  t h e  t w o  e n a n t i o m e r s  a n d  i s  p r o t e c t e d  t o  a  l a r g e  e x t e n t  f r o m  
i m p u r i t i e s  f r o m  t h e  s a m p l e  m a t r i x .  T h u s  t h e  l i f e  o f  t h e  c h i r a l  p h a s e  i s  
e x t e n d e d  a n d  i n  m a n y  c a s e s  r e s o l u t i o n  m a y  b e  i m p r o v e d .  P r o b l e m s  w i t h  
t h i s  t e c h n i q u e  m a y  a r i s e  w i t h  t h e  s o l v e n t  c o m p a t a b i l i t y  o f  t h e  t w o  
c o l u m n s ,  a n d  a l s o  t h e  r e s o l u t i o n  i s  s t i l l  d e p e n d e n t  o n  t h e  c o r r e c t  c h o i c e  
o f  c h i r a l  p h a s e .
A n o t h e r  a l t e r n a t i v e  t o  t h i s  i s  t o  u s e  a n  a c h i r a l  c o l u m n  f o r  t h e  a n a l y s i s  
t o g e t h e r  w i t h  a  c h i r a l  d e t e c t o r  t o  p r o v i d e  e n a n t i o m e r i c  q u a n t i t a t i o n .
S u c h  d e t e c t o r s  a r e  a l r e a d y  c o m m e r c i a l l y  a v a i l a b l e  a n d  a r e  g e n e r a l l y  u s e d  
i n  s e r i e s  w i t h  a  U V  d e t e c t o r ,  T h e  t o t a l  c o n c e n t r a t i o n  i s  d e t e r m i n e d  b y  
t h e  U V  s p e c t r o p h o t o m e t e r ,  w h i l e  t h e  c h i r a l  d e t e c t o r  a l l o w s  t h e  
e n a n t i o m e r i c  r a t i o  t o  b e  d e t e r m i n e d .  A l t h o u g h  s u c h  d e t e c t o r s ,  i n  t h e o r y ,  
p r o v i d e  t h e  i d e a l  s o l u t i o n  t o  c h i r a l  a n a l y s i s ,  d o u b t s  h a v e  a r i s e n  
c o n c e r n i n g  t h e  s e n s i t i v i t y .  H o w e v e r ,  c o n t i n u e d  d e v e l o p m e n t  i n  b o t h  t h e  
f l o w  c e l l  d e s i g n  a n d  t h e  e l e c t r o n i c  c i r c u i t r y  s h o u l d  i m p r o v e  t h i s  
s i t u a t i o n ,
T h e  u s e  o f  c a p i l l a r y  z o n e  e l e c t r o p h o r e s i s  h a s  a l s o  b e g u n  t o  a t t r a c t  
c o n s i d e r a b l e  i n t e r e s t  a s  a  s e p a r a t i v e  t e c h n i q u e ,  s i n c e  i t  p r o d u c e s  r a p i d  
s e p a r a t i o n s  w i t h  v e r y  h i g h  e f f i c i e n c i e s  a n d  i s  t h e r e f o r e  p o t e n t i a l l y  
u s e f u l  f o r  c h i r a l  r e s o l u t i o n s .  T h e  t e c h n i q u e  i n v o l v e s  c a p i l l a r i e s  f i l l e d  
w i t h  a  b u f f e r  s o l u t i o n ,  a l o n g  w h i c h  a  p o t e n t i a l  i s  a p p l i e d .  C h a r g e d  
s p e c i e s  m o v e  a l o n g  t h e  p o t e n t i a l  g r a d i e n t  a t  d i f f e r i n g  r a t e s ,  d e p e n d i n g  
o n  t h e i r  c h a r g e  a n d  s i z e .  E n a n t i o m e r i c  r e s o l u t i o n s  o f  a  n u m b e r  o f  a m i n o  
a c i d s  h a s  b e e n  a c h i e v e d  b y  i n c l u d i n g  a  c o p p e r  c o m p l e x  i n  t h e  b u f f e r  
[ 4 7 9 3 ,  w i t h  w h i c h  t h e  a m i n o  a c i d s  f o r m  d i a s t e r e o m e r i c  t e r n a r y  c o m p l e x e s ,
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c o m p l e x e s .  I t  i s  a l s o  p o s s i b l e  t o  a d d  o t h e r  c o m p o u n d s  t o  t h e  b u f f e r s ,
i n c l u d i n g  m i c e l l e s ,  a n d  h e n c e  i t  m a y  b e  p o s s i b l e  t o  u s e  t h e  c h i r a l  
s e l e c t o r s  m o r e  c o m m o n l y  u s e d  a s  m o b i l e  p h a s e  a d d i t i v e s  t o  s e p a r a t e s  a  
w i d e r  r a n g e  o f  e n a n t i o m e r s .
W i t h  a l l  t h e  r a n g e  o f  t e c h n i q u e s  a v a i l a b l e ,  t h e  r e s o l u t i o n  o f  d r u g  
e n a n t i o m e r s  i s  s t i l l  a  d i f f i c u l t  a n d  e x p e n s i v e  t a s k .  A  l a r g e  n u m b e r  o f  
t h e  c h i r a l  s e l e c t o r s ,  w h e t h e r  f o r  G L C ,  H P L C  o r  m o b i l e  p h a s e  a d d i t i v e s  a r e  
o n l y  t o t a l l y  e f f e c t i v e  f o r  t h e  r e s o l u t i o n  o f  a m i n o  a c i d s  a n d  a r e  n o t  w e l l  
s u i t e d  t o  o t h e r  c o m p o u n d s .  O f  t h e  t e c h n i q u e s  w h i c h  c a n  b e  u s e d  f o r  d r u g  
a n a l y s i s ,  t h e r e  a p p e a r s  t o  b e  i n h e r e n t  d i s a d v a n t a g e s  f o r  e a c h  i n d i v i d u a l  
m e t h o d .
T h e r e  i s  a n  u r g e n t  n e e d  f o r  s o m e  f o r m  o f  r e l i a b l e  g u i d e  t o  w h i c h  m e t h o d s  
a r e  s u i t e d  t o  w h i c h  c o m p o u n d s ,  w h i c h  h a s  b e e n  p a r t l y  m e t  b y  a  b o o k l e t  b y
D r  I . W .  W a i n e r  e n t i t l e d  " A  P r a c t i c a l  G u i d e  t o  t h e  S e l e c t i o n  a n d  U s e  o f
H P L C  C h i r a l  S t a t i o n a r y  P h a s e s "  C 4 8 0 L  T h i s  d e t a i l s  t h e  s t r u c t u r a l  
r e q u i r m e n t s  o f  s o l u t e s  f o r  e a c h  p h a s e  a n d  p r o v i d e s  a d d i t i o n a l  i n f o r m a t i o n  
o n  s u i t a b l e  e l u e n t s ,  t o g e t h e r  w i t h  r e f e r e n c e s  t o  l i t e r a t u r e  s e p a r a t i o n s .  
H o w e v e r  t h e  s c o p e  o f  t h e  b o o k  i s  l i m i t e d  t o  H P L C  s t a t i o n a r y  p h a s e s  a n d  
d o e s  n o t  a t t e m p t  t o  i n c l u d e  m o b i l e  p h a s e  a d d i t i v e s  o r  G L C  s t a t i o n a r y  
p h a s e s .
and separation is effected by differences in the stability of the pair of
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I t  i s  a l s o  t r u e  t o  s a y  t h a t ,  i n  a d d i t i o n  t o  t h e  d i f f i c u l t y  o f t e n  
e x p e i ' i e n c e d  i n  r e p r o d u c i n g  p u b l i s h e d  r e s u l t s ,  m u c h  o f  t h e  l i t e r a t u r e  
r e p o r t s  t h e  s u c c e s s  o f  a  m e t h o d  b a s e d  o n  i t s  a b i l i t y  t o  r e s o l v e  t h e  
e n a n t i o m e r s  o f  a  p u r e  c o m p o u n d .  W h i l e  t h i s  i s  a  s t a r t ,  i t  c a n n o t  b e  
a s s u m e d  t h a t  t h e  m e t h o d  w i l l  b e  e q u a l l y  s u c c e s s f u l  i n  r e s o l v i n g  t h e  
c o m p o u n d  i n  a  b i o l g i c a l  f l u i d ,  w h e r e  t h e r e  a r e  m a n y  o t h e r  i n t e r f e r e n c e s  
w h i c h  a f f e c t  t h e  b e h a v i o u r  o f  t h e  m e t h o d ,
I n  c o n c l u s i o n ,  i t  m u s t  b e  r e m e m b e r e d  t h a t  e n a n t i o s e l e c t i v e  a n a l y s i s  i s  
s t i l l  a  r e l a t i v e l y  n e w  t e c h n i q u e ,  a n d  w h i l e  i t  i s  b e g i n n i n g  t o  r e c e i v e  a  
r e l a t i v e l y  h i g h  p r i o r i t y ,  t h e r e  i s  s t i l l  a  l o n g  w a y  t o  g o  b e f o r e  r e a c h i n g  
t h e  s t a g e  w h e r e  c h i r a l  a n a l y s i s  c a n  b e ,  a n d  i n d e e d  i s  p e r f o r m e d  o n  a  
r o u t i n e  b a s i s .
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